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NOVEL USE OF DUAL ANTI-INFLAMMATORY THERAPY TO OVERCOME
DRUG RESISTANCE AND IMPROVE FUNCTIONAL RECOVERY
FOLLOWING SPINAL CORD INJURY
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Jennifer Natalie Dulin, B.S.
Supervisory Professor: Raymond J. Grill, Ph.D.

Abstract

Over 1.2 million Americans are currently living with a traumatic spinal cord injury (SCI).
Despite the need for effective therapies, there are currently no proven effective treatments that
can improve recovery of function in SCI patients. Many therapeutic compounds have shown
promise in preclinical models of SCI, but all of these have fallen short in clinical trials.
P-glycoprotein (Pgp) is an active transporter expressed on capillary endothelial cell
membranes at the blood-spinal cord barrier (BSCB). Pgp limits passive diffusion of bloodborne drugs into the CNS, by actively extruding drugs from the endothelial cell membrane. Pgp
can become pathologically up-regulated, thus greatly impeding therapeutic drug delivery
(‘multidrug resistance’). Importantly, many drugs that have been evaluated for the treatment of
SCI are Pgp substrates. We hypothesized that Pgp-mediated drug resistance diminishes the
delivery and efficacy of neuroprotective drugs following SCI.
We observed a progressive, spatial spread of Pgp overexpression within the injured spinal
cord. To assess Pgp function, we examined spinal cord uptake of systemically-delivered
riluzole, a drug that is currently being evaluated in clinical trials as an SCI intervention. Bloodto-spinal cord riluzole penetration was reduced following SCI in wild-type but not Pgp-null
rats, highlighting a critical role for Pgp in mediating spinal cord drug resistance after injury.
Others have shown that pro-inflammatory signaling drives Pgp up-regulation in cancer and
epilepsy. We have detected inflammation in both acutely- and chronically-injured spinal cord
vi

tissue. We therefore evaluated the ability of the dual COX-/5-LOX inhibitor licofelone to
attenuate Pgp-mediated drug resistance following SCI. Licofelone treatment both reduced
spinal cord Pgp levels and enhanced spinal cord riluzole bioavailability following SCI. Thus,
we propose that licofelone may offer a new combinatorial treatment strategy to enhance spinal
cord drug delivery following SCI.
Additionally, we assessed the ability of licofelone, riluzole, or both to enhance recovery of
locomotor function following SCI. We found that licofelone treatment conferred a significant
improvement in hindlimb function that was sustained through the end of the study. In contrast,
riluzole did not improve functional outcome. We therefore conclude that licofelone holds
promise as a potential neuroprotective intervention for SCI.
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CHAPTER 1
Introduction

Spinal Cord Injury: Prevalence, Consequences, and Clinical Management
Spinal cord injury (SCI) can be fundamentally described as an event causing damage to the
spinal cord, resulting in partial to complete loss of neurological function below the level of
injury. SCI is a particularly devastating form of trauma for which no proven effective treatment
is yet available; as a result, the majority of SCI patients suffer from lifelong paralysis and other
functional impairments. Recently, the impact of SCI in the United States has been found to be
greater than previously thought. In 2009, the Christopher & Dana Reeve Foundation’s Paralysis
Resource Center published the largest, most comprehensive study of SCI and paralysis
statistics in the U.S. in history (1). This report, the result of an exhaustive survey of more than
33,000 American households, revealed that approximately 1,275,000 individuals (0.4% of the
U.S. population) are currently living with SCI; a startlingly high figure compared to a previous
estimate of 262,000 (2). Most cases of SCI result from accidental trauma; the most commonly
reported causes of SCI are work-related accidents (28%), motor vehicle accidents (24%), and
sporting or recreation accidents (16%) (1). The majority of injuries (80.8%) are sustained by
males, and the average age at injury is 40.2 years (2). Notably, the cost of SCI is substantial,
both to the individual—the estimated lifetime cost of SCI to a 25-year old patient is $3,273,270
(2) —and to society. The financial burden incurred by SCI on the American health care system
amounted to $40.5 billion in 2009, a figure that continues to grow (1).
SCI most often occurs when a ballistic insult to the spinal column results in a contusion
and compression to the spinal cord (3, 4). However, SCI can also result from other forms of
trauma such as penetrating injuries from stab or gunshot wounds, or non-traumatic events such
as cancer, infection, or ischemia. SCI can be classified as solid cord injury, laceration,
contusion/cavity-type injury, or massive compression (5). Furthermore, injury may occur at any
level of the spinal cord, from the first cervical level to the conus medullaris and cauda equina.
For these reasons, the resulting neurological deficits can vary dramatically from patient to
patient. It is also partially because of its pathological diversity that SCI remains such a
challenging condition for which to develop effective therapeutic treatments.
The physiological impact of SCI depends upon a number of factors. The location of injury
largely determines the degree of function retained by the patient, with injuries to more rostral
regions of the spinal cord typically resulting in the greatest degree of functional impairment
(Fig. 1.1). An individual’s level of injury is determined by diagnostic imaging, such as MRI
2
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(On previous page)
Figure 1.1. Anatomy and innervation of the human spinal cord. (a) The human spinal cord
is approximately 42-45 cm in length, and about 1 cm in diameter. The spinal cord is divided
into 8 cervical segments (C1-C8), 12 thoracic segments (T1-T12), 4 lumbar segments (L1-L5),
5 sacral segments (S1-S5), and 1 coccygeal segment (Co1). The spinal cord proper ends at
approximately between vertebral levels L1 and L2, and is succeeded by the conus medullaris
(L2-L5) and cauda equina (S1-S5). Spinal nerve roots at levels C7 and above exit the vertebral
column above the corresponding vertebral body, and spinal nerve roots below C7 exit below
the corresponding vertebra (6). (b) Dermatomes, the areas of skin innervated by each individual
spinal nerve [adapted from (7)]. (Note that the face and head are innervated by the twelve
cranial nerves, rather than the spinal nerves.) Injury to the spinal cord results in loss of
sensation at and below the dermatome innervated by the spinal nerve at that level, as well as
loss of motor control of muscles innervated by spinal nerves at and below the level of injury.
(c) Cross-section of the spinal cord. Neuronal cell bodies are located in the gray matter, and
ascending and descending axonal fiber tracts are located in the white matter. The central canal
is filled with cerebrospinal fluid and extends the full length of the spinal cord. SCI can lead to a
condition called syringomyelia, in which obstruction of the central canal results in the
formation of a fluid-filled cyst (syrinx) which can cause adverse neurological effects.
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and/or CT, in combination with a comprehensive neurological evaluation (3). SCI patients with
high cervical injuries may lose function in all four limbs (tetraplegia). Patients receiving
injuries above cervical level 5 (C5) often lose diaphragm function, thus forcing the patient to
rely on a mechanical ventilator to breathe. Approximately 55% of injuries to the spinal cord
occur at cervical levels, whereas injuries to the thoracic, lumbar, or sacral spinal cord levels are
evenly distributed with each representing about 15% of all injuries (3). Injuries to more caudal
spinal cord locations are generally associated with an improved prognosis compared to cervical
SCI. However, injuries below cervical levels can still result in loss of sensory and motor
function in the trunk and legs (paraplegia), bowel and bladder incontinence, and sexual
dysfunction.
Severity of injury is the largest predictor of an SCI patient’s functional outcome (8). The
majority of injuries are termed ‘incomplete’, with some degree of sensory or motor function
retained below the level of injury; in a ‘complete’ injury, no below-level movement or feeling
is retained at all (2). To assess the severity of injury, the patient undergoes neurological testing
in which the degree of above- and below-level sensory function and muscle strength are
evaluated. Injury severity is diagnosed according to the assessment criteria of the American
Spinal Injury Association (ASIA) Impairment Scale (AIS)1 (7). According to AIS
classification, a patient categorized as ASIA A has sustained a complete SCI, whereas a patient
receiving an ASIA D or -E rating retains a relatively high level of function below the
neurological level of injury (See APPENDIX A for ASIA Standards for Neurological
Classification of SCI Worksheet). The specific functional deficits resulting from an injury to
the spinal cord are determined by the particular motor and sensory pathways that are damaged
(Fig. 1.2). Anatomically, a complete injury affects all ascending and descending spinal tracts,
though not necessarily as a result of a complete spinal cord transection, with no axons
traversing the injury site. A complete SCI can also result from chronic spinal cord compression
1

While the ASIA Spinal Cord Injury Classification system has now been widely adopted as the standard
motor and sensory assessment scheme for SCI patients, there also exist other functional ranking systems
including the Modified Benzel Classification (9), the Walking Index for Spinal Cord Injury (WISCI)
(10), and the Spinal Cord Injury-Functional Ambulation Inventory (SCI-FAI) (11). Additionally, the
AIS does not score outcome measures such as bowel, bladder, and sexual function or degree of
independence. Functional deficits of this nature may be assessed by rating systems such as the Spinal
Cord Independence Measure (SCIM) (12), the Barthel Index (13), or the ASIA Autonomic Standards
Assessment Form (APPENDIX A).
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Figure 1.2. Organization of spinal motor and sensory pathways. Cartoon depicting a cross
section of the spinal cord, with the locations of select white matter spinal tracts and gray matter
neuron pools highlighted and labeled (14). Left half illustrates the location of the lower motor
neuron pools of the ventral horn (dark blue), and the sensory neurons of the dorsal horn (dark
pink). Flexed arm cartoon in ventral horn illustrates the flexor-extensor rule: motor neurons
innervating flexor muscles (e.g., biceps) are located more dorsal to those innervating extensor
muscles (e.g., triceps); as well as the proximal-distal rule: motor neurons innervating distal
muscles (hands) are located laterally, and motor neurons that innervate proximal muscles
(shoulders) are located medially. Right half depicts the major descending motor pathways
(light blue) and ascending sensory pathways (light pink) of the spinal cord white matter
columns. The corticospinal tract (CST) is comprised of fibers originating from cortical motor
neurons and synapsing on lower motor neurons of the ventral horn (dark blue). Fibers of the
lateral corticospinal tract (90% of CST axons) control the distal musculature, including fine
control of the hands and fingers, and the ventral corticospinal tract (remaining 10% of CST
axons) carries fibers that innervate proximal musculature. The ventral spinocerebellar tract
conveys information about joint position (proprioception) to the cerebellum, and plays an
important role in coordination. The lateral spinothalamic tract is a major conduit for pain and
temperature sensation. The dorsal column of the spinal cord contains the fasciculus gracilis and
fasciculus cuneatus, which transmit fine touch, vibration, and proprioceptive information from
spinal levels below and above spinal level T6, respectively. Orientations of human silhouettes
indicate neuronal layering, in which fibers within a tract (or neurons in a pool) are organized in
layers corresponding to the order in which fibers are added to or exit the tract along the rostralcaudal axis.
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or ischemia due to loss of blood supply, and in these cases function can be recovered by
removing decompression or reperfusion, respectively (15). In contrast, an incomplete SCI only
partially damages the spinal cord at the level of injury, damaging some spinal tracts and sparing
others. Incomplete injuries may be described as one of five ‘classical’ clinical syndromes (Fig.
1.3), collections of common functional deficits attributed to generally similar patterns of
damage to spinal cord tracts (7). For example, unilateral damage to the spinal cord generally
leads to loss of ipsilateral motor function and contralateral sensory function, similar to that
observed following lateral hemisection in Brown-Séquard syndrome (See Fig. 1.3 for a
description of this syndrome). However, spinal injuries are highly heterogeneous, and an
individual’s degree of functional impairment is always assessed on a case-by-case basis. The
ASIA grading system is at best a rough classification of injury severity, and a patient’s ASIA
score upon initial evaluation is not a reliable predictor of his or her recovery trajectory2. In
general, in SCI patients with incomplete injuries, the extent of function that is eventually
recovered is inversely proportional to the severity of injury; in other words, the greater the
initial neurological deficit, the less function the patient can expect to regain (17).

Physiological Consequences of Spinal Cord Injury
Perhaps the most recognizable functional deficit resulting from SCI is paralysis, which
results from damage to the descending spinal motor tracts and/or lower motor neurons of the
spinal cord. Paralysis is one of the principal factors affecting quality of life for the majority of
SCI patients. According to the 2009 Christopher & Dana Reeve Foundation’s Paralysis
Resource Center report, 48% of individuals with paralysis resulting from SCI report “a lot of
difficulty” or “complete inability” moving (1). The degree of motor function lost due to SCI
depends on the spinal motor pathways affected by injury. For example, damage to the lateral
corticospinal tract (CST), the major motor pathway allowing fine motor control of the
extremities, will impact an individual’s ability to perform tasks requiring manual dexterity,

2

This is particularly true due to the effects of spinal shock, a transient phenomenon occurring in the first
days to weeks following injury to the spinal cord. Spinal shock may be defined as a reduction or
absence of spinal reflexes below the injury level that are gradually recovered (16). The precise etiology
and physiological significance of spinal shock are not yet clear.
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Figure 1.3. Clinical syndromes associated with incomplete spinal cord injury. The
American Spinal Injury Association (ASIA) has described five clinical syndromes commonly
exhibited by patients with an incomplete SCI (7). Each of these conditions can be identified by
its set of common functional deficits; in each syndrome, a conserved pattern of tissue damage
results in a unique array of neurological symptoms due to the organization of fiber tracts in the
spinal cord. The most common of these, central cord syndrome (left), is often a result of
hyperextension injury. This condition is characterized by significant muscle weakness in the
arms and hands (upper limbs) with a smaller degree of impairment in the legs and feet (lower
limbs). The functional deficits in central cord syndrome are due to neuronal layering in the
spinal cord gray matter. Anterior cord syndrome (middle) results most often from a loss of
blood supply from the anterior spinal arteries, which supply the anterior two-thirds of the spinal
cord. This type of injury spares the dorsal spinal columns, thus preserving below-level sense of
light touch and proprioception; however, below-level motor function and at- and below-level
pain and temperature sensation is lost. Brown-Séquard syndrome (right) results from a lateral
hemisection of the spinal cord, resulting in 1) loss of below-level motor control, proprioception,
and sense of vibration on the ipsilateral side, 2) contralateral loss of below-level pain and
temperature sensation, and 3) total at-level sensory loss on both sides (resulting from at-level
sensory fiber decussation). Not pictured: Cauda equina syndrome, which results from damage
to the lower motor neurons of the lumbosacral nerve roots, causing flaccid paralysis of lower
limb muscles and loss of bowel and bladder reflexes; conus medullaris syndrome, damage to
the conus medullaris (L1-L2), which results in similar functional deficits to cauda equina
syndrome.
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such as writing, picking up a fork, or carrying out personal hygienic routines. This type of
functional impairment can be devastating, as it dramatically decreases a person’s degree of
independence and quality of life. In a 2004 survey in which tetraplegic SCI patients ranked the
abilities that would most dramatically improve their quality of life if regained, 48.7% rated
regaining arm and hand function as most important, in comparison, only 7.8% of respondents
ranked regaining walking ability as most important (18).
Following damage to spinal motor tracts, spared parallel descending pathways can recover
a modest degree of lost motor function, generally for coarse, voluntary movements.
Approximately 41% of SCI patients experience some degree of spontaneous neurological
recovery within the first year following injury (19). However, fine motor control cannot be
recovered unless spared CST axons undergo compensatory sprouting (20), or severed CST
axons regenerate across the lesion (21), to a sufficient enough extent to have a significant
functional impact. Despite limited functional recovery, the lack of extensive regenerative CST
growth following injury generally results in permanent loss of fine control of the extremities
(6). Restoring even partial function to tetraplegic patients is therefore a highly desirable goal,
and the development of novel therapies to promote CST regeneration remains a major objective
in SCI research (22).
SCI can also affect the autonomic nervous system; depending on the type of injury, a
patient may experience bowel, bladder, and sexual dysfunction. In fact, regaining sexual
function was ranked as the highest priority by the greatest percentage of surveyed SCI
paraplegics (26.7%), followed closely by improved bowel and bladder function and eliminating
autonomic dysreflexia (18%) (18). Neurogenic bladder resulting from SCI can perhaps be best
understood as “failure to store” and/or “failure to empty” urine due to dysfunction of the
urinary sphincters (23). Complications resulting from neurogenic bladder are injury-specific
but very frequently lead to upper and lower urinary tract infections, which usually plague the
SCI patient throughout his or her lifetime. Bowel dysfunction resulting from SCI is also
complex and depends on the type of injury. Patients may suffer from debilitating constipation
as well as the humiliation of accidental bowel incontinence (24). Individuals with impaired
bowel function must follow personalized bowel management regimens, which can be
incredibly time-consuming and difficult to manage (23). Moreover, approximately 36% of
those living with SCI require assistance with bowel care, a socially agonizing experience that
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can severely detract from quality of life (25). Men with SCI commonly experience erectile and
ejaculatory dysfunction as well as infertility (26), whereas female SCI patients may suffer from
impaired sexual arousal and anorgasmia (27). The most potentially life-threatening
complication of SCI is autonomic dysreflexia, a condition that can occur in patients with
injuries above spinal cord level T6, the location of the splanchnic outflow (a major sympathetic
output) (28). In autonomic dysreflexia, strong, below-level afferent sensory input, such as tight
clothing, an overfilled bladder, or an ingrown toenail, is unable to travel past the spinal lesion
site, and as a result it stimulates neurons in the sympathetic ganglia. The major reflex
sympathetic response that results causes a sudden, significant vasoconstriction below the level
of SCI; this response runs unopposed by the parasympathetic system which lies above the level
of injury. The exaggerated, hyperreflexive sympathetic response is characterized by extreme
hypertension, bradycardia, sweating, headaches, and anxiety (29). If the sensory stimulus is not
removed, the sympathetic reflex response will continue to increase in the presence of persistent
input; this can lead to seizures, hemorrhage, and death (28).
In addition to these serious consequences of SCI, patients also frequently suffer from
uncontrolled muscle spasticity (29), chronic neuropathic pain (30), and a systemic
inflammatory response that impacts peripheral organs including the lungs and kidneys (31),
liver (32), bladder (33), and testes (34). A recent clinical study reported that the majority of
acute traumatic SCI patients experience multiple organ failure (35). Life expectancy of SCI
patients varies with severity of injury, age at injury, and time since sustaining the injury;
however, life expectancy for those with SCI is universally lower than that for uninjured persons
(2). Currently, the causes of death that most greatly impact life expectancy for SCI patients are
pneumonia, septicemia and pulmonary embolism (2). Clearly, the field of translational SCI
research is an area with multiple unmet needs for therapeutic intervention.
The culmination of the myriad of complications experienced by SCI patients is a
dramatically reduced quality of life. SCI is a complex condition that profoundly impacts not
only multiple aspects of physical health, but psychological and social well-being as well.
Researcher Kim D. Anderson of the University of California Reeve-Irvine Research Center
summarizes the difficulties faced by those living with SCI:
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What constitutes quality of life? That is a very subjective question because people
value different things. After a spinal cord injury, many things are lost …. Being
paralyzed is so much more than not being able to walk. Physiologically, there are
severe impairments in bladder, bowel, cardiac, respiratory, sensory, and sexual
function. Socially, relationships are difficult to maintain, and reintegration into
society is quite challenging. Financially, initial and long-term medical costs are
extremely burdening and, unfortunately, large proportions of people living with
paralysis are not able to return to full-time work and, thus, are dependent upon state
and federal assistance. Psychologically, the loss of a “normal” life can be devastating
for months or years depending upon the person, and this can result in further
physiological, social, and financial problems. All of these issues factor in definitions
of the quality of life. [emphasis added] (18)

Clinical Management of Spinal Cord Injury
SCI is a form of acute trauma that must be managed in a careful, timely, and judicious
manner in order to optimize patient outcome. Surgical intervention is needed to remove
fractured bone or disc fragments compressing the spinal cord tissue (decompression) and to
realign and stabilize the vertebral column (36). Though the optimal timing for surgical
decompression has been debated, it is currently believed that surgery should ideally be
performed between 8 and 24 hours after SCI (37). Once in the clinic, most acute SCI patients
are first subjected to a comprehensive preoperative evaluation, unless decompressive surgery is
deemed emergent (38). This evaluation includes a medical history, complete neurological
sensory and motor evaluation, assessment of autonomic and cardiovascular dysfunction,
laboratory blood tests, electrocardiogram, and diagnostic imaging (39). In addition, there is a
considerable possibility that the trauma producing SCI has also resulted in injury to other vital
organs, e.g., the brain or liver; thus, a full physical evaluation must be performed. Such
thorough medical evaluations are critical in determining outcome due to the potential
importance of systemic factors, for example, hemodynamic stability, on spinal cord perfusion
(39). Following preoperative evaluation, the patient may be administered medications such as
antibiotics, anxiolytics, or agents to promote gastrointestinal (GI) motility, depending on the
circumstances. After spinal surgery, the median length of acute-care hospitalization for an SCI
patient is about twelve days (2).
There are currently no proven effective, FDA-approved interventions that can improve
functional outcome if administered to an acute SCI patient. However, if patients meet the
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inclusion criteria for a currently enrolling clinical trial, they may be presented with the option
of receiving an experimental treatment. Due to some clinical studies demonstrating modest
functional improvement if administered within eight hours of injury, many hospitals have
historically administered high-dose methylprednisolone sodium succinate (MPSS), a synthetic
anti-inflammatory corticosteroid, for acute SCI patients (19). However, the use of MPSS has
now dramatically declined due to the considerable negative side effects associated with highdose steroids, as well as mounting criticism surrounding the clinical trials reporting its
therapeutic benefits (40, 41). A 2006 survey revealed that only 24% of spinal surgeons believed
MPSS improved patient outcome and that in fact, most surgeons continued to administer the
drug primarily out of a fear of litigation (42).
For SCI patients with incomplete, sub-acute (weeks) or chronic (months) injuries, physical
rehabilitation may be a useful tool to improve functional recovery. Studies of body weightsupported treadmill training indicate that gait rehabilitation produces a modest improvement in
patients with chronic SCI (43). The average patient with a motor incomplete SCI generally
spends between five and six weeks in a clinical rehabilitation unit subsequent to leaving an
acute care facility (2). After completing rehab, however, SCI patients are far from finished with
medical care. During the chronic phase of injury, a plethora of medical complications may
arise; each year, 30-50% of all individuals with SCI will be readmitted to the hospital (2).
These patients are at particularly high risk for complications such as urinary tract infections,
respiratory disease, pressure sores, and circulatory problems, all of which can be lifethreatening if untreated (2). In addition, SCI patients will likely require regular follow-up
medical care; for example, to assess efficacy of pain and spasticity medications, to evaluate
whether adjustments need to be made to bladder or bowel programs, and to receive routine
neurological and psychological evaluations. As a result, the lifetime cost of SCI-associated
medical care can be as high as $4 million (2).

Experimental Models of Spinal Cord Injury
The inherent complexity of the molecular and cellular pathophysiology of SCI requires the
use of experimental animal models in SCI research. These in vivo models are critical tools for
evaluating the effects of experimental treatments on complex physiological processes like
axonal regeneration, and examining clinically relevant outcome measures such as locomotor or
12

neurosensory function. Since human SCI is a highly heterologous condition with many
variables affecting outcome, selection of the appropriate experimental model can be
challenging for SCI researchers. Furthermore, the myriad of anatomical, behavioral, and
pathophysiological differences between humans and laboratory animals can limit experimental
studies in a variety of ways. Regardless, experimental animal models are invaluable in the
ongoing search for effective new therapies for SCI (6).
The most common cause of SCI in human patients is contusion and/or compression injury
(4), and a variety of animal models have been developed to approximate human contusion
injury pathology (44). One of the most frequently used models is the weight-drop model of
SCI, such as the NYU Spinal Cord Injury Device (45), which entails dropping a calibrated
weight from a defined height onto the exposed spinal cord, resulting in a rapid and controlled
displacement of spinal cord tissue (45, 46). Another common contusion injury model utilizes a
mechanical impactor, such as the Ohio State University Electromechanical Spinal Cord Injury
Device (47) or the Infinite Horizon Spinal Impactor Device (48), to deliver a rapid forcecontrolled contusion to the exposed spinal cord. A review of the various experimental
contusion/compression injury models emphasizes the importance of consistency in force and
displacement parameters in producing reproducible histological and behavioral outcomes (49).
Though spinal contusion injury models are frequently used due to their approximation of
human spinal contusion pathology, models of spinal cord transection and hemisection are also
frequently utilized in SCI research. In an experimental transection model, the spinal cord is
completely severed via a scissor or blade; in a hemisection model, either the dorsal or lateral
half of the spinal cord is incised at one or more spinal levels (47). Though complete transection
of the spinal cord is a relatively rare occurrence in humans, these models have a particular
utility for investigating the mechanisms of SCI pain (50), regeneration of CST axons (51, 52),
or to kindle a more hospitable environment for the introduction of therapeutic stem cells, which
can be sensitive to the high levels of inflammation associated with contusion/compression
injuries (47, 52-54). Dorsal hemisection models are useful for the study of discrete lesions of
motor or sensory pathways; this type of injury usually leaves gray matter intact, allowing the
researcher to assess the suitability of gray versus white matter for regenerative or plastic growth
(47). Lateral hemisection models are suitable for assessing the ability of spared pathways on
the contralateral uninjured half of the spinal cord to sprout and/or contribute to recovery of
function (47).
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Experimental animals are also useful for modeling injuries that produce different types of
neurological deficits. Contusion/compression models can be tailored to produce mild,
moderate, or severe injuries, which are associated with increasing degrees of impairment in
neurological and motor recovery (55). Additionally, selecting the location of injury in animal
models allows the experimenter to examine specific behavioral outcome measures. Cervical
SCI models result in loss of fine motor control and ability to perform tasks requiring forelimb
dexterity, while preserving normal hindlimb function (6). Models of cervical injury are
frequently utilized to investigate the efficacy of treatment on CST regeneration by examining
performance in fine motor tasks. In contrast, thoracic injury models produce hindlimb
functional deficits, and as such are best suited for evaluating parameters such as locomotor
recovery and the development of neuropathic pain (56). Whereas animals with cervical injuries
of sufficient severity can lose their ability to ambulate and feed, animals with thoracic injuries
retain full use of the forelimbs and can still perform these functions. Because of the
significantly greater amount of post-operative animal care needed with cervical injury models,
thoracic injury models are generally more practical to the researcher.
The vast majority of experimental SCI studies utilize rats and mice. The advantages of
rodent models, aside from the relatively low cost and ease of experimentation, include the
abundance of reproducible rodent SCI models, the relative homogeneity of genetic background
and the ease of genetic manipulation, and the wealth of sensitive behavioral assessments
developed for mice and rats. Rodent models are useful in optimizing the parameters of delivery
for, or assessing the potential harmful side effects of, a novel or exploratory therapy (57).
Rodents have been used extensively to assess the potential neuroprotective benefits of novel
treatments for SCI, and rodent studies have also led to great gains in knowledge of the
pathophysiology of SCI. However, there are key disadvantages to relying upon rodent models.
First, there are key differences in the pathophysiology of SCI between mice, rats, and humans
(6, 58-60). For example, the cellular inflammatory process exhibited by rats is different than
that of humans, and is better modeled using nonhuman primates (61). Perhaps the most obvious
disadvantage is the discrepancy between the nervous systems of rodents and humans, both in
size and in the anatomy of neural networks (6). Large animals offer an advantage in that axonal
regeneration must occur over a larger distance within the spinal cord, similar to humans (57).
Additionally, because neuroanatomical tract distribution is different in bipeds and quadrupeds,
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the regenerative growth and locomotor recovery of bipedal nonhuman primates following SCI
are more clinically relevant than those of quadrupedal rodents (6, 61).
It is clear that rodent models alone are inadequate for assessing the safety and efficacy of
novel therapies. Treatments exhibiting efficacy in rodents must subsequently be validated in
large animal models, such as pigs or nonhuman primates, before translation to clinical trials.
Recently, Levine and colleagues have pointed to the naturally occurring canine disorder of
thoracolumbar intervertebral disk herniation as a useful model of large animal SCI, providing
an alternative to nonhuman primates for the validation of therapies (62). Other models of large
animal SCI, such as pigs (63) and felines (64), have also historically been used in experimental
research studies. Ultimately, the choice of experimental animal utilized must be based on a
careful consideration of many factors, including the nature of the research question being
investigated or the intervention being tested, and the suitability of the animal model in
addressing those questions.

§

Molecular and Cellular Pathophysiology of Spinal Cord Injury
Contusion injury, such as that occurring when a fractured disc impinges into the spinal
cord tissue secondary to fracture-dislocation or burst fracture of the spinal column, represents
the most common type of SCI (3). This type of traumatic SCI is characterized by a biphasic
pattern of injury (Fig. 1.4). The immediate mechanical insult (primary injury) is a direct result
of acute contusion and/or compression of the spinal cord tissue by displaced disc or bone
fragments. Immediately, there is disruption of the vasculature causing hemorrhage, substantial
cell death within the gray matter due to both the actual mechanical force of impact as well as
ischemic insult, generation of a necrotic epicenter of injury, and mechanical shearing of axons
in the white matter (3, 6, 65). The primary insult to the spinal cord sets into motion a
prolonged, expanding wave of secondary injury, which can best be described as a cascade of
pathological cellular and molecular processes that contribute to further tissue death and
degeneration during sub-acute and chronic injury (6). A central goal of current SCI research is
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Figure 1.4. Timeline of pathological secondary injury processes following spinal cord
injury. (a) Cartoon depiction of an uninjured spinal cord, illustrating the presence of normal,
healthy myelinated axons and gray matter. (b) Traumatic injury to the spinal cord results in an
immediate death of neurons in the gray matter, thereby generating a necrotic epicenter of
injury. This cell death is caused by both force of impact to the cell bodies, and hemorrhagic and
ischemic insult due to mechanical disruption of the microvasculature. The large blood vessels
on the spinal cord surface are more resistant to physical damage as a result of contusion injury.
However, disruption of the spinal cord blood supply via occlusion of the spinal arteries leads to
gray matter infarction, and subsequent reperfusion of the ischemic tissue results in the
generation of cytotoxic free radicals, exacerbating injury (65). The mechanical force of the
primary injury also instantly severs axonal fibers within the white matter of the cord; however,
the primary injury causes considerably more damage to the gray matter with relative sparing of
the peripheral white matter. Within minutes, activated microglia accumulate at the site of injury
and begin to secrete cytotoxic factors including pro-inflammatory cytokines (66). (c) In the
days to weeks following SCI, secondary injury processes continue to shape pathological
changes to the injured spinal cord. Within hours, there is a massive invasion of neutrophils
from the bloodstream, producing free radicals and pro-inflammatory cytokines. The first few
days to weeks after injury are characterized by: accumulation of activated microglial cells and
invasion of peripheral macrophages/monocytes that also secrete pro-oxidative and proinflammatory factors; healing of the damaged BSCB; axonal degeneration; and proliferation of
glial cells that begin to form the glial scar (67). (d) Several weeks to months post-SCI, there is
deposition of components of the extracellular matrix that cause inhibition of axonal
regeneration. During this time, the glial scar also stabilizes around the cystic cavity that forms
at the epicenter, presenting an additional barrier to regrowth of axons. Demyelination and
degeneration of axons in and surrounding the injury site cause the spinal cord to atrophy due to
loss of white matter volume (68). Furthermore, there is T cell invasion and chronic macrophage
activation in the injured cord that may last months to years (69, 70).
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to develop a better understanding of the complex pathophysiology of secondary injury, in order
to identify and target the molecular mechanisms contributing to cell death (71).
The earliest aspects of the secondary injury cascade can be largely attributed to a massive
influx of cytotoxic substances into the spinal cord tissue in the minutes to hours following
injury, a direct result of the cellular damage and vascular disruption caused by the primary
insult (65). Early events in the initial pathological cascade include extracellular accumulation
of excitotoxic neurotransmitters, oxidative stress resulting from free radical formation and lipid
peroxidation, ionic imbalance, edema formation, and an infiltration of immune cells that secrete
cytotoxic factors such as cytokines and chemokines, free radicals, pro-inflammatory lipid
mediators, and proteases (65, 71). Each of these in turn activates downstream intracellular
signaling pathways, resulting in further cell death and demyelination in the acutely injured
spinal cord (68). Diffusible factors such as cytokines also serve to recruit additional immune
cells into the injured cord for days to weeks following injury, thus perpetuating the secondary
injury pathology further. Furthermore, inflammation mediates a progressive opening of the
blood-spinal cord barrier (BSCB), allowing inflammatory immune cells and cytotoxic factors to
permeate into the cord (72). These pathological events are not simply confined to the acute
phase; apoptosis, demyelination, BSCB breakdown, and axonal degeneration have been shown
to continue into the chronic phase, weeks to months following SCI (73-76). Clearly, the process
of secondary injury is extraordinarily complex, and as such is not fully understood.
Many drug compounds that have been evaluated as potential therapeutics for preclinical
and clinical SCI are intended to target the early components of secondary injury, with the goal
of attenuating the destructive cascade as early as possible and protecting the spinal cord from
further secondary injury-induced damage (77). One such drug, riluzole, is a neuroprotective
compound that has to date been evaluated in nine experimental studies as a potential SCI
intervention (78-86), and is currently being evaluated in a Phase I clinical trial as an acute
intervention for human SCI patients (87). Riluzole exerts an anti-glutamatergic effect by both
blocking voltage-sensitive Na+ channels and attenuating Ca2+-dependent presynaptic glutamate
release, thus protecting neurons against excitotoxic cell death (88, 89). Interest in riluzole as a
treatment for SCI originated because of the central role of excitotoxicity in early secondary
injury, as well as the fact that riluzole is already FDA-approved for treatment of the
neurodegenerative disease amyotrophic lateral sclerosis (ALS), thus making it a highly
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translatable drug for clinical SCI studies (89). Other neuroprotective compounds that have been
evaluated in SCI clinical trials include MPSS (90), the neuronal membrane component
monosialoganglioside GM-1 (91), and the tetracycline antibiotic minocycline (77).
Unfortunately, clinical trials in SCI patients have thus far failed to produce any statistically
significant functional improvements, with the dubious exception of MPSS3 (96). Despite the
failure to translate neurological benefits in preclinical studies to human SCI patients, preclinical
evaluation of neuroprotective compounds continues to push forward in the hope of finding a
novel effective therapy.

Role of Inflammation in Spinal Cord Injury Pathophysiology
Inflammation is the endogenous, multifaceted physiological response to injury or disease,
and it encompasses a host of molecular and cellular processes with complex, diverse effects on
the different tissues and organ systems in the body (97). Inflammation is one of the major
forces in the secondary injury cascade, and as such, plays a central role in the
pathophysiological processes that occur in the acutely injured spinal cord (98). Components of
the molecular and cellular inflammatory response drive a host of adverse pathological events
following SCI, such as cell death (98), disruption of the BSCB (72), generation of the glial scar
(99, 100), and sensitization of neural pathways leading to neuropathic pain (30). For this
reason, attenuating inflammation following SCI has been viewed as a promising therapeutic
strategy for decades, and to date researchers continue to investigate the efficacy of anti3

The clinical studies leading to the widespread of the steroid MPSS as an acute SCI intervention are
controversial (40, 92). This is chiefly due to the fact that those studies reporting its neurological benefits
exhibited statistical significance only when subjected to extensive post-hoc analysis. NASCIS I, a large,
randomized multicenter clinical trial (1979-1984), showed no benefit of acutely (<12 hours post-SCI)
administered MPSS over the opioid antagonist drug naloxone or placebo in improving neurological
outcome up to one year post-injury (93). A subsequent study, NASCIS II (19, 94), was conducted to
evaluate the efficacy of a much higher dose of MPSS for acute SCI. NASCIS II, like NASCIS I, failed
to show any overall neurological improvement in patients receiving MPSS. However, a post hoc
analysis detected a small gain in functional outcome of a small subgroup of patients who received the
drug 3-8 hours post-injury. As a direct result of this finding, the high-dose MPSS infusion tested in
NASCIS II quickly became a standard of care for acute SCI in many clinical settings throughout the
world, despite the failure of subsequent clinical studies to replicate these findings (92). Today, MPSS is
widely considered to be ineffective for improving function in acute SCI patients; moreover, the harmful
side effects of high-dose steroid treatment actually make MPSS a dangerous clinical approach for acute
SCI (40, 41, 95).
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inflammatory treatment as a neuroprotective intervention for SCI. However, the cellular
inflammatory response is also extraordinarily complex, and paradoxically, it alters the local
environment in ways that both foster and discourage regenerative regrowth (101).
Injury to the spinal cord invokes a complex cellular response involving several different
immune cell types. There is an invasion of peripheral circulating immune cells (i.e.,
neutrophils, dendritic cells, and macrophages) into the injured spinal cord, as well as
widespread activation of resident microglial cells (102). The major activities of these immune
cells include phagocytosis of cellular debris, presentation of degraded peptides to helper Tlymphocytes, secretion of pro-inflammatory cytokines, chemokines, and growth factors, and
free radical production (102). The dual nature of the effect of inflammation in the injured spinal
cord microenvironment becomes apparent upon examining the multifaceted role of activated
microglia (103). Following injury, activated microglial cells release factors, such as glial cell
line-derived neurotrophic factor and transforming growth factor-beta1 (TGF-beta1), that
promote neurite growth and survival (104). In contrast, these cells also produce proinflammatory cytokines and reactive oxygen species (ROS) that promote neuronal cell death
and secrete proteoglycans that are inhibitory to neurite growth (66). These diverse functions of
microglia and other immune cell types underlie the complexity of the inflammatory response
and its duality in promoting both tissue damage and repair after SCI.
Historically, much attention has been focused on the potential of immunosuppressive
therapies to improve functional recovery after SCI, an initiative that has been largely motivated
by the desire to combat immune cell-mediated tissue damage in the injured spinal cord (102).
However, as more information has been gained about the intricate forces contributing to tissue
damage and tissue repair following SCI, it has become increasingly apparent that more targeted
therapies must be developed. These therapies must be able to attenuate the destructive effects
of the cellular immune response, such as secretion of cytotoxic factors, while preserving the
processes that enhance repair and regrowth, such as clearance of cellular debris and secretion of
growth factors. This type of therapeutic goal will be achieved by specifically inhibiting the
intracellular signaling cascades that mediate tissue-destructive effects within the injured spinal
cord; one particularly important target is pro-inflammatory signaling. One of the hallmarks of
the acute inflammatory response after SCI is the oxidative metabolism of arachidonic acid
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Figure 1.5. Phospholipase A2 activation and oxidative arachidonic acid metabolism
mediate secondary neuronal injury in the injured spinal cord. Injured spinal cord tissue is
an environment rich in neuroinflammation and excitotoxicity. Under these conditions, high
levels of pro-inflammatory cytokines, reactive oxygen species (ROS), and excitatory amino
acids lead to activation of the lipolytic enzyme phospholipase A2 (PLA2). When PLA2 becomes
activated, it hydrolyzes membrane-bound phospholipids into the free polyunsaturated fatty
acid, arachidonic acid (AA), which in turn is metabolized by cyclooxygenase (COX-1/2) and 5lipoxygenase (5-LOX) enzymes into the potent pro-inflammatory mediators, the prostaglandins
and the leukotrienes, respectively. These bioactive eicosanoids, along with ROS produced via
oxidative AA metabolism, contribute to further neuronal injury and tissue damage within the
injured spinal cord. This pro-inflammatory cascade is a major and destructive component of the
secondary injury process following SCI. Pharmacotherapies targeting multiple elements of this
signaling network have been evaluated extensively in preclinical and clinical SCI studies.
These include the PLA2 inhibitor GM1 ganglioside, COX inhibitors such as ibuprofen and
naproxen, the 5-LOX inhibitor zileuton, as well as the cysteinyl leukotriene (CysLT) receptor
antagonist montelukast.
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(AA). This cascade is triggered by the activation of the phospholipase A2 (PLA2) family of
lipolytic enzymes (Fig. 1.5). The PLA2 family contains the isoforms cytosolic PLA2 (cPLA2),
Ca2+-independent PLA2 (iPLA2) and secretory PLA2 (sPLA2), and each are activated
differentially by Ca2+ and/or phosphorylation (105). All classes of PLA2 isoforms are known to
be expressed in the spinal cord, though their individual roles following injury have yet to be
fully understood (106). It is known that PLA2 activation begins within a few minutes after SCI
and sets into motion a variety of downstream events promoting inflammation and oxidative
stress, thus exacerbating neuronal injury and spread of secondary pathology (107). Thus, PLA2
and its downstream effectors are critical elements driving the acute SCI pathological cascade,
making them a major target for neuroprotective therapies.
PLA2 activation, one of the earliest events in the neuroinflammatory process following
SCI, is induced largely by activated microglia that accumulate at the site of injury within
minutes (108). These activated microglia secrete free radicals and pro-inflammatory cytokines
such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), resulting in
increased neuronal PLA2 expression and activation (105, 107). Excitatory amino acids, released
by cellular membrane damage upon injury, further induce PLA2 activation (105). Activated
PLA2 exerts a hydrolytic activity on membrane phospholipids within the injured tissue,
releasing the polyunsaturated omega-6 fatty acid, AA. The enzymes cyclooxygenase (COX)-1
and COX-2, and 5-lipoxygenase (5-LOX), which are also stimulated by SCI (108, 109),
catalyze rate-limiting steps in the conversion of AA into the bioactive eicosanoids, 20-carbon
lipids that are potent mediators of inflammation and secondary injury. High levels of ROS are
also produced during this process of oxidative AA metabolism. These free radicals contribute
to further neuronal damage, exacerbate the cellular inflammatory response, and promote
upstream PLA2 activation, thus perpetuating the secondary injury cascade (107).
Because the PLA2 pro-inflammatory signaling network plays such an early and central role
in SCI secondary pathology, various groups have evaluated the therapeutic potential of
inhibiting PLA2 family members. Michael-Titus and colleagues demonstrated that inhibiting
both cPLA2 and iPLA2 enzyme activity shortly following SCI in rats conferred some
neuroprotection (110). In addition, there is much preclinical evidence indicating the
neuroprotective benefits of the gangliosides, inhibitors of intracellular PLA2 (111), though
clinical studies examining the efficacy of gangliosides for acute SCI have not seen therapeutic
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benefits in human patients (91). Until recently the specific contributions of the different PLA2
isoforms to SCI pathology have been unclear. López-Vales et al. demonstrated that in mice,
blocking all three PLA2 isoforms actually inhibits recovery; interestingly, the cPLA2 GIVA
isoform was shown to exert a tissue-protective effect (106). These findings demonstrate that a
deeper understanding of the divergent roles of PLA2 isoforms within the injured spinal cord is
needed in order to develop more effective, targeted therapies. In fact, the majority of
investigations have not focused on PLA2, but rather on the therapeutic potential of targeting
downstream components of this network, such as COX signaling.

Cyclooxygenase and Lipoxygenase in Spinal Cord Injury
COX-1 and COX-2 are the rate-limiting enzymes in the biological pathway converting AA
into the prostanoids—the prostaglandins, thromboxanes, and prostacyclin (Fig. 1.6). Activity of
COX-1 and -2 is inhibited by classical non-steroidal anti-inflammatory drugs (NSAIDs), a class
of nonselective COX inhibitors that includes such commonly used drugs as aspirin and
ibuprofen (112). Structurally and functionally, COX-1 and -2 are very similar, both catalyzing
the stepwise conversion of AA into the prostaglandins PGG2/PGH2 (112). The crucial
distinction between these two enzymes lies in their tissue-specific expression. COX-1 is
expressed constitutively in most tissues, whereas the inducible isoform COX-2 is not usually
detectable in most normal tissue (though it is constitutively expressed in some tissues under
normal conditions (113)) but rather is expressed predominantly by immune cells, such as
activated macrophages, under inflammatory conditions. Thus, COX-1 activity plays a variety of
normal homeostatic roles in various tissues of the body, but the induction of COX-2 activity is
usually a strong indicator of the pathophysiological inflammatory response (112, 114).
The prostanoids are synthesized directly from the COX product PGH2 via the activity of
different enzymes, and are ubiquitously expressed throughout the body. The prostanoids have
diverse physiological functions, e.g., protection of the gastric mucosa, controlling menstruation
and parturition, and maintaining normal kidney function; during disease pathophysiology, they
also play central roles in the inflammatory process (115, 116). In the central nervous system
(CNS), COX-derived prostanoids have been shown to be strong contributors to the pathological
processes of a host of neurodegenerative diseases and neurological insults (117). COX
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Figure 1.6. Cyclooxygenase enzymes generate prostanoids from arachidonic acid.
Cyclooxygenase (COX) enzymes, COX-1 and COX-2, both catalyze the conversion of
arachidonic acid (AA) into prostaglandin G2 (PGG2), then PGH2. Prostaglandin synthases
convert PGH2 into the prostaglandins PGD2, PGE2, and PGF2. PGH2 can be shunted into the
thromboxane (TXA2) pathway via thromboxane synthase activity, or it be converted into
prostacyclin (PGI2) by prostacyclin synthase. Non-steroidal anti-inflammatory drugs (NSAIDs)
block COX-1/2 activity, thus inhibiting production of the pro-inflammatory prostaglandins,
mediators of inflammatory pain and arthritis (112).
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signaling is central in pain transmission in the spinal cord, both under normal physiological
conditions as well as during pathophysiological pain states following SCI (118-120). The
specific contribution of COX signaling to secondary SCI pathology has long been a subject of
investigation. It has been demonstrated that increased spinal cord COX-2 expression (121) and
prostanoid synthesis (122) occur from very early after injury. Studies utilizing treatment with
NSAIDs or COX-2-specific inhibitors prior to injury (119, 123-128) or shortly following injury
(121, 129-137) have largely detected improvement in neurological and histological outcome in
animal models of SCI. Of these preclinical studies, the drug that has been most frequently
evaluated is indomethacin, a nonselective COX inhibitor (77). However, the clinical relevance
of the findings is dubious; relatively few studies of indomethacin’s efficacy have reported
behavioral outcome, and most utilized pre-treatment or very early treatment during an
unrealistic window of efficacy. According to Kwon and colleagues (77), greater potential may
lie in ibuprofen, which has demonstrated neurological benefits even when administered up to a
week following SCI (136).
The lipoxygenase (LOX) family of enzymes is parallel to the COX pathway in the
oxidative AA metabolism signaling network. The LOX family is comprised of 5-LOX, 12LOX, and 15-LOX, all of which catalyze the conversion of AA into bioactive eicosanoids (Fig.
1.7). The 12-LOX and 15-LOX pathways produce the lipoxins, which are unique among the
lipid mediators in that they exert anti-inflammatory action (138) and, interestingly, appear to
play a role in attenuating inflammatory pain within the spinal cord (139). 5-LOX, however,
catalyzes the rate-limiting step in the conversion of AA into the pro-inflammatory leukotrienes:
leukotriene B4 (LTB4) and the cysteinyl leukotrienes (CysLTs). The leukotrienes have long
been recognized for their fundamental role in promoting and sustaining inflammation,
especially in asthma and the allergic response (140). As such, drugs such as the 5-LOX
inhibitor zileuton and the CysLT receptor antagonist montelukast are commonly used in the
clinical treatment of asthma and bronchial constriction.
Though the potential role of lipoxins in SCI has not yet been explored, it is now known
that the leukotrienes are important mediators in the secondary pathogenesis of SCI.
Experimental studies have revealed that LTB4 levels are increased within the injured spinal
cord in the hours to days following SCI (141, 142). Genovese and colleagues have shown that
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Figure 1.7. Lipoxygenase enzymes catalyze conversion of arachidonic acid into the proinflammatory leukotrienes and the anti-inflammatory lipoxins. Arachidonic acid (AA),
freed by PLA2 hydrolysis of membrane phospholipids, is metabolized by 5-lipoxygenase (5LOX) and the 5-lipoxygenase-activating protein (FLAP) into 5-hydroperoxyeicosatetraenoic
acid (5-HPETE). 5-HPETE is reduced to 5-hydroxyeicosatetraenoic acid (5-HETE), and then
converted by 5-LOX to leukotriene A4 (LTA4). Via the activity of LTA4 hydrolase, LTA4 is
converted into the pro-inflammatory lipid mediator, leukotriene B4 (LTB4). LTB4 is a potent
chemoattractant mediating leukocyte infiltration into the spinal cord and aggravating the
secondary injury process. Via glutathione-S-transferase II activity in cells such as mast cells,
LTA4 can also be converted into leukotriene C4 (LTC4), a member of the cysteinyl leukotriene
(CysLT) family. LTC4 can then be converted to the other two CysLTs, leukotrienes D4 (LTD4)
and -E4 (LTE4), by the enzymes gamma-glutamyl transpeptidase and dipeptidase, respectively
(143). 15-lipoxygenase (15-LOX), expressed in leukocytes, produces the anti-inflammatory
lipoxins, which promote processes such as vasorelaxation and inhibition of polymorphonuclear
cell infiltration through the vascular endothelium (138).
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5-LOX knockout mice exhibit reduced neutrophil infiltration, neuronal death, and axonal
degeneration after SCI compared to wild-types; additionally, they found that these mice have
improved motor function following SCI (144). In a subsequent study, the same
group showed similar histological and functional improvements with zileuton and montelukast
treatment, specifically revealing the importance of the CysLTs in driving SCI pathology (142).
Recently, Saiwai et al. demonstrated that interaction between LTB4 and its receptor, the
leukocyte-specific LTB4 receptor 1 (BLT1), promotes the infiltration of neutrophils,
macrophages, and microglia into the injured spinal cord within the first week following SCI
(145). Importantly, blocking the LTB4-BLT1 axis reduced secondary pathophysiologies
including neuronal death and white matter loss, and enhanced motor recovery. Together, these
studies reveal that both LTB4 and CysLT signaling mediate secondary SCI pathology early
after injury.

Pharmacological Inhibition of COX and 5-LOX Activity
COX inhibition has been extensively evaluated as a potential neuroprotective therapy for
acute SCI, but there are multiple complications with the clinical use of COX inhibitors. The
first-generation COX inhibitors, the classical NSAIDs, nonselectively inhibit COX-1 and COX2; common over-the-counter drugs such as aspirin and ibuprofen belong to this class of drugs,
and each inhibits COX-1 and -2 at approximately equal potency. Though these drugs are very
widely used to treat inflammatory pain, long-term or high-dose NSAID use is associated with
adverse side effects. About 1% of chronic NSAID users experience GI complications such as
ulcers and GI bleeding (112) and acute renal failure (113). Because of the potential severity of
these side effects, NSAIDs are implicated in almost half of all drug-related medical
emergencies (146). These side effects have been largely attributed to the inhibitory action of
NSAID treatment on normal physiological COX-1 activity, which is necessary for protection of
gastric and renal tissues (113). In 1988, it was discovered that the inducible COX-2 isoform is
the primary COX enzyme responsible for inflammatory pain, thus opening the door for a new
approach to anti-inflammatory treatment (112). The COX-2-specific inhibitors, the coxibs,
were developed in the 1990s as a novel solution to sidestep GI irritation while still maintaining
therapeutic efficacy comparable to classical NSAIDs (147). The coxibs have indeed
demonstrated improved GI tolerability over NSAIDs in clinical trials (148). However,
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subsequent studies have found that COX inhibitors—most notably, rofecoxib (Vioxx)—can
cause a dramatic increase in potentially fatal cardiovascular side effects including heart attack,
stroke, and thrombosis (149). As a result, rofecoxib was pulled off the market in 2004, and to
date there has been relatively little progress in the development of safer COX inhibitors with
enhanced tolerability (149).
Based on the findings that both COX and 5-LOX signaling contribute to the secondary
pathology of SCI (121, 142), one may speculate that inhibiting the COX arm of AA
metabolism alone may be an insufficient strategy by which to attenuate inflammation in the
acutely injured spinal cord. Rather, dual blockade of both COX and 5-LOX pathways may be
crucial in order to overcome the potent inflammation that drives vascular disruption, cell death,
and a host of other destructive processes early after SCI. Lending support to this idea is the
finding that AA can be “shunted” into one arm of AA metabolism when the other is blocked,
effectively compensating for pharmacological inhibition of one pathway by increasing AA flux
through the other pathway. An example of the AA shunt can be found in the phenomenon of
aspirin-induced asthma. In this condition, treatment of asthmatic patients with NSAIDs acutely
exacerbates the symptoms of asthma (150), primarily due to COX inhibition promoting
formation of leukotrienes in the lungs (151). Further evidence for the concept of an AA shunt
can be found in studies of lung cancer, a disease for which it is known that the prostanoids and
leukotrienes both exert pro-tumorigenic effects (152). Ye and colleagues showed that
pharmacological COX-2 inhibition decreased levels of the COX product PGE2, but actually
increased LTB4 levels, in cigarette smoke-induced colonic adenomas (153). Notably, they
found that dual inhibition of COX-2 and 5-LOX inhibited tumor growth more effectively than
either COX-2 inhibition or 5-LOX inhibition alone, illustrating a synergistic effect of
simultaneously blocking both pathways (153). Furthermore, clinical studies of heavy cigarette
smokers found that one month of treatment with the COX-2 inhibitor celecoxib suppressed
PGE2 but markedly increased LTB4 levels in the alveolar macrophages of smokers’ lungs (154,
155). As a result of these findings, dual COX/5-LOX inhibition has been suggested as an
effective prophylactic for lung cancer prevention with efficacy superseding that of COX or 5LOX inhibition alone (152). Together, this data demonstrates that COX inhibition can lead to a
shunt of AA metabolism toward the 5-LOX pathway, increasing production of the proinflammatory leukotrienes, which paradoxically enhances the inflammatory response (156).
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It is because of both of these undesirable effects of COX inhibition—the marked increase
in GI, renal, and cardiovascular side effects, as well as the shunting of AA through the proinflammatory 5-LOX pathway—that a new strategy in anti-inflammatory therapy has received
increasing attention in the last decade. The approach of dual COX and 5-LOX inhibition has
gained popularity because of the benefits of increased anti-inflammatory potential (compared to
classical anti-inflammatory drugs), as well as its demonstrated utility in blocking the
development and progression of cancer, in which both COX and 5-LOX products promote
cancer cell growth and survival (157). The dual-acting COX/5-LOX inhibitor that has been
most extensively studied in human clinical trials is licofelone, which has now successfully
passed Phase III clinical trials for osteoarthritis (158). Licofelone is a competitive inhibitor of
COX-1, COX-2, and 5-LOX enzymes and blocks formation of the pro-inflammatory
prostanoids and leukotrienes, while exhibiting improved GI tolerability compared to classical
NSAIDs such as naproxen (158, 159). Importantly, licofelone does not inhibit the 12-LOX or
15-LOX pathways, which synthesize the anti-inflammatory lipoxins (160) (Fig 1.7), as
previous generations of COX/LOX inhibitors have done (161). In addition, studies have shown
that treatment with licofelone is neuroprotective and improves behavioral outcome in
experimental models of Huntington’s disease (162, 163) and Parkinson’s disease (164). These
findings strongly suggest a potential neuroprotective role of licofelone treatment for other
neurological disorders.
In summary, experimental studies have found that COX and 5-LOX activity are both
detrimental to neurological outcome following SCI, and as a result it is thought that early
inhibition of these pathways should produce neuroprotective, beneficial effects in SCI.
However, to date no one has performed an extensive evaluation of the neuroprotective
properties of combined COX/5-LOX inhibition in an acute SCI model. Due to the recent
clinical advancement of dual COX/5-LOX inhibitors such as licofelone, which confer
neuroprotective benefits while exhibiting reduced side effects versus classical antiinflammatory drugs, a combined anti-inflammatory therapeutic approach for acute SCI may
therefore be a promising, novel therapeutic strategy.
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The Blood-Spinal Cord Barrier, P-glycoprotein, and Drug Resistance
The BSCB is the specialized system of capillary endothelial cells (ECs) and associated
structures that serves the important function of limiting the diffusion of substances between the
bloodstream and the spinal cord tissue (Fig. 1.8) (165, 166). The BSCB is similar to the bloodbrain barrier in its composition and functionality; however, there are key differences between
the two barrier systems, and as such the BSCB should be considered as distinct and separate
from the blood-brain barrier (166). One major distinction is that BSCB permeability is
moderately higher than that of its counterpart in the brain (166), probably because of relatively
lower expression of some tight junction and adherens junction proteins (167). Compared to the
blood-brain barrier, which has been a topic of frequent investigation, much remains to be
understood about BSCB properties under normal physiological or pathological conditions.
BSCB dysfunction following traumatic SCI has been extensively studied by assessing its
permeability to tracer molecules of various sizes. Intravascular delivery of low molecular
weight, fluorescently-labeled tracers, albumin-binding dyes, and contrast agents such as
gadolinium allows BSCB function to be assessed both histologically (168-170) and via
functional imaging techniques such as dynamic contrast-enhanced MRI (DCE-MRI) (171,
172). Using these techniques, it has become evident that an extended time course of BSCB
disruption takes place following trauma to the spinal cord. The mechanical force of injury
instantly compromises the integrity of the BSCB, and the secondary injury cascades appear to
contribute to a biphasic pattern of barrier breakdown over the days to weeks following SCI
(72). Roughly, peak disruption occurs early after injury, barrier properties are re-established by
2-4 weeks post-SCI (173-176), and a secondary disruption appears to occur in the weeks to
months following injury, with gradual restoration of barrier integrity (177). In addition, loss of
BSCB integrity is not limited to the initial site of injury, but spreads along the axis of the spinal
cord, likely due to factors such as oxidative stress that are associated with the spread of
secondary injury pathology (72, 173). Unfortunately, a cohesive understanding of the BSCB
response to SCI still remains elusive, in large part because of the literature’s considerable
variability in SCI models used, time windows analyzed, and size of vascular tracers utilized.
The changes in the BSCB underlying increased permeability after SCI include
compromised tight junctional integrity and increased vesicular transcellular transport (166,
178). These morphological changes are thought to be largely driven by the sustained release of
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Figure 1.8. The blood-spinal cord barrier. Illustration depicting the components of the
blood-spinal cord barrier (BSCB), the system of microvascular structures that tightly regulates
the flow of substances between the bloodstream and spinal cord. Capillaries within the spinal
cord are composed of endothelial cells (ECs) that lack cell membrane fenestrations and
pinocytic vacuoles, thus preventing transcellular diffusion of molecules (179). Instead, a variety
of active transporters are expressed on the luminal and adluminal EC membranes, allowing
selective transport of substances in and out of the cell. Tight junctions (TJ) between ECs
restrict the paracellular passage of substances. The basal lamina is composed of a layer of
extracellular matrix which is maintained by the other cells of the BSCB; it engulfs capillary
ECs as well as pericytes, which are cells that associate with the outer wall of the capillary.
Pericytes function as regulators of EC proliferation, migration, and differentiation (166). The
outermost component of the BSCB is comprised of the endfoot processes of astrocytes. These
processes secrete factors that maintain the barrier properties of the BSCB, but are not actually
involved in directly limiting molecular diffusion (166).
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pro-oxidative and pro-inflammatory factors by infiltrating immune cells (166, 180, 181). Active
transport at the BSCB is a sophisticated system allowing for the selective uptake and efflux by
ECs of a very large variety of endogenous and exogenous compounds, thus greatly influencing
BSCB permeability to specific substrates. Despite the central role that transporter systems play
in a large number of neurological diseases (182-188), SCI-associated changes in BSCB
selective transport has not been extensively studied. It has been shown that differential EC
expression of glucose-1 transporter (Glut-1) following injury is closely linked to blood vessel
permeability (189). Additionally, several studies have demonstrated acute and chronic changes
in expression of glutamate transporters (190-192) and the water transport channels, aquaporins
(193, 194) after SCI. However, there is one particular class of BSCB transporters that is known
to play a significant role in several CNS pathologies, but which has not yet been characterized
in SCI—the ATP-binding cassette (ABC) transporters.

P-glycoprotein: Multidrug Efflux Transporter
The ABC transporter superfamily is among the largest and oldest classes of proteins
known. Members of this family of transmembrane proteins share a conserved domain structure,
each possessing two nucleotide-binding domains (the active sites for ATP hydrolysis), and two
substrate-binding domains (195, 196). All ABC transporters share a common function of
translocation of substrates from one side of the lipid bilayer to the other, though the incredible
variability in substrate recognition and the diverse expression patterns of these proteins give
them an extraordinary range of biological functions (182). ABC transporters are evolutionarily
ancient; expressed in bacteria and archaebacteria, they serve a vital function in the active
import of nutrients, peptides, ions, and vitamins (195). In mammals, this family of transporters
functions in the transport of both endogenous and xenobiotic substrates between different
biological compartments, and are particularly important for the function of blood-tissue barriers
(197). Many ABC transporter family members are expressed at the blood-CNS barriers where
they have important roles in maintaining homeostasis in the brain and spinal cord, and are also
implicated in various disease pathologies (182, 198).
P-glycoprotein (Pgp, ABCB1/MDR1) is one of the most extensively characterized ABC
transporters. Pgp is a 170-kDa, 12-transmembrane glycoprotein expressed on cell membranes
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of a variety of cell and tissue types. Its fundamental mechanism of action is to extrude
substrates against their concentration gradients from within the cell membrane to the
extracellular space, using the energy from ATP hydrolysis. The crystal structure of Pgp was
recently solved (199), revealing the structural basis for the transporter’s substrate binding and
efflux activity (Fig. 1.9). Pgp can exist in two fundamental conformations: 1) an “inward facing
conformation”, in which a large, open cytoplasmic pocket allows the binding of two ATP
molecules from the cytosol and one molecule of substrate from the inner leaflet of the cell
membrane; 2) an “outward facing conformation”, assumed via an ATP hydrolysis-powered
conformational shift, which exposes the substrate-binding domain to the extracellular space,
thus releasing the substrate (199).
Pgp is expressed in several tissues of the body, where its efflux transport activity allows it
to serve a variety of functions. In the intestinal epithelium, Pgp regulates drug absorption (200);
in hepatocytes, it regulates excretion of bile salts (201); it regulates renal clearance of drugs in
the kidney (202). Pgp is expressed on the luminal membrane of capillary ECs of the bloodbrain- and blood-spinal cord barriers, where it limits the blood-to-CNS penetration of various
substances (203). Pgp is also expressed in the blood-testis barrier (204), blood-placental barrier
(205), and the retinal pigment epithelium (206). The ability of one single transporter protein to
perform such a wide range of biological actions is due to a remarkably broad substrate
specificity (203). Pgp possesses a promiscuous binding pocket, with an upper half rich in
hydrophobic and aromatic residues, and a lower half with charged and polar residues; it is this
domain that enables Pgp to bind such hundreds of compounds with dramatically different
structures and sizes (199). Pgp is able to bind several types of endogenous substrates, e.g., bile
salts (201), endogenous opioid peptides (207), oxidized lipids (208), somatostatin and
substance P (209), endogenous steroid hormones (210), beta amyloid peptide (211), and
platelet-activating factor (212). Furthermore, Pgp also recognizes a staggering variety of
xenobiotic substrates, including the therapeutic drugs colchicine, taxol, paclitaxel, phenytoin,
rapamycin, ivermectin, glucocorticoids, cyclosporin A, dexamethasone, digoxin, and HIV
protease inhibitors, to name a few (203). This substrate promiscuity equips Pgp with the ability
to serve a highly protective “gatekeeper” function at the blood-CNS barriers, limiting the CNS
entry of a multitude of potentially cytotoxic compounds (213). This protective function,
however, is a double-edged sword—it is precisely because of Pgp’s strict “gatekeeping”
activity that it is now recognized as a major obstacle to therapeutic drug delivery (214).
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Figure 1.9. Mechanism of P-glycoprotein-mediated active transport. Cartoon depicting the
conformational change of P-glycoprotein (Pgp) which occurs during efflux transport of
substrates. (a) Pgp is a 12-transmembrane glycoprotein with two large intracellular domains. In
the inward-facing conformation of Pgp, its two structurally similar halves form a large internal
pocket which allows access to the cytoplasm and the inner leaflet of the membrane. Substrate
(blue) originating from the extracellular space diffuses into the lipid membrane and enters
directly from the inner leaflet into Pgp’s substrate binding pocket (green). Substrate binding
stimulates binding of one ATP molecule to each of Pgp’s two nucleotide-binding domains. (b)
(View rotated 90°) ATPase activity is thought to cause a dimerization of the nucleotide-binding
domains, thus shifting Pgp to the outward facing conformation, and releasing bound substrate
into the extracellular space. It is through this drug efflux transport activity that Pgp expressed at
the BSCB limits drug penetration from bloodstream to spinal cord tissue. Illustration is based
on crystal structure of Pgp from Aller et al. (199).
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Pgp is notorious for the phenomenon of multidrug resistance (MDR), for which it received
its original genetic nomenclature, MDR1 (215). Pgp was first described in colchicine-resistant
tumor cells (216), and it has since become well established that overexpression of Pgp causes
simultaneous cross-resistance to chemotherapeutics in multiple types of cancer (217, 218). As a
result, a major goal of current oncology research is overcoming Pgp-mediated MDR in order to
improve the efficacy of cancer therapy (219, 220). More recently, it has become recognized that
pathological Pgp overexpression also presents a significant impediment to the therapeutic
treatment of CNS diseases4. Several preclinical studies have detected altered brain Pgp
expression in models of epilepsy (221, 222), cerebral ischemia (223), ALS (224, 225), and
Alzheimer’s disease (226). In addition, clinical studies have shown altered brain Pgp
expression and activity in patients with Parkinson’s disease (227-229), Alzheimer’s disease
(230), seizure (231), schizophrenia (232), and HIV encephalitis (233). In neurological diseases
where Pgp is overexpressed at the blood-brain barrier, delivery of therapeutic drugs to the brain
can be dramatically impaired. It is therefore evident that Pgp-mediated pharmacoresistance is a
barrier to the effective treatment of not only cancer, but multiple neurological diseases, and it
must be overcome in order to improve treatment of these disorders.
There are a variety of pharmacological Pgp inhibitors available; however, the use of these
inhibitors to combat Pgp-mediated pharmacoresistance has been historically difficult due to
low tolerability, pharmacokinetic interactions with chemotherapeutics, and cross-interactions
with other ABC transporters (220). Recently, some have suggested that rather than directly
inhibiting Pgp activity, modulating Pgp expression by targeting the intracellular mechanisms
that drive its up-regulation may be a more effective strategy to overcome drug resistance (187,
214, 234).

Whether it is disease-associated pathophysiological mechanisms, or the

pharmacological compounds used to treat the disease itself, which drives Pgp overexpression in
neurological diseases largely remains unclear. According to in vitro studies in brain capillaries,
ABCB1 gene expression in the CNS can be up-regulated by pro-inflammatory mediators (e.g.,
TNF-α, endothelin-1, and PGE2), oxidative stress, or nuclear receptors (198, 214). However, to
date relatively few studies have examined the mechanisms of Pgp regulation in clinically
relevant animal models. Some important insight can be gained from the work of Potschka and

4

In this dissertation, the term “pathological Pgp overexpression” will be used to indicate Pgp upregulation and/or overexpression driven by pathological, disease-associated mechanisms.
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colleagues, who have characterized the molecular mechanisms responsible for Pgp
overexpression in drug-resistant epilepsy (221). Through their studies, they have formulated a
model describing how seizure activity induces Pgp overexpression via a glutamate-signaling
cascade involving COX-2 and the prostaglandin E receptor 1 (EP1) (Fig. 1.10) (222, 235).
Notably, Potschka et al. have demonstrated that treatment with the COX-2 inhibitor celecoxib
counteracted seizure-induced Pgp overexpression and enhanced therapeutic brain delivery of
the anti-epileptic drug phenytoin in rats (236). These promising findings may lead the way
toward a simple strategy to overcome resistance to therapeutic drug delivery for epileptic
patients. Such a strategy could also have potential for the attenuation of drug resistance in CNS
pathologies with shared pathological characteristics such as glutamate toxicity or
neuroinflammation.
Interestingly, Milane et al. have recently demonstrated that mice expressing mutant
SOD1—a commonly used model of the neurodegenerative disease ALS—overexpress Pgp in
the brain and exhibit decreased brain concentrations of systemically administered riluzole
(224). Though this group has not yet isolated the pathway(s) underlying this phenomenon, it is
tempting to speculate that signaling through the glutamate/COX-2/PGE2 axis is a likely
candidate, since glutamate excitotoxicity is a major component of ALS pathology (237). In
addition, several groups have shown that COX inhibition is also effective in attenuating Pgpmediated MDR in various cancer cell lines (238-241), suggesting that COX-mediated proinflammatory signaling may even be a universal pathway by which Pgp becomes pathologically
overexpressed.

A Potential Role for P-glycoprotein in Spinal Cord Injury
In 2000, Bernards and colleagues (242) were the first to acknowledge the potential role of
Pgp in limiting therapeutic delivery of methylprednisolone to the spinal cord. Systemic, highdose MPSS is fraught with side effects (e.g., pneumonia and sepsis) that can seriously threaten
the health of an already critical acute SCI patient, which is one of the major reasons why MPSS
use for acute SCI has dramatically declined (40, 95). Koszdin et al. demonstrated that in the
pig, spinal cord bioavailability of MPSS is dramatically lower following i.v. administration
compared to intrathecal injection, an observation that they speculated was due to Pgp efflux
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Figure 1.10. Model of P-glycoprotein transcriptional activation by seizure activity in the
brain. Seizure activity in the brain releases glutamate into the extracellular space, activating
NMDA receptors on endothelial cells (222). NMDA receptor activation allows Ca2+ influx into
the cell, triggering PLA2 activation and AA release (105). COX-2 oxidative metabolism of AA
yields production of the pro-inflammatory prostaglandin PGE2, which in turn activates the
downstream endothelial EP1 receptor (222, 235, 244). Potschka (2010) suggests that the
transcription factor nuclear factor-kappaB (NF-kB) is a likely transcriptional activator of
ABCB1 in this scenario, based on evidence that COX-2 signaling in the brain can induce NFkB activation (245, 246). Figure from: Heidrun Potschka, Targeting regulation of ABC efflux
transporters in brain diseases: A novel therapeutic approach, Pharmacology & Therapeutics,
Volume 125, Issue 1, January 2010, Pages 118-127. Reprinted with permission (234).
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activity (242). Subsequently, Bernards (243) found that MPSS bioavailability in the pig spinal
cord could be increased by treating with the Pgp inhibitor cyclosporin-A. The authors proposed
that inhibiting Pgp activity could reduce the therapeutic dose of MPSS for SCI patients and
consequently the harmful peripheral side effects of high-dose glucocorticoid treatment (242,
243). These are significant findings, as they are the first (and only) studies to propose that Pgp
might decrease the efficacy of therapeutic intervention for SCI. Nevertheless, whether Pgp
becomes pathologically overexpressed in the injured spinal cord, and whether SCI patients
become resistant to treatment, are topics that have not yet been investigated. Braughler and Hall
performed a series of studies in the early 1980s in which they analyzed MPSS levels in injured
cat spinal cord (247-250). However, most of these studies only reported measurements taken
within hours of a single large bolus; the authors did not perform longitudinal assessments of
spinal cord MPSS levels in a 24-hour continuous, high-dose treatment paradigm such as that
utilized in the National Acute Spinal Cord Injury Study (NASCIS) II (94). To date, no group
has yet performed an experimental study examining spinal cord resistance to systemic drug
treatment following SCI.
Development of drug resistance in the injured spinal cord could have potential to impact
the therapeutic efficacy of drugs other than MPSS as well. Significantly, several drugs that
have been evaluated as potential SCI interventions, in addition to drugs that are used clinically
for the treatment of pain in SCI patients, are known Pgp substrates, and thus susceptible to Pgpmediated drug resistance (TABLE 1.1). This list includes riluzole, a drug that is currently being
evaluated in a clinical trial as an acute SCI intervention (87). Because Milane and colleagues
have recently shown that Pgp-mediated drug resistance hampers riluzole treatment in ALS
(224), it is reasonable to speculate that shared pathological mechanisms (i.e., glutamate
excitotoxicity, inflammation, and oxidative stress) could underlie a similar phenomenon in SCI.
Pgp-mediated drug resistance in SCI patients would have dramatic implications, with the
capacity to impact not only the current riluzole clinical trial, but the efficacy of other
neuroprotective drugs for SCI, as well as the treatment of patients with chronic SCI pain and
spasticity. Despite decades of intensive research, there are no effective therapies that can
improve functional recovery in SCI patients. Thus, the prospect of multidrug resistance
following injury to the spinal cord is a potentially major obstacle to treatment that must be
investigated.
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Drug

Preclinical Evidence of
Therapeutic Benefits for SCI

Clinical Trials and/or Clinical Use

Evidence that P-glycoprotein
Activity Affects Therapeutic Efficacy
and/or CNS Disposition

NASCIS I: No benefit of MPSS over naloxone
or placebo (Bracken et al., 1985)

Methylprednisolone
sodium succinate
(MPSS)

MPSS exhibits neuroprotective
effects in preclinical models
of acute SCI (Young and
Bracken, 1992; Tator, 1996,
1998; Zeidman et al., 1996;
Amar and Levy, 1999)

NASCIS II: Post-hoc analysis detected modest
neurological improvement in a subset of
patients receiving MPSS 3-8 h post-injury
(Bracken et al., 1990, 1992); subsequently
criticized due to questionable statistical
analysis and lack of clinically significant
functional outcome measures (Tator, 2006;
Hurlbert and Hamilton, 2008)
NASCIS III: No significant difference in motor
recovery or FIM with 24-h or 48-h MPSS
treatment (Bracken et al., 1998)
The clinical use of MPSS for acute SCI has
greatly declined, as the evidence suggesting
harmful medical side effects of high-dose
MPSS is more consistent than evidence
suggesting its therapeutic benefit (Hawryluk
et al., 2008)

Minocycline

Neuroprotective effects for
acute SCI (Lee et al., 2003;
Stirling et al., 2004; Festoff
et al., 2006; Yune et al.,
2007)
Attenuated neuropathic pain in
SCI rats (Marchand et al.,
2009)

Phase I/II trial, Minocycline and Perfusion
Pressure Augmentation in Acute Spinal
Cord Injury (NCT00559494) (University of
Calgary, 2007- [cited 2012 Mar 13])
Current status: Currently recruiting

Methylprednisolone is a Pgp substrate
(Saitoh et al., 1998)
Intravascular delivery of MPSS results
in lower spinal cord bioavailability
than intrathecal delivery in pigs; Pgp
knockout mice have increased spinal
cord penetration of i.p. MPSS
(Koszdin et al., 2000)
Pgp inhibition with cyclosporin-A
increased CSF levels of i.v.-delivered
MPSS in the pig (Bernards, 2006)

Minocycline is a substrate and inhibitor
of Pgp (Milane et al., 2007)
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Riluzole

Neuroprotective effects for
preclinical models of acute
SCI (Fehlings and Agrawal,
1995; Schwartz and Fehlings,
2001, 2002; Wang et al.,
2004)
Reversed neuropathic pain
behavior in SCI rats (Hama
and Sagen, 2010)

Phase I trial, Safety of Riluzole in Patients
with Acute Spinal Cord Injury
(NCT00876889) (The Methodist Hospital
System, 2009- [cited 2012 Feb 29])
Current status: Ongoing, but not recruiting
participants

Riluzole is a Pgp substrate (Milane et
al., 2007)
Pgp overexpression in the mSOD1
mouse brain decreases brain
concentrations of i.p.-delivered
riluzole (Milane et al., 2010)

Attenuated spastic muscle
activity in rats (Kitzman,
2009)

Nimodipine

Improved spinal cord axonal
function and blood flow in
preclinical SCI models
(Fehlings et al., 1989)

Lamotrigine

Amitriptyline

(Continued from previous page)

Phase III RCT (France) (Petitjean et al., 1998):
Compared to MPSS and placebo, no
difference detected between groups (study
likely underpowered)
Blind RCT (France) (Pointillart et al., 2000):
Compared to MPSS, no neurological
differences detected between groups

Nimodipine is a Pgp substrate (Zhang
et al., 2003)

-

Lamotrigine is used clinically as a pain
treatment in SCI patients (Baastrup and
Finnerup, 2008; Wiffen et al., 2011)

Lamotrigine is a Pgp substrate
(Potschka et al., 2002; Luna-Tortos
et al., 2008)

-

Amytriptyline is used clinically as a pain
treatment in SCI patients (Baastrup and
Finnerup, 2008)

Amitriptyline is a Pgp substrate (Uhr
et al., 2000)
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(On previous pages)
TABLE 1.1. Several drugs that have been evaluated for the treatment of spinal cord injury
are substrates of P-glycoprotein. Abbreviations: FIM, functional independence measure;
NASCIS, North American Spinal Cord Injury Study; RCT, randomized controlled trial.
References are listed in bibliography (19, 40, 82, 85, 87, 93, 94, 224, 225, 242, 243, 251-279).
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CHAPTER 2
Materials & Methods
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Animals and Surgeries
All applicable institutional and governmental regulations concerning the ethical use of
animals were followed during the course of this research. This study was carried out in strict
accordance with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The animal protocol used in this study was
approved by The University of Texas Health Science Center Institute for Animal Care and Use
Committee. All efforts were made to minimize suffering and distress.

Animals
Adult female Sprague-Dawley rats weighing 250-300 g were used for Pgp immunoblot
studies (See Chapter 3). Adult male Sprague-Dawley rats weighing 250-300 g were used for all
remaining studies. All wild-type Sprague-Dawley rats were purchased from Harlan
Laboratories (Houston, Texas).
Transgenic mice: Adult female mdr1a/b constitutive double knockout mice (FVB.129P2Abcb1atm1BorAbcb1btm1Bor N12) and wild-type mice (FVB.129P2) were purchased from
Taconic (Germantown, New York).
Transgenic rats: Four-week-old male mdr1a knockout rats (SD-Abcb1atm1sage) were
purchased from SAGE Labs (St. Louis, Missouri).

Spinal Cord Injury Surgery
All surgical procedures were performed on animals that were deeply anesthetized with a
ketamine cocktail [ketamine (80 mg/kg), xylazine (10 mg/kg), acepromazine (0.75 mg/kg)] at a
dose of 0.01 ml/kg body weight. Spinal cord injury surgeries were performed as previously
described (48). Incisions were made on the animals’ dorsal skin and overlying muscles and the
vertebral column was exposed. A laminectomy was performed at thoracic level 10 (T10) and
the vertebral column was stabilized using forceps that grasp the ventral surface of the lateral
spinous processes at vertebral levels T9 and T11. Using an Infinite Horizon Spinal Impactor
Device (Precision Systems and Instrumentation, LLC, Fairfax Station, VA), moderate
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contusion/compression injuries were delivered to the T10 spinal cord using 150 kdynes of force
with a 1 s dwell. Immediately following injury, the overlying muscles were sutured and the
skin was securely closed using stainless steel wound clips.

Post-Operative Animal Care
Beginning on the day of surgery, animals received Baytril injections (2.5 mg/kg s.c., b.i.d.)
for 10 days to prevent post-operative infections. Beginning on post-operative day one (DPI 1),
animals’ bladders were manually expressed 2-3 times daily until control of bladder function
was completely regained. To minimize pain, animals received buprenorphine injections (0.02
mg/kg s.c., b.i.d.) for one week following surgery. To prevent dehydration, animals received
0.9% saline (3-5 ml s.c.) daily for five days following surgery.

Exclusion Criteria
To maximize reproducibility of results, spinal cord-injured animals were excluded from
this study if the force of impact to the spinal cord fell outside a range between 150 and 175
kdynes, a criterion that is consistent with previous studies (48). Additionally, injured animals
exhibiting an open field locomotor score greater than two on DPI 1 were also excluded.

Drug Treatment
Licofelone (Santa Cruz Biotechnology) was suspended in 0.5% carboxymethylcellulose in
0.9% saline (vehicle) to a final concentration of 50 mg/ml, and administered to animals via oral
gavage (100 mg/kg). Riluzole (Sigma-Aldrich) was dissolved in ethanol to a concentration of
50 mg/ml, and this stock solution was stored at -20°C for up to 3 months. Riluzole stock
solution was diluted with vehicle to a final working concentration of 2.5 mg/ml, and
administered to animals (8 mg/kg i.p.). All working drug solutions were prepared fresh daily.

Behavioral Assessments
Open Field Locomotor Testing
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Animals’ locomotor function was examined using the Basso, Beattie and Bresnahan (BBB)
open field locomotor scale (280). This test is a sensitive measure of multiple aspects of
hindlimb function that is commonly used to assess locomotor recovery following SCI. Animals
were allowed to acclimate to the open field testing environment (a 40”-diameter plastic wading
pool) in groups of four for 10 minutes daily until they ceased to exhibit fear-associated
behavior (e.g., crouching, cowering away from the examiner, vocalizing) and displayed signs
of comfort (e.g., grooming, accepting treats from the examiner’s hand, exhibiting continuous
locomotion and exploration). No further acclimation to the testing environment was performed.
Baseline testing began once the examiner felt confident that all animals were comfortable in the
testing environment. Animals were placed into the open field and allowed to freely explore for
a period of 4 minutes. Two independent observers scored each hindlimb using a scoring sheet
(Fig. 2.1). Hindlimb BBB scores were rated using the 21-point BBB open field rating scale
(APPENDIX B), and inter-rater reliability was confirmed. For each animal, the locomotor scores
for both hindpaws were averaged to produce one score per test session. Animals were tested
once prior to receiving SCI surgery (baseline measurement) and again on post-operative days 1,
2, 3, 5, 7, 10, 14, 21, 28, 35, and 42. BBB data did not pass the Shapiro-Wilk normality test (p
< 0.05) and therefore nonparametric statistical analysis was chosen to analyze the effects of
treatment on BBB scores. For each individual time point, BBB scores were analyzed using a
nonparametric Kruskal-Wallis test followed by a Dunn’s post-test.

Photobeam Activity System
A photobeam activity system (PAS) (San Diego Instruments, San Diego, California) was
employed to study multiple measures of locomotion and overall activity. PAS chambers were
made up of 16” x 16” x 16” Plexiglas enclosures, equipped with interlocking infrared
photobeam emitters and receptors spaced at regular intervals. Animal movement (“activity
data”) in the PAS chamber is monitored by infrared light beam breaks. The PAS stores a
sequential list of data, recording when each beam was broken, including X-Y location, serial
number, and timestamp, on the computer analyzer. The analyzer allows the viewer to develop a
dynamic view of several aspects of spontaneous activity, including: total activity, total
ambulatory activity, total fine movement, time at rest, number of rearing events and the amount
of time spent rearing.
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Figure 2.1. BBB scoring sheet. Hindlimb locomotor function was rated systematically using
this scoring sheet. Both hindlimbs were rated and assigned an individual BBB score using the
BBB locomotor rating scale (See APPENDIX B). Abbreviations: DPO, days post-operation;
plantar Pl., plantar placement of the paw; toe clear., toe clearance during swing of the
hindlimb; W/O supp., without weight support; W supp., with weight support. Scoring sheet
obtained with permission from the authors of: A Sensitive and Reliable Locomotor Rating
Scale for Open Field Testing in Rats, D. Michele Basso, Michael S. Beattie, Jacqueline C.
Bresnahan, Journal of Neurotrauma. February 1995: 1-21. (280)
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To avoid behavior specific to a novel environment, animals were allowed to acclimate to
the PAS chambers for a 15-minute period on the day before baseline testing. During testing,
animals were individually placed in PAS chambers, and the tester immediately left the room.
PAS testing was performed in a dark environment during the dark cycle (in the evening), to
encourage maximum animal activity. Each PAS chamber was cleaned with Cavicide medical
disinfectant (Kerr) between tests in order to eliminate olfactory cues. PAS testing was
performed once prior to receiving SCI surgery (“Baseline”) and again on post-operative days 7,
14, 21, 28, 35, and 42. All session activity was recorded over a 20-minute period and exported
in tabular format. All PAS data was analyzed using two-way repeated measures ANOVA,
followed by a Bonferroni post-test. The following parameters were assessed:
Distance, speed, and rest time: Distance of movement (cm), average movement speed
(cm/s), and time spent at rest (s) over the testing period were calculated. A “rest” period
was defined as a period of 2.0 seconds or more with no beam breaks.
Fine movement and ambulatory movement: The PAS software differentiated between
ambulatory movement (continual locomotion over several beam breaks) and fine
movement (movement without displacement, which indicates grooming, head movements,
and other stereotypical behaviors). Ambulatory movement was defined as the distance
(cm) of movement over the testing period. Fine movement was defined as the total distance
(cm) of beam breaks attributed to small movements confined to an area of ≤2 x 2 beams
following a minimum resting delay of 0.5 s (281).
Rearing events and rearing time: Number of rearing events was determined automatically
by the PAS by calculating the number of events breaking upper-level photobeams. We also
extrapolated the cumulative time spent by animals in the rearing position, which has been
suggested to be more indicative of a rat’s rearing ability/endurance (281).

Tissue Processing
All animals were deeply anesthetized with Beuthanasia (390 mg/ml pentobarbital sodium,
50 mg/ml phenytoin sodium) (75 mg/kg i.p.). For all of the following experiments (except
microarray and qRT-PCR studies, for which perfusion was not performed), animals were
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transcardially perfused with ice-cold saline. Tissue was then harvested, immediately snapfrozen on either dry ice or liquid nitrogen, and stored at -80°C.

Microarray Analysis
Spinal cord tissue from T10 was harvested immediately following sacrifice and snapfrozen in liquid nitrogen. Total RNA from spinal cord tissue was isolated using the mirVana
miRNA Isolation Kit (Ambion). RNA was applied to RatRef 12 whole genome arrays
(Illumina). Arrays were hybridized, washed and scanned by The University of Texas Medical
School Microarray Core Laboratory. Data was analyzed with Illumina BeadStudio software.
Group data was compared by Student’s t test. All microarray experiments were performed in
collaboration with Dr. Meredith Moore in The University of Texas Medical School,
Department of Neurosurgery.

Quantitative Real-Time PCR
DNase-treated total RNA, isolated as above, was reverse transcribed using the High
Capacity Reverse transcriptase kit (Ambion). The cDNA was amplified in the presence of gene
specific primers and fluorescent probes with TaqMan Fast Universal reagents (Applied
Biosystems, Inc.). abcb1b (Rn01529260_m1) expression was examined and the housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase (gapdh, Rn01775763_g1) was used as an
internal control. Expression levels of abcb1b were normalized to gapdh expression levels. Data
collection and Ct analysis was performed with a StepOne Plus real-time thermocycler and
associated software (Applied Biosystems, Inc.). Data was analyzed by one-way ANOVA,
followed by the Student-Newman-Keuls post test. All qRT-PCR experiments were performed
in collaboration with Dr. Meredith Moore in The University of Texas Medical School,
Department of Neurosurgery.

Immunohistochemistry
For all immunohistochemical procedures, frozen spinal cord tissue was cryosectioned in
the coronal plane to a thickness of 10 µm. Sections were directly mounted to gelatinized slides,
51

air dried, and post-fixed in 4% paraformaldehyde at 4°C for 15 minutes, then in 1:2 acetic acid:
methanol solution at -20°C for 10 minutes.
DAB Staining
Following post-fixation, sections were washed 3X for 10 minutes in tris-buffered saline
(TBS, 10 mM Tris, pH 8.0; 150 mM NaCl), then incubated for 30 minutes in H2O2 buffer
(0.6% H2O2 in TBS) at room temperature. Sections were washed 2X for 10 minutes in TBS,
then blocked with blocking-permeabilization buffer (BPB) (5% normal horse serum in TBS,
0.1% Triton-X-100) for 1 hour. Sections were then incubated in BPB containing primary
antibody (1:250 mouse monoclonal anti-P-glycoprotein C219, Calbiochem) for 2 hours at room
temperature, then washed 3X for 10 minutes in TBS. Samples were incubated in BPB
containing 1:200 biotinylated anti-mouse IgG antibody (Vector Labs) for 3 hours at room
temperature, then washed 3X for 10 minutes in TBS. Samples were processed with the
Vectastain ABC Kit (Vector Labs), and immunoreactivity was then visualized by incubation in
diaminobenzidine (DAB) solution. Samples were counter-stained with hematoxylin to visualize
nuclei. Sections were dehydrated, mounted, and coverslipped with Fluoromount-G (Fisher).
Immunofluorescence
Following post-fixation, sections were washed 3X for 10 minutes in TBS, then nonspecific IgG was blocked with 5% normal serum for 1 hour. Sections were then incubated in
TBS containing primary antibodies against P-glycoprotein (1:250 mouse monoclonal anti-Pglycoprotein C219, Calbiochem), GFAP (1:1000 rabbit polyclonal, Dako), von Willebrand
factor (1:1500 rabbit polyclonal, Sigma-Aldrich), ED2/CD163 (1:750 mouse monoclonal,
Serotec), or 5-lipoxygenase (1:1000 goat polyclonal, Novus Biologicals) overnight at 4ºC on a
rotating shaker. Sections were washed 3X for 10 minutes in TBS, and incubated with Alexa
Fluor conjugated secondary antibodies (1:500, Invitrogen) for 3 hours. Sections were washed,
dried, and coverslipped with Fluoromount-G.
For all immunohistochemical experiments, labeled sections were imaged using an
Olympus BX61 wide-field upright microscope with fluorescence optics with a SPOT Flex
microscope digital camera. Every sixth section in series was chosen for histological analysis.
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Immunoblotting
Tissue samples were homogenized in Tissue Protein Extraction Reagent (T-PER, Thermo
Scientific) containing protease inhibitor cocktail tablets (Complete Mini, Roche) using an
electric tissue homogenizer. Lysate was centrifuged at 14,000 x g for 30 minutes at 4°C, and
the supernatant was removed and stored at -80°C. Protein concentration of samples was
determined using a Pierce BCA Protein Assay (Thermo Scientific), using bovine serum
albumin as the standard. Approximately 50-100 µg of tissue lysate was resolved onto
polyacrylamide Tris-HEPES-SDS gels (Thermo Scientific) under reducing conditions. HeLa
cell lysate (Santa Cruz Biotechnology) was used as a positive control for immunodetection of
Pgp. Equality of loading was confirmed by Coomassie Brilliant Blue staining of gels. Proteins
were transferred to Immobilon-FL PVDF membranes (Millipore) using a semi-dry transfer
apparatus. For Pgp detection, transfer buffer was prepared without methanol to optimize large
protein transfer efficiency. Following transfer, non-specific antigens were blocked by
incubation in Odyssey Blocking Buffer (LI-COR Biosciences) for 1 hour at 4°C. Blots were
then incubated in blocking buffer containing primary antibodies at the following
concentrations:
P-glycoprotein (C219): 1:250 mouse monoclonal, Calbiochem (#513710)
Mdr-1 (D-11): 1:100 goat polyclonal, Santa Cruz Biotechnology (#sc-55510)
Beta-actin: 1:20,000 mouse monoclonal, Abcam (#ab6276)
1:20,000 rabbit polyclonal, Abcam (#ab8227)
Cyclooxygenase-1: 1:200 mouse monoclonal, Cayman Chemical (#160110)
Cyclooxygenase-2: 1:200 rabbit polyclonal, Cayman Chemical (#160126)
5-Lipoxygenase: 1:250 mouse monoclonal, BD Biosciences (#610694)
Membranes were incubated in primary antibodies at room temperature for 1 hour, or at 4°C
overnight. Blots were then washed in TBS containing 0.1% Tween-20 (TBST), 5X for 5
minutes, then incubated in blocking buffer containing species-specific IRDye-conjugated
infrared secondary antibodies (1:500, LI-COR Biosciences). Blots were imaged using the
Odyssey Infrared Imaging System (LI-COR Biosciences). This detection method has the
advantages of high sensitivity of detection and increased signal-to-noise ratio over
chemiluminescence, as well as capability to detect two different antigens on the same blot
simultaneously. Band intensity was quantified using Odyssey software (LI-COR), and data was
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analyzed using one-way ANOVA followed by the Student-Newman-Keuls post test (when
more than two groups were compared), or by Student’s t test (when two groups were
compared).

Enzyme-Linked Immunosorbent Assay
A 1.5-cm piece of spinal cord tissue spanning the epicenter of injury was harvested, snapfrozen in liquid nitrogen, and stored at -80°C. Homogenization buffer (0.1 M phosphate, pH
7.4, 1 mM EDTA, 10 µM indomethacin; 1 ml per 100 mg tissue) was added and tissue was
homogenized on ice using a Polytron homogenizer. For detection of PGE2 only, a purification
step was performed using a PGE2 Affinity Sorbent Kit (Cayman Chemical Co., Ann Arbor,
MI). PGE2, LTB4, and CysLT levels were quantified using the appropriate EIA kits (Cayman
Chemical). All samples were prepared and analyzed in triplicate, and absorbance at 405 nm
was read in a Model 680 Microplate Reader (Bio-Rad). Standard curves were generated and
sample concentrations were determined using Cayman EIA data analysis worksheets
(www.caymanchem.com/analysis/eia). Data was analyzed by one-way ANOVA followed by
the Student-Newman-Keuls post test. ELISA experiments for chronic spinal cord samples were
performed in collaboration with Dr. Henry Strobel in The University of Texas Medical School,
Department of Biochemistry and Molecular Biology.

Metabolomic Profiling
Six hours following the final drug treatment, animals were sacrificed and tissue was
immediately harvested and snap-frozen in liquid nitrogen. A 10-mm segment of spinal cord
tissue encompassing the lesion site was utilized for metabolomic analysis. Unbiased
metabolomic profiling of spinal cord samples from uninjured and chronic SCI rats was
performed using liquid-/gas chromatography coupled to mass spectrometry (LC/GC-MS) as
previously described (282). At the time of publication, the metabolomics platform is capable of
detecting approximately 2,400 named metabolites, of which 257 metabolites were detected
within this study. A data normalization step was performed to correct variation resulting from
instrument inter-day tuning differences. Each compound was corrected in run-day blocks by
registering the medians to equal one (1.00) and normalizing each data point proportionately
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(termed the “block correction”). Following log2 transformation and imputation with minimum
observed values for each compound, Welch’s two-sample t test was used to identify
biochemicals that differed significantly between two groups. Lists of biochemicals that
achieved statistical significance (p ≤ 0.05), as well as those approaching significance (0.05 < p
< 0.10), are given in TABLES 4.1 & 4.2. An estimate of the false discovery rate (Q value) was
calculated to take into account the multiple comparisons that normally occur in metabolomicbased studies; as Q values were reasonable for p ≤ 0.05, no Q value cutoff was established for
this study. Outliers were defined as 1.5*(inter-quartile range) and removed from analyses. Heat
maps of metabolomics data (Figs. 4.7, 4.8, & 4.10a) were generated using the open-source
software package MultiExperiment Viewer version 4.7.3, part of the TM4 Microarray Software
Suite (Dana-Farber Cancer Institute, Boston) (283). Scaled, imputed, log2-transformed data
was used to generate heat maps and to perform clustering analysis. Pearson distances (1-r,
where r is the Pearson correlation coefficient) were used as the pairwise distance between
individual replicates for hierarchical clustering by biochemical.

High-Performance Liquid Chromatography
All reagents used for HPLC experiments were HPLC-grade (ChromaSolv, Sigma-Aldrich).
Riluzole stock solutions (1 mM) were prepared by dissolving riluzole in 1:1 H2O:CH3OH.
Stock solutions were stored for up to 3 months at -20°C. Serial dilutions of riluzole stock
solutions were prepared and known amounts of riluzole were injected onto the HPLC system in
the following quantities: 0.05, 0.1, 0.5, 1, and 2 nmoles. A calibration curve was generated
using Empower 3 Chromatography Data Software program (Waters) (Fig. 2.2). The R2 value
obtained for the riluzole calibration curve was 0.998.
Tissue Extraction of Riluzole
Animals were dosed with riluzole, and sacrificed 2 hours later. Animals were transcardially
perfused with ice-cold saline, and spinal cords were immediately harvested, rinsed, and snapfrozen on dry ice.
Spinal cord riluzole extraction: A 1.5-cm segment of spinal cord tissue centered around
the lesion site was homogenized, and riluzole was extracted with ethyl acetate as
previously described (284). Samples were re-suspended in 100 µl mobile phase buffer.
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Figure 2.2. HPLC chromatograph and calibration curve for riluzole. Known amounts of
riluzole were injected onto the HPLC system, generating a series of chromatographic peaks that
were integrated to produce a calibration curve (inset). AU, absorbance units.
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Plasma riluzole extraction: Whole blood was obtained by cardiac puncture immediately
following sacrifice, and plasma was recovered by centrifugation at 1,300 x g for 10 min at
4°C. Plasma samples were diluted 1:2 in 0.01 M phosphate buffer, pH 7.4 and riluzole was
recovered via solid-phase extraction as previously described (285). Samples were resuspended in 75 µl mobile phase buffer and filtered through Millex-GV4 0.22 µM
membranes (Millipore) before injection onto the HPLC system.
High-Performance Liquid Chromatography Separation and Analysis
The HPLC system consisted of a Waters 515 HPLC pump, a Waters 996 Photodiode Array
Detector, and a CI-10B integrator (LDC Analytical). Separation was achieved through a
ZORBAX Extend-C18 column (4.6 x 150 mm) (Agilent Technologies) with a 20-mm ODS
pre-column (Custom LC, Inc.). The mobile phase consisted of 68% CH3OH and 32% of [1%
TEA in H2O, adjusted to pH 3.2 with H3PO4]. The flow was isocratic with a constant flow rate
of 0.5 ml/min. The sample injection volume was 100 µl (spinal cord samples) or 75 µl (plasma
samples). Absorbance was continuously monitored at a wavelength of 254 nm. Riluzole peaks
(retention time = ~9 minutes) were identified and integrated at 264 nm, and quantified using
previously run calibration curves. Naïve spinal cord and plasma samples were spiked with 0.5
nmoles riluzole and extracted, then analyzed by HPLC to determine percent recovery of
riluzole (63.2% in spinal cord; 76.4% in plasma). Riluzole concentrations in spinal cord
samples were normalized to plasma concentrations to obtain a spinal cord/plasma ratio for each
animal. Riluzole concentrations were analyzed by one-way ANOVA followed by the StudentNewman-Keuls post test.

Statistical Analysis
All statistical analysis was performed using SigmaPlot 11 (Systat Software, Inc., Chicago,
Illinois) or GraphPad Prism 5. Student’s t test was used for comparisons between two groups.
For comparisons among more than two groups for parametric data, one-way ANOVA followed
by the Student-Newman-Keuls post test was used. Multiple-group, repeated-measures
comparisons of parametric data were performed using a two-way repeated measures ANOVA,
followed by appropriate multiple comparisons tests. Nonparametric data (BBB scores) were
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compared across groups using a Kruskal-Wallis test followed by a Dunn’s post-test. p values <
0.05 were considered statistically significant.
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CHAPTER 3
Assessment of P-glycoprotein Expression and Function
Following Spinal Cord Injury in the Rat
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Background
It has long been known that treatment with chemotherapeutic drugs can induce
overexpression of Pgp in multiple types of cancer, conferring tumor cells with simultaneous
cross-resistance to multiple cytotoxic chemotherapeutic compounds (286-288). This
phenomenon, known as multidrug resistance, is a major obstacle to the efficacy of cancer
therapy, and identifying new avenues to circumvent this obstacle remains a chief priority in the
field of oncology research (289, 290). More recently, several preclinical and clinical studies
have shown that in neurological diseases characterized by high levels of excitotoxicity,
oxidative stress, and inflammation in the brain, Pgp can become pathologically overexpressed
at the blood-brain barrier (223, 224, 235, 244). As a consequence, it is now acknowledged that
Pgp overexpression presents a formidable obstacle to effective CNS drug delivery in patients
suffering from neurological diseases (214).
Pgp expression and function in the healthy and diseased brain has been a subject of much
investigation over the last few decades. Despite this, relatively few groups have focused on the
role of Pgp drug efflux activity in the BSCB. Bernards and colleagues have drawn attention to
Pgp efflux activity as a barrier to penetration of systemically-delivered methylprednisolone into
spinal cord tissue in SCI patients (242, 243). They emphasized that the high dose of MPSS
needed to approach therapeutic spinal cord levels is associated with harmful peripheral side
effects that might be avoided by circumventing Pgp efflux activity. However, whether Pgp
undergoes pathological up-regulation following SCI, as has been observed in other
neuroinflammatory conditions, has not yet been addressed. If multidrug resistance does develop
in the spinal cord following traumatic injury, then Pgp may present an even more
insurmountable barrier to effective delivery of neuroprotective drugs than previously
speculated (243).

Specific Aims
1. A central feature of multidrug resistance in neurological diseases is overexpression of
Pgp at the blood-brain barrier (234). Previous work has shown that the BSCB undergoes
multiple structural and functional alterations after traumatic SCI (72, 168, 173, 291);
however, Pgp expression at the BSCB in response to SCI has not yet been investigated.
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We therefore sought to assess the temporal and spatial expression profiles of Pgp within
the spinal cord following SCI.
2. The functional consequence of pathological Pgp overexpression at the blood-brain
barrier is reduced brain penetration of blood-borne drugs such as riluzole (224).
Therefore, we anticipated that Pgp overexpression within the injured spinal cord would
also correspond with reduced spinal cord drug bioavailability. We investigated this
possibility by evaluating spinal cord concentrations of systemically-delivered riluzole
during acute and sub-acute phases of SCI, and using transgenic mdr1a-/- rats to delineate
the role of Pgp in conferring spinal cord drug resistance5.

Results
Expression of ABC Transporter Genes Following Spinal Cord Injury
In humans, there is only one Pgp gene product that confers multidrug resistance—MDR1
(292). Rodents express two 90% homologous isoforms, Mdr1a (Abcb1a) and Mdr1b (Abcb1b),
and both confer multidrug resistance (293). The distinction between the expression patterns of
these two isoforms is somewhat unclear. It has been reported that only the Mdr1a gene product
is expressed in rodent brain capillary endothelial cells under normal conditions (294, 295) and
loss of mdr1a gene expression results in heightened CNS sensitivity to drugs (296). Schinkel
and colleagues demonstrated that the accumulation of digoxin (a Pgp substrate) in the brains of
mdr1a/1b-/- mice was only slightly greater than that of mdr1a-/- mice (295). However, other
studies have reported an increased expression of both mdr1a and mdr1b genes in mouse brain
capillary endothelial cells in response to inflammatory lipopolysaccharide (LPS) treatment
(245), which is accompanied by an increase in Pgp protein expression and activity (297). The
differential regulation of both Mdr1a and Mdr1b gene products under pathological conditions is
unclear, but their considerable functional redundancy suggests that both may play a role in
multidrug resistance under neuroinflammatory conditions.
Microarray analysis was performed to detect changes in expression of ABC transporter
genes within the T10 spinal cord at one week after SCI (n = 6) compared to uninjured controls
5

The term drug resistance is used in this dissertation to indicate a reduction in the spinal cord
penetration of drug from the plasma following systemic (i.v. or i.p. delivery) of that drug.
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(n = 6) (TABLE 3.1). Microarray data revealed differential expression of several ABC
transporter genes within the lesion site of animals one week after injury. Of these family
members, abcb1b, encoding the Mdr1b isoform of Pgp, exhibited the most dramatic upregulation with ten-fold higher expression levels compared with controls (+10.05-fold, p <
0.001)6. Among other family members exhibiting up-regulation was abcb4 (mdr2), a selective
transporter of phosphatidylcholine, expression of which was increased substantially in injured
tissue (+6.07-fold, p < 0.001).

TABLE 3.1. Differential expression of ABC transporter genes 7 days following spinal cord
injury. DNA microarray gene expression data for ABC transporter family members at 7 days
following SCI in the rat T10 spinal cord. Gene expression is represented as fold change versus
uninjured control levels (0 indicates no change in expression versus controls). Up-regulated
genes are highlighted in green and down-regulated genes are highlighted in red. abcb1b (bold)
encodes rat P-glycoprotein. All gene expression data included in this table are p < 0.01 versus
uninjured controls.
6

The Illumina microarray chip used in this study did not contain a probe against abcb1a.
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We also detected significantly decreased expression of several ABC transporter family
members during acute SCI. Genes exhibiting the most prominent down-regulation included
abcc2, encoding the multidrug resistance-associated protein 2 (MRP2), (-13.92-fold, p <
0.001), and abcd2, encoding the adrenoleukodystrophy-related protein (ALDRP), (-5.54-fold, p
< 0.001). Like Pgp, MRP2 is expressed on the luminal membrane of brain capillary endothelial
cells and possesses broad substrate specificity, contributing to efflux of drugs and other
compounds (298). ALDRP does not contribute to multidrug resistance, but its dysfunction is
implicated in the neuroinflammatory disease adrenoleukodystrophy (299). It is possible that
more than one member of the ABC transporter family, for which we have observed differential
expression after SCI, may play a role in the pathophysiology and/or treatment of SCI. For this
study, we chose to focus specifically on investigating Pgp, largely due to its extensively
described role in a variety of diseases including cancer and several neurodegenerative diseases
(224, 227, 230, 300).
To corroborate our microarray data and assess whether Pgp undergoes SCI-induced upregulation at the transcriptional level, we next performed quantitative real time PCR (qRTPCR) analysis of abcb1b gene expression (Fig. 3.1). Our results revealed a twelve-fold increase
in the lesion site of rats 7 days post-SCI (RQ = 9.10 ± 0.67, n = 3) compared with expression in
uninjured controls (0.76 ± 0.12, n = 4). Moreover, we observed that abcb1b gene expression
was also increased three-fold in the T10 cord of rats 8 months post-SCI (2.60 ± 0.24, n = 5)
compared to age-matched, uninjured controls (0.87 ± 0.077, n = 5). These findings suggest that
Pgp transcription is increased not only in the acutely-injured spinal cord, but in the chronic
phase of injury as well.

Expression of P-glycoprotein Within the Injured Spinal Cord
Pgp expression in the brain is restricted to the luminal membrane of capillary endothelial
cells; although one group has reported Pgp expression in the membranes of astrocyte foot
processes (301-304), their observations have not been replicated and thus remain dubious
(203). We therefore examined the localization of Pgp expression in rat spinal cord tissue. In the
wild-type, uninjured rat, Pgp immunoreactivity was restricted to spinal cord blood vessel
endothelial cells, and was not observed on astrocytes (Fig. 3.2). Immunohistochemical staining
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Figure 3.1. Expression of abcb1b is increased during acute and chronic spinal cord
injury. qRT-PCR gene expression data for T10 spinal cord tissue from rats 7 days and 8
months post-SCI, versus age-matched, uninjured control expression levels. RQ, relative
quantity of abcb1b expression (fold change). All data are mean ± s.e.m. *, p < 0.001 versus
uninjured, age-matched controls.
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Figure 3.2. P-glycoprotein expression is localized to blood vessels in the intact spinal
cord. (a) Coronal spinal cord section with Pgp immunoreactivity in green. Cartoon indicates
field of view (red-bounded box). Scale bar = 250 µm. (b) Pgp immunoreactivity co-localizes
with the endothelial marker von Willebrand factor (vWF), but not with the astrocytic marker
glial fibrillary acidic protein (GFAP). Scale bar = 100 µm.
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Figure 3.3. P-glycoprotein is expressed on the luminal surface of spinal cord blood
vessels. Pgp immunoreactivity (brown) is localized to the luminal surface of capillary
endothelial cells in the intact spinal cord (arrowhead). Nuclei are stained blue. Scale bar = 10
µm.
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also revealed strong Pgp localization on the luminal surface of capillary endothelial cells in the
spinal cord (Fig. 3.3), consistent with previous reports (305). We did not observe localization
of Pgp immunoreactivity in any other cell types. To evaluate whether different cell types might
also express Pgp following SCI, we also examined Pgp immunoreactivity in the spinal cord
lesion site 7 days after injury (Fig. 3.4). We did not observe co-localization with macrophages
(Fig. 3.4a) or astrocytes (Fig. 3.4b) at this time point; rather, Pgp expression still appeared to
be restricted to capillary endothelial cells.

Figure 3.4. P-glycoprotein expression is localized to blood vessels 7 days following spinal
cord injury. Pgp immunoreactivity (green) co-localizes with blood vessel endothelial cell
markers within the spinal cord lesion site one week post-SCI. (a) Pgp co-localizes with spinal
cord vasculature and not with macrophages. von Willebrand factor (vWF), blue; ED2, rat
mature macrophage antigen, red. (b) Pgp does not co-localize with astrocytes. Glial fibrillary
acidic protein (GFAP), blue. Scale bars = 100 µm.
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For subsequent studies, we elected to examine spinal cord Pgp expression via immunoblot
analysis. Mice and rats express two distinct Pgp gene products, Mdr1a and Mdr1b, both of
which are expressed in the CNS, though the Mdr1a isoform more predominantly so (198). To
verify the efficacy of the anti-Pgp antibody for immunodetection in western blots, we
performed SDS-PAGE on total protein samples from uninjured spinal cord tissue harvested
from mdr1a/b-/- mice (Fig. 3.5) as well as mdr1a-/- rats (Fig. 3.6) (double mdr1a/b knockout
rats were not available at the time of this study). mdr1 knockout animals exhibited normal
phenotypes, and were indistinguishable from wild-types. We observed multiple non-specific
bands on immunoblots for both mouse and rat samples (Fig. 3.7, arrowheads), most likely as a
result of the high concentration of the primary antibody (1:100) used for immunodetection. Pgp
was identified as the prominent band migrating to ~170 kDa, which was conspicuously absent
in spinal cord tissue lysates from mdr1 knockout animals (Figs. 3.5, 3.6). Pgp
immunoreactivity often appeared as a diffuse band, an observation which is likely attributed to
variable states of glycosylation, as Pgp is normally heavily glycosylated (10-15 kDa of
glycosylation) on its N-terminal domain (203).

Figure 3.5. P-glycoprotein is absent in spinal cords of mdr1a/b-/- mice. Representative
immunoblot of total protein extract from spinal cord tissue of uninjured wild-type and mdr1a/b
knockout mice. Immunoreactivity against Pgp is conspicuously absent in samples from
knockout mice. Immunoreactivity in upper band (indicated by arrowhead) is due to nonspecific binding.
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Figure 3.6. P-glycoprotein is absent in spinal cords of mdr1a-/- rats. Representative
immunoblot of total protein extract from spinal cord tissue of uninjured wild-type and mdr1a
knockout rats. Pgp immunoreactivity is absent in samples from knockout rats.
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Figure 3.7. P-glycoprotein immunoblots exhibit multiple non-specific bands. Pgp
immunoreactivity in protein samples from spinal cord tissue of (a) uninjured wild-type and
mdr1a/b knockout mice, and (b) uninjured wild-type and mdr1a knockout rats. HeLa cell lysate
is a positive control for human MDR immunoreactivity. Arrowheads indicate non-specific
bands. Band of Pgp immunoreactivity (170 kDa) is labeled at left.
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We next investigated the temporal and spatial expression profile of Pgp within the injured
spinal cord. Pgp expression levels at 72 hours, 7 days, 4 months, and 10 months post-SCI were
quantified and compared to uninjured, age-matched controls via immunoblot analysis. We
observed that Pgp expression was significantly higher within the lesion site of injured animals,
compared with thoracic cord tissue of uninjured controls, at all time points from 72 hours to 10
months post-SCI (Fig. 3.8). At 3 days post-injury, expression of the transporter protein was
nearly three-fold greater than that of uninjured controls, and at 10 months post-SCI, levels were
more than four-fold greater. These findings corroborate our gene expression data (Fig. 3.1),
providing further evidence that Pgp expression is increased in the spinal cord injury site in both
the acute and chronic phases of injury.
Previous studies in our lab have revealed that BSCB dysfunction following SCI is
sustained into the chronic phase of injury; moreover, this barrier dysfunction spreads to spinal
cord regions centimeters away from the T10 lesion site in the rat. This progressive spread of
BSCB failure is characterized by reduced expression of adherens junction proteins and
increased vascular permeability to large molecules, such as immunoglobulin G (IgG) and
albumin (unpublished studies performed by Dr. Raymond Grill). One major goal of our
laboratory is to develop a more comprehensive understanding of vascular pathology following
injury to the spinal cord. The previously reported deficits in BSCB function have described
components of passive BSCB failure—leakiness or increased permeability to small and large
molecules due to increased passive paracellular and transcellular diffusion (177). However, it
has not previously been investigated whether SCI also induces changes in active transport at the
BSCB. The pathological changes in the properties of the BSCB are widely thought to solely
encompass passive changes that enhance barrier permeability. An overarching goal of the
current study is to investigate whether deficits in the BSCB following SCI extend to alterations
in active transport as well.
We evaluated whether there were progressive, spatial changes in Pgp expression patterns
following SCI by examining protein levels in spinal cord regions several segments removed
from the initial site of injury. We found that Pgp expression was significantly increased within
the cervical enlargement (C6-C7) of the spinal cord at 7 days, 4 months, and 10 months postSCI (Fig. 3.9). Furthermore, Pgp expression was increased in the lumbar enlargement (L3-L4)
of the spinal cord at 4 months and 10 months following injury (Fig. 3.10). Thus, the
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Figure 3.8. P-glycoprotein expression is increased in the spinal cord lesion site during
acute and chronic spinal cord injury. Pgp expression levels in T10 spinal cord tissue were
quantified by immunoblot analysis and normalized to β-actin. Representative immunoblots are
shown below the graph (U, Uninjured; S, SCI). Pgp expression is significantly increased at 3
days [Uninjured = 1.00 ± 0.09 (n = 7); SCI = 2.92 ± 0.63 (n = 6), p = 0.0073], 7 days,
[Uninjured = 1.00 ± 0.15 (n = 6); SCI = 1.61 ± 0.29 (n = 7), p < 0.001], 4 months [Uninjured =
1.00 ± 0.07 (n = 5); SCI = 1.93 ± 0.27 (n = 6), p = 0.011], and 10 months [Uninjured = 1.00 ±
0.05 (n = 8); SCI = 4.36 ± 0.67 (n = 4), p < 0.001] following SCI. All data are mean ± s.e.m. *,
p < 0.05 versus uninjured, age-matched controls.
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Figure 3.9. P-glycoprotein expression is increased in the cervical spinal cord following
spinal cord injury. Pgp expression levels in cervical spinal cord tissue were quantified by
immunoblot analysis and normalized to β-actin. Cartoon indicates region of spinal cord tissue
analyzed. Representative immunoblots are shown below the graph (U, Uninjured; S, SCI). Pgp
expression is significantly increased at 7 days, [Uninjured = 1.00 ± 0.16 (n = 6); SCI = 1.89 ±
0.15 (n = 8), p = 0.002], 4 months [Uninjured = 1.00 ± 0.11 (n = 6); SCI = 1.97 ± 0.33 (n = 6),
p = 0.021], and 10 months [Uninjured = 1.00 ± 0.11 (n = 8); SCI = 1.61 ± 0.16 (n = 5), p =
0.009] following SCI. All data are mean ± s.e.m. *, p < 0.05 versus uninjured, age-matched
controls.
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Figure 3.10. P-glycoprotein expression is increased in the lumbar spinal cord during
chronic spinal cord injury. Pgp expression levels in lumbar spinal cord tissue were quantified
by immunoblot analysis and normalized to β-actin. Cartoon indicates region of spinal cord
tissue analyzed. Representative immunoblots are shown below the graph (U, Uninjured; S,
SCI). Pgp expression is significantly increased at 4 months [Uninjured = 1.00 ± 0.07 (n = 6);
SCI = 2.60 ± 0.42 (n = 6), p = 0.004] and 10 months [Uninjured = 1.00 ± 0.07 (n = 6); SCI =
1.93 ± 0.27 (n = 5), p = 0.011] following SCI. All data are mean ± s.e.m. *, p < 0.05 versus
uninjured, age-matched controls.
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pathological increase in Pgp expression after SCI is not merely restricted to the lesion site.
Rather, our data suggests that increased Pgp expression is a progressive and spatially expanding
phenomenon, which may reflect a larger, ongoing BSCB pathology secondary to SCI.

Role of P-glycoprotein in Spinal Cord Riluzole Bioavailability Following Spinal Cord Injury
Riluzole is an FDA-approved drug for the treatment of ALS that has neuroprotective and
anti-glutamatergic properties (88). Milane and colleagues have demonstrated that riluzole is a
substrate of Pgp efflux (225), and that Pgp overexpression in the brain of mice expressing
mutant human SOD1 results in reduced brain bioavailability of riluzole subsequent to systemic
delivery (224). Riluzole is currently being investigated as an acute neuroprotective SCI
intervention in an ongoing national clinical trial (87). The impetus to translate riluzole to the
clinic is fueled by several preclinical studies demonstrating its ability to improve histological
and functional outcome in animal models of SCI (78-86). If our observations of increased Pgp
expression following SCI have the functional consequence of reduced spinal cord riluzole
levels, similar to that observed by Milane and colleagues (224), these findings would be highly
clinically relevant. We therefore sought to examine whether spinal cord riluzole bioavailability
is altered following SCI, and if so, whether Pgp mediates this phenomenon.
In a pharmacokinetics study, Milane et al. (306) showed that following i.p. delivery, the
extent of brain penetration of riluzole is directly proportional to plasma riluzole levels in wildtype mice at a dosing concentration of 10 mg/kg (306), establishing the brain/plasma riluzole
concentration ratio as an effective indicator of plasma-to-brain riluzole penetration. The same
group has also demonstrated increased brain/plasma ratios of riluzole in mdr1a knockout mice
(225), and reduced brain/plasma ratios in mSOD1 mice with increased brain Pgp expression
(224). These experiments highlight the vital role of Pgp activity at the blood-brain barrier in
determining plasma-to-brain penetration of riluzole. We therefore designed an experiment
modeled on those previous studies, in order to examine whether the plasma-to-spinal cord
penetration of riluzole is altered following SCI. Three weeks following SCI, rats were treated
with a single systemic (i.p.) bolus of riluzole, and drug concentrations in spinal cord and
plasma samples were quantified. We found that the spinal cord/plasma ratio of riluzole was
significantly decreased in rats 3 weeks after SCI versus uninjured controls (Fig. 3.11).
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Figure 3.11. Spinal cord riluzole bioavailability is decreased 21 days after SCI. (a)
Schematic illustrating experimental timeline. Three weeks following SCI, animals received a
single i.p. bolus of riluzole (RLZ). Two hours later, riluzole concentrations in whole spinal cord
tissue and in plasma were measured by HPLC. Spinal cord riluzole concentrations were
normalized to plasma concentrations to determine the spinal cord/plasma ratio. (b) Spinal cord
riluzole levels were significantly reduced in animals three weeks post-SCI (74.1 ± 5.20%, n =
7) versus uninjured controls (100 ± 9.21%, n = 7, p = 0.031). (c) Raw riluzole concentrations in
plasma and spinal cord tissue were significantly decreased in injured rats compared to
uninjured controls. Plasma: Uninjured = 100 ± 4.95%; SCI = 69.7 ± 6.66; p = 0.003. Spinal
cord: Uninjured = 100 ± 5.19; SCI = 52.3 ± 6.00; p < 0.001. All data are mean ± s.e.m.,
expressed as percent of control values. *, p < 0.05 versus uninjured, age-matched controls.
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We also examined raw plasma concentrations of riluzole, in order to determine whether the
pharmacokinetics of riluzole were altered following SCI. Plasma riluzole levels were also
significantly reduced in injured rats (Fig. 3.11c). We speculate that this observation might be
due to pathological alterations in drug metabolism or excretion during this time point of subacute SCI. Milane and colleagues showed that mdr1a-/- mice exhibited higher plasma riluzole
levels (following i.p. injection), presumably due to a reduced biliary excretion rate (306); in
contrast, our observed reduction in plasma levels may be explained by increased excretion of
riluzole from the plasma compartment because of injury-induced up-regulation of Pgp in the
liver. Because the degree of spinal cord riluzole penetration is determined solely by plasma
bioavailability (and alterations in blood-spinal cord barrier transport), the spinal cord/plasma
concentration ratio is a more accurate representation of plasma-to-spinal cord riluzole
penetration than raw spinal cord riluzole levels alone (306). Thus, the reduction that we have
observed in drug plasma bioavailability of injured rats is not sufficient to explain the more
pronounced reduction in raw spinal cord riluzole levels (Fig. 3.11c). Based on the significant
reduction in spinal cord/plasma riluzole ratios following injury, we conclude that there is a
reduced degree of plasma-to-spinal cord riluzole penetration into the spinal cord, compared to
uninjured controls, by three weeks after SCI.
To assess whether this phenomenon might be mediated by Pgp, we utilized mdr1a
knockout rats for a subsequent assessment of spinal cord riluzole bioavailability after SCI.
Because mdr1a-/- rats do not express Pgp at the blood-brain barrier (307) or the BSCB (Fig.
3.6), they are an ideal tool with which to study spinal cord Pgp function in a rat SCI model7.

7

There is a wealth of evidence in the literature that mdr1a is the predominant isoform of Pgp expressed
at the blood-brain barrier under normal conditions (203). Moreover, a comparison of Pgp transport
activity between mdr1a and mdr1a/1b knockout mice reveals that the loss of both gene products does
not substantially affect the brain disposition of systemically-delivered drugs compared to the loss of
Mdr1a alone (295); thus, the majority of Pgp function at the blood-brain barrier is most likely normally
mediated through the Mdr1a isoform. Despite this, we have observed up-regulation of mdr1b gene
expression during acute and chronic SCI (TABLE 3.1 & Fig. 3.1). Expression of mdr1b has been shown
to be up-regulated by neuroinflammatory conditions (245, 297); thus, it is conceivable that the
development of resistance to riluzole in the injured spinal cord may be at least partially mediated by the
Mdr1b gene product. We chose to utilize the mdr1a-/- rat for these studies—despite the availability of
single- and double mdr1 knockout mouse lines—largely because of the distinct behavioral and
pathophysiological differences between mouse and rat models of SCI (6, 60). Only mdr1a knockout rats
were available for purchase from Sage Labs at the time these experiments were performed.
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Ten days after SCI was performed on wild-type and mdr1a-/- rats, we administered a single i.p.
bolus of riluzole then examined spinal cord and plasma riluzole concentrations via HPLC (Fig.
3.12). We found that normalized spinal cord/plasma riluzole levels were significantly decreased
in wild-type rats following injury (p = 0.002), but that there was no detectable difference in
drug levels between KO injured and uninjured groups (p = 0.375). Notably, normalized spinal
cord/plasma riluzole levels were significantly higher in KO rats, than in WT rats, 10 days postSCI (p = 0.006). These findings illustrate a critical role for Pgp function in the development of
spinal cord drug resistance to riluzole following SCI.
We also evaluated plasma riluzole concentrations (Fig. 3.13). There was no significant
difference in plasma riluzole levels between uninjured wild-type rats (100 ± 5.83%) and injured
wild-type rats (104 ± 4.74%, p = 0.479). There was also no significant difference in plasma
riluzole levels between uninjured wild-type rats and mdr1a-/- rats (89.3 ± 2.13%, p = 0.577).
This was an unexpected finding, in light of the observations of Milane et al. that mdr1a-/- mice
exhibited higher plasma riluzole levels compared to wild-type mice after i.p. injection (306).
However, our observation is likely explained by the fact that the Mdr1b isoform is expressed at
normal levels in the liver of mdr1a-/- rats (Fig. 3.14); thus, Mdr1b function probably plays a
compensatory role in the excretion of riluzole from the plasma in the absence of Mdr1a.
There appeared to be a slight decrease, but no significant difference, in plasma riluzole
levels of mdr1a-/- rats following injury (KO SCI = 75.2 ± 5.04 %, p = 0.258). Compared with
our observations of decreased plasma riluzole levels at 3 weeks after injury, the lack of effect
of SCI on plasma drug levels at 10 days after injury suggests that there may be a timedependent effect on riluzole pharmacokinetics in wild-type rats. Interestingly, we observed a
significant effect of genotype on plasma riluzole levels between injured groups (but not
between uninjured groups); riluzole plasma levels were significantly lower in mdr1a-/- rats
compared to wild-type rats. This finding suggests that mdr1a knockout rats probably have
enhanced metabolism or clearance of riluzole compared to wild-types at 10 days post-SCI,
although investigation as to the possible mechanism(s) underlying this requires further study.
In conclusion, we have found that spinal cord/plasma ratios of systemically-delivered
riluzole were significantly higher in mdr1a-/- rats compared to wild-type rats after SCI (Fig.
3.12). Curiously, we did not observe an increase in raw riluzole spinal cord concentrations in
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Figure 3.12. Spinal cord riluzole bioavailability is decreased 10 days after spinal cord
injury in wild-type but not mdr1a-/- rats. Abbreviations: WT, wild-type; KO, mdr1a
knockout; U, uninjured; S, 10 days post-SCI. (a) Schematic illustrating experimental timeline.
Ten days following SCI, animals received a single i.p. bolus of riluzole (RLZ). Two hours later,
riluzole concentrations in T10 spinal cord tissue and in plasma were measured by HPLC.
Spinal cord riluzole concentrations were normalized to plasma concentrations to determine the
spinal cord/plasma ratio. (b) Normalized spinal cord riluzole levels were significantly reduced
in WT rats with SCI (81.6 ± 3.54%, n = 9) versus WT uninjured controls (100 ± 8.73%, n = 10,
p = 0.002). There was no significant effect of injury on spinal cord/plasma riluzole ratios in KO
rats (KO uninjured = 95.8 ± 6.94%, n = 6; KO SCI = 97.8 ± 6.91%, n = 7, p = 0.375).
Normalized riluzole levels were significantly higher in injured KO rats compared to injured
WT rats (p = 0.006). All data are mean ± s.e.m., expressed as percentage of wild-type,
uninjured controls. *, p < 0.05.
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Figure 3.13. Plasma riluzole concentrations are decreased in injured mdr1a-/- rats
compared to injured wild-type rats. Abbreviations: WT, wild-type; KO, mdr1a knockout; U,
uninjured; S, 10 days post-SCI. Plasma riluzole levels were significantly reduced in KO rats
with SCI (75.2 ± 5.04%) versus WT rats with SCI (104 ± 4.74%, p = 0.002). WT uninjured =
100 ± 5.83%; KO uninjured = 89.3 ± 2.13%). All data are mean ± s.e.m., expressed as
percentage of wild-type, uninjured controls. *, p < 0.05.
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Figure 3.14. mdr1a-/- rats express Mdr1b in the liver. “Western blots showing undetectable
levels of Mdr1a protein in the brain and small intestine (S. Intestine) of knockout (KO) rats. In
the liver sample, the band with a size that was apparently similar to that of the Mdr1a protein in
KO rats may represent the up-regulated Mdr1b protein because of the cross-reactivity of the
antibody. The weak potential Mdr1b protein was detected in the kidney of KO rats as well but
not as strongly as in liver.” Quoted from Xiaoyan Chu, Zuo Zhang, Jocelyn Yabut, Sarah
Horwitz, John Levorse, Xiang-qing Li, Lei Zhu, Harmony Lederman, Rachel Ortiga, John
Strauss, Xiaofang Li, Karen A. Owens, Jasminka Dragovic, Thomas Vogt, Raymond Evers,
and Myung K. Shin, Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout
Rats Generated by Zinc Finger Nucleases, Mol Pharmacol February 2012 81:220-227.
Reprinted with permission (307).
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uninjured mdr1a-/- rats compared to wild-type rats (Fig. 3.15), which may be attributable to
compensatory activity of another drug efflux transporter. Despite this, our finding that spinal
cord riluzole delivery is significantly diminished following SCI in wild-type but not mdr1a-/rats provides compelling support for the central role of Pgp in mediating post-SCI spinal cord
drug resistance.

Figure 3.15. Raw spinal cord riluzole concentrations are decreased 10 days after spinal
cord injury in wild-type but not mdr1a-/- rats. Abbreviations: WT, wild-type; KO, mdr1a
knockout; U, uninjured; S, 10 days post-SCI. Spinal cord riluzole levels were significantly
reduced in WT rats with SCI (66.2 ± 2.84%) versus WT uninjured controls (100 ± 10.18%, p <
0.001). There was no significant effect of injury on spinal cord/plasma riluzole ratios in KO
rats (KO uninjured = 93.8 ± 4.49%; KO SCI = 100.2 ± 5.94%, p = 0.767). Raw spinal cord
riluzole levels were significantly higher in injured KO rats compared to injured WT rats (p =
0.004). All data are mean ± s.e.m., expressed as percentage of wild-type, uninjured controls. *,
p < 0.05.
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CHAPTER 4
Characterization of Inflammation in the Injured Spinal Cord
&
The Effects of Licofelone Treatment on P-glycoprotein
Expression and Riluzole Bioavailability
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Background
Increased P-glycoprotein expression is a hallmark of diseases such as cancer, and it has
recently been shown to occur in a number of neurological diseases as well. Multidrug
resistance caused by heightened Pgp-mediated drug efflux attenuates the efficacy of therapeutic
drugs indicated to treat these diseases, and overcoming this phenomenon is a highly desirable
goal. Because pharmacological Pgp inhibition is not a viable therapeutic solution to overcome
drug resistance (300), a more desirable strategy is to prevent Pgp overexpression by
pharmacologically targeting the molecular mechanisms that up-regulate it (234). There is a
wealth of evidence that inflammation drives pathological increases in Pgp expression. For
example, prolonged (hours) exposure to TNF-α and endothelin-1 increase Pgp expression and
activity in brain capillary endothelial cells (308). Other inflammatory mediators, such as IL-1β,
as well as substances such as LPS, have been shown to have differential effects on Pgp
expression in various in vitro and in vivo models of central- and peripheral nervous system
inflammation (198). Because of the complex nature of inflammatory response, and the diversity
of results observed in various dose-dependent and context-dependent models, the exact nature
of inflammatory regulation of Pgp expression is still relatively unclear.
Potschka and colleagues have gained much insight into the pathological up-regulation of
Pgp via COX signaling in rodent models of seizure (See Fig. 1.10) (187). In addition to their
work, a variety of recent studies have substantiated the role of COX signaling in driving Pgp
up-regulation in experimental models of cancer (238-241, 309). Thus, there appears to be a
growing body of evidence showing that pro-inflammatory COX signaling is important for
driving pathological Pgp overexpression in various diseases, and that inhibiting this pathway
can enhance therapeutic drug delivery. In Potschka’s model, it is not indicated exactly how the
COX-dependent up-regulation of Abcb1 gene expression occurs at the transcriptional level,
though the author speculates that the transcription factor NF-kB is a likely candidate based on
evidence that brain COX-2 activity can induce NF-kB activation (245, 246). More recently,
other groups have published findings that NF-kB does indeed promote increased Pgp
expression in a kainic acid-induced seizure model (310), and that NF-kB mediates increased
transcription of Mdr1b in cerebral LPS-induced inflammation (245, 297). Thus, it appears
likely that pro-inflammatory COX signaling acts via NF-kB activation to promote upregulation of Pgp in neuroinflammatory diseases. Interestingly, the parallel pro-inflammatory
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5-LOX branch of oxidative AA metabolism is an upstream activator of NF-kB activation as
well (311-313). Furthermore, it has been shown that inhibiting 5-LOX activity blocks NF-kB
activation during cerebral ischemia (314). Given the intimate relationship between COX and 5LOX signaling (155, 315), one might speculate that these two pro-inflammatory signaling
pathways may act via a common mechanism to promote Pgp up-regulation in the diseased
CNS.
We have observed increased Pgp expression within the spinal cord at acute (72 hours, 7
days) and chronic (4 months, 9 months) time points after injury (See Chapter 3). Given the
large amount of evidence supporting a role for inflammation in driving Pgp up-regulation, we
became interested in whether inflammation could also be detected within the injured spinal
cord at each of these time points. Because there has historically been much interest in the role
of inflammation in acute SCI, a number of studies have investigated the presence of COX- and
5-LOX pathway components within the injured spinal cord at early time points (121, 141). In
contrast, relatively little is known about whether inflammatory signaling persists beyond a
period of several weeks post-SCI. This unexplored question is largely attributed to the fact that
the chronically-injured spinal cord has historically been a subject of relatively little study.
Because COX and 5-LOX are both known to contribute to destructive SCI secondary
pathology, and because of evidence that COX signaling drives Pgp overexpression in
neuroinflammatory conditions (as well as indirect evidence that 5-LOX signaling may do the
same), we evaluated whether components of these two pathways are expressed at acute and
chronic time points following SCI, mirroring the time points at which we have previously
detected increased Pgp expression. We also sought to develop a deeper understanding of the
metabolic processes at work in the far chronically-injured spinal cord, as there is very little
known about the molecular processes shaping SCI pathology during this time frame.
We have shown that Pgp confers resistance to riluzole uptake in the spinal cord during the
sub-acute phase of SCI (See Chapter 3). Previous studies have shown that pharmacological
COX inhibition down-regulates Pgp-mediated drug resistance in clinically relevant models of
seizure and cancer (236, 238, 241). Therefore, our next goal in this study was to assess the
efficacy of anti-inflammatory drug treatment to 1) abrogate Pgp overexpression and 2) enhance
delivery of systemically-administered riluzole to the injured spinal cord tissue. There are
undesirable side effects associated with the clinical use of COX inhibitors; namely, high
incidence of gastrointestinal side effects, as well as the shunting of AA into the parallel, pro87

inflammatory 5-LOX pathway, resulting in an antagonized inflammatory response. In order to
circumvent these undesirable side effects of selective COX inhibition, for this study we elected
to instead utilize the dual COX/5-LOX inhibitor, licofelone, for its superior anti-inflammatory
properties and improved GI tolerance in humans.

Specific Aims
1. Several studies have shown that pro-inflammatory signaling drives pathological Pgp
overexpression (238-240, 244, 309, 310). Here, we have demonstrated that spinal cord
expression of Pgp is increased during the acute and chronic phases of SCI. Therefore,
we aimed to assess the presence of components of pro-inflammatory COX and 5-LOX
pathways at time points at which we have observed increased Pgp expression—72
hours, 7 days, 4 months, and 10 months following SCI.
2. Furthermore, the biochemical environment of the chronically-injured spinal cord has
not previously been well characterized. In order to supplement our understanding of the
pathological changes occurring in chronic SCI, we sought to characterize the long-term
metabolic alterations in the chronically-injured cord via a metabolomic analysis of
spinal cord tissue 9 months following SCI.
3. We have demonstrated that Pgp mediates a SCI-induced decrease in riluzole
bioavailability in the weeks following injury. Other groups have shown that treatment
with anti-inflammatory COX inhibitors is an effective strategy to attenuate upregulation of Pgp and enhance CNS delivery of therapeutic drugs that are Pgp substrates
(236, 238, 241). Licofelone is a dual COX/5-LOX inhibitor with improved GI
tolerability in humans, as well as enhanced anti-inflammatory properties compared to
COX inhibitors. Therefore, we aimed to evaluate the efficacy of licofelone to attenuate
Pgp overexpression and enhance spinal cord riluzole bioavailability following SCI.
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Results
Assessment of COX/5-LOX Enzymes and Pro-Inflammatory Mediators in the Acutely-Injured
Spinal Cord
Previous studies in our laboratory have revealed substantial increases in expression of 5LOX and production of the CysLTs in the spinal cord lesion site at 24 hours post-SCI (Fig.
4.1). In order to evaluate whether the COX and 5-LOX pro-inflammatory signaling pathways
are up-regulated at additional acute time points following injury, particularly those during
which we have observed Pgp up-regulation (Figs. 3.8-3.10), we performed immunoblot
analysis of T10 spinal cord tissue at 72 hours and 7 days post-SCI. At 72 hours, we observed
significantly increased expression of all three enzymes (Fig. 4.2), the most dramatic of which
being a nearly five-fold increase in COX-2 expression. At 7 days post-injury, we only detected
a significant (three-fold) increase in COX-2 expression, and no change in COX-1 or 5-LOX
versus uninjured controls (Fig. 4.3).

Figure 4.1. 5-lipoxygenase expression and cysteinyl leukotriene production are increased
24 hours following spinal cord injury. (a) Top: 5-LOX immunoreactivity (red) is virtually
undetectable in the thoracic spinal cord tissue of uninjured controls (left panel), but is markedly
increased in the T10 lesion site of rats 24 hours post-SCI (right panel), especially in the gray
matter. Bottom: Plane of view for fluorescent images is indicated by the blue line (horizontal
plane) in the cartoon. Image provided courtesy of Dr. Raymond Grill. Scale bar = 200 µm. (b)
Cysteinyl leukotrienes are increased more than two-fold in the spinal cord lesion site compared
to uninjured controls 24 hours post-SCI. *, p < 0.05. ELISA data provided courtesy of Dr.
Meredith Moore.
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Figure 4.2. Expression of cyclooxygenase-1/-2 and 5-lipoxygenase is increased in the
spinal cord lesion site 72 hours after spinal cord injury. Protein expression levels are
normalized to β-actin and expressed as a percentage of uninjured control expression levels. 72
hr post-SCI, there is significantly increased expression of COX-1 (Uninjured = 100 ± 5.79%, n
= 6; SCI = 271 ± 19.0%, n = 8, p < 0.001), COX-2 (Uninjured = 100 ± 8.06%, n = 6; SCI = 474
± 53.9%, n = 8, p < 0.001), and 5-LOX (Uninjured = 100 ± 5.49% n = 6; SCI = 308 ± 35.4%, n
= 8, p < 0.001) in the T10 lesion site. Representative immunoblots pictured for COX-1 and
COX-2 are from the same sample. All data are mean ± s.e.m. *, p < 0.05 versus uninjured
controls.
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Figure 4.3. Expression of cyclooxygenase-2 is increased in the spinal cord lesion site 7
days after spinal cord injury. Protein expression levels are normalized to β-actin and
expressed as percentage of uninjured control expression levels. 7 days post-SCI, there is
significantly increased expression of COX-2 (Uninjured = 100 ± 46.8%, n = 6; SCI = 300 ±
63.0%, n = 6, p = 0.029), but not COX-1 (Uninjured = 100 ± 32.6%, n = 6; SCI = 134 ± 24.7%,
n = 7, p = 0.418) or 5-LOX (Uninjured = 100 ± 10.8%, n = 6; SCI = 111 ± 15.4%, n = 8, p =
0.561) in the T10 lesion site. Representative immunoblots pictured for COX-1 and COX-2 are
from the same sample. All data are mean ± s.e.m. *, p < 0.05 versus uninjured controls.
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Assessment of Inflammation in the Chronically-Injured Spinal Cord
Because the spinal cord biochemical environment after a period of 1-2 months post-SCI
has received relatively little attention compared to the acutely-injured spinal cord, it is
unknown whether inflammation is present during the chronic phase of injury. Two goals of the
current study were to 1) examine whether COX/5-LOX activity is detectable in the injured
spinal cord at several months post-injury, and 2) develop a more comprehensive understanding
of the cytotoxic biochemical processes at work in the chronically-injured spinal cord
environment. A previous study in our laboratory (performed by Dr. Raymond Grill) has
provided novel evidence of pro-inflammatory AA metabolism within the spinal cord during the
chronic period of injury. Specifically, this study has revealed increased expression of the
cysteinyl leukotriene receptor 1 within the dorsal horn of the lumbar spinal cord 4 months
following spinal contusion injury at T10 (Fig. 4.4). This is an intriguing finding when
compared to our observations of increased Pgp expression in the lumbar spinal cord at 4
months post-SCI (Fig. 3.10), and raises the question of whether pro-inflammatory 5-LOX
signaling in the lumbar spinal cord may contribute to this component of BSCB pathology.

Figure 4.4. Increased expression of the cysteinyl leukotriene receptor 1 four months after
spinal cord injury. Immunofluorescent labeling for the cysteinyl leukotriene receptor 1
(CysLTR1, green) in the dorsal horn of the lumbar spinal cord. Inset in (a) indicates field of
view (red-bounded square). Dashed line in (a) indicates boundary of gray and white matter in
dorsal horn. (a) Spinal cord section from naïve, uninjured, age-matched control animal. (b)
Spinal cord section from animal 4 months post-SCI. Arrowheads indicate cells exhibiting
increased CysLTR1 expression. Image provided courtesy of Dr. Raymond Grill.
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Additional investigations in our lab (performed by Dr. Raymond Grill) have shown that at 4
months post-SCI, 5-LOX expression within the spinal cord near the lesion site appears to be
closely associated with the vasculature (Fig. 4.5). This observation may hold interesting
implications for BSCB pathology at far chronic time points.

Figure 4.5. 5-lipoxygenase expression is localized to the spinal cord vasculature 4 months
after spinal cord injury. Immunofluorescent labeling of 5-LOX (red) and the endothelial cell
marker, rat endothelial cell antigen-1 (RECA-1, green) in thoracic spinal cord tissue of rats 4
months after SCI. 5-LOX immunoreactivity appears to be ensheathing the capillary endothelial
cells. 5-LOX was undetectable in age-matched, uninjured controls (data not shown). Scale bar
= 60 µm. Image provided courtesy of Dr. Raymond Grill.
We used ELISA to measure levels of the major AA-derived mediators, PGE2 and LTB4,
within spinal cord tissue of rats at the far chronic time point of nine months post-SCI. PGE2
levels were undetectable in the spinal cord of uninjured, age-matched controls (n = 3) but
increased to 87.1 ± 4.91 pg/ml in the lesion site of chronic SCI animals (n = 3) (p < 0.001, Fig.
4.6a). LTB4 levels were similarly undetectable in uninjured controls (n = 6) but were
significantly increased in T10 spinal cords of chronic SCI rats (n = 6) (10.6 ± 1.67) (p < 0.001,
Fig. 4.6b).
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Figure 4.6. Increased levels of prostaglandin E2 and leukotriene B4 in the spinal cord 9
months after spinal cord injury. Prostaglandins and leukotrienes are present in the lesion site
of spinal cords nine months following SCI. PGE2 levels (a) and LTB4 levels (b) in T10 spinal
cord segments of age-matched, uninjured controls (undetectable) and animals 9 mo post-SCI
(black bars). PGE2 (87.1 ± 4.91 pg/ml, n = 3) and LTB4 (10.6 ± 1.67 pg/ml, n = 6). *, p < 0.001
versus uninjured controls. All data are mean ± s.e.m.

Metabolomic Profiling of the Chronically-Injured Spinal Cord
To gain a more complete understanding of the biochemical environment within the
chronically-injured spinal cord, metabolomic profiling was performed for T10 spinal cord
tissue from far chronic (9 months) post-SCI animals (n = 8) and uninjured, age-matched
controls (n = 9). A total of 257 metabolites were identified in spinal cord samples, from the
Metabolon library comprising 2,400 named molecules. Tissue expression levels of 126 of these
compounds were altered in chronic SCI samples (TABLE 4.1). Metabolites belonged to diverse
molecular classes (e.g., amino acids, nucleotides, and lipids), and hierarchical clustering
revealed multiple clusters of biochemicals similarly altered in SCI tissue (Fig. 4.7-4.8). For
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Class

Sub-class

Glycine, serine and threonine
metabolism

Alanine and aspartate metabolism

Glutamate metabolism
Amino acid
Lysine metabolism
Phenylalanine & tyrosine metabolism
Valine, leucine and isoleucine
metabolism

Cysteine, methionine, SAM, taurine
metabolism

Biochemical Name
glycine
homoserine
betaine
alanine
aspartate
N-acetylaspartate (NAA)
asparagine
glutamate
glutamine
gamma-aminobutyrate (GABA)
N-acetylglutamate
N-acetyl-aspartyl-glutamate
(NAAG)
2-aminoadipate
N6-acetyllysine
tyrosine
isoleucine
leucine
valine
taurine
S-adenosylhomocysteine (SAH)
methionine
N-acetylmethionine
2-hydroxybutyrate (AHB)

Fold Change
(SCI + VEH /
Uninjured)

p Value

−1.35
−1.18
2.22
1.19
−1.22
−2.38
−1.47
−1.45
1.06
−1.33
−1.33

< 0.001
0.0780
< 0.001
0.0236
0.0091
< 0.001
0.0557
< 0.001

−1.79

< 0.001

1.38
1.47
1.15
1.40
1.45
1.40
1.52
−1.43
1.18
2.53
1.65

0.0040
0.0014

0.0982
0.0650
0.0220

0.0581
< 0.001
< 0.001
0.0036
0.0012
0.0012
0.0260
< 0.001
< 0.001
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Urea cycle; arginine-, proline-,
metabolism
Creatine metabolism
Butanoate metabolism
Glutathione metabolism
Fructose, mannose, galactose, starch,
and sucrose metabolism

Carbohydrate

Glycolysis, gluconeogenesis, pyruvate
metabolism

Nucleotide sugars, pentose metabolism
Ascorbate and aldarate metabolism
Nicotinate and nicotinamide metabolism
Cofactors and
vitamins
Pantothenate and CoA metabolism

Pyridoxal metabolism

citrulline
trans-4-hydroxyproline
creatine
2-aminobutyrate
glutathione, oxidized (GSSG)
cysteine-glutathione disulfide
maltose
mannose
mannose-6-phosphate
glycerate
glucose-6-phosphate (G6P)
glucose
fructose-6-phosphate
3-phosphoglycerate
1,3-dihydroxyacetone
lactate
arabitol
ribulose
arabinose
dehydroascorbate
nicotinamide
nicotinamide adenine
dinucleotide (NAD+)
pantothenate
phosphopantetheine
coenzyme A
3'-dephosphocoenzyme A
pyridoxal

1.55
2.05
−1.16
1.72
3.19
3.19
1.61
2.77
2.57
1.37
2.53
2.73
2.29
−1.35
2.22
1.23
−1.64
1.40
−5.26
1.86
1.32

0.0158
< 0.001
0.0314
0.0035
< 0.001
< 0.001
0.0062
< 0.001
< 0.001
0.0313
< 0.001
< 0.001
< 0.001
0.0195
< 0.001
< 0.001
0.0033
0.0433
< 0.001
0.0388
0.0292

1.45

< 0.001

1.69
1.12
−2.56
−2.78
2.17

< 0.001
0.0459
< 0.001
< 0.001
< 0.001
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Riboflavin metabolism
Tocopherol metabolism
Krebs cycle
Energy

Oxidative phosphorylation
Medium chain fatty acid

Long chain fatty acid

Lipid

Fatty acid, monohydroxy
Fatty acid, dicarboxylate
Eicosanoid
Endocannabinoid
Fatty acid metabolism (also BCAA
metabolism)

Carnitine metabolism

Glycerolipid metabolism
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flavin adenine dinucleotide (FAD)
riboflavin (Vitamin B2)
alpha-tocopherol
malate
acetylphosphate
phosphate
caproate (6:0)
pelargonate (9:0)
oleate (18:1n9)
cis-vaccenate (18:1n7)
arachidate (20:0)
eicosenoate (20:1n9 or 11)
dihomo-linoleate (20:2n6)
arachidonate (20:4n6)
13-HODE + 9-HODE
2-hydroxyglutarate
15-HETE
oleic ethanolamide
palmitoyl ethanolamide

1.42
1.78
−1.43
1.28
−1.28
−1.25
1.81
−1.11
−1.23
−1.43
−1.18
−1.89
−1.49
−1.32
1.93
−1.69
1.89
−1.96
−2.22

0.0036
< 0.001
< 0.001
< 0.001
0.0788
< 0.001
0.0526
< 0.001
0.0204
< 0.001
0.0658
0.0016
0.0755
0.0776
0.0051
< 0.001
0.0013
< 0.001
< 0.001

propionylcarnitine

1.42

0.0682

acetylcarnitine
myristoylcarnitine
palmitoylcarnitine
stearoylcarnitine
oleoylcarnitine
choline phosphate
glycerophosphoethanolamine

1.24
−1.56
−1.75
−1.47
−2.08
−1.14
1.18

0.0648
0.0791
0.0236
0.0812
0.0078
0.0076
0.0558

Ketone bodies

Lysolipid

Monoacylglycerol
Sphingolipid
Mevalonate metabolism

Sterol/Steroid

glycerol
glycerol 3-phosphate (G3P)
glycerophosphorylcholine (GPC)
3-hydroxybutyrate (BHBA)
2-docosahexaenoyl GPE
2-palmitoyl GPC
1-stearoyl GPC
2-stearoyl GPC
1-oleoyl GPC
2-oleoyl GPC
1-docosahexaenoyl GPC
2-docosahexaenoyl GPC
1palmitoylglycerophosphoinositol
1-stearoylglycerophosphoinositol
1arachidonoylglycerophosphoinosi
tol
1-oleoylglycerol (1-monoolein)
2-oleoylglycerol (2-monoolein)
palmitoyl sphingomyelin
stearoyl sphingomyelin
3-hydroxy-3-methylglutarate
cholesterol
7-alpha-hydroxycholesterol
7-beta-hydroxycholesterol

−1.20
1.41
2.09
1.50
−1.27
−1.52
−1.37
−1.45
−1.52
−1.35
−1.69
−1.61

0.0164
0.0514
< 0.001
< 0.001
0.0929
0.0442
0.0754
0.0306
0.0168
0.0032
0.0263
0.0286

−2.63

0.0015

−2.33

0.0314

−2.13

0.0011

−2.04
−1.79
1.60
−1.39
−2.56
−1.15
1.77
1.46

< 0.001
0.0049
< 0.001
0.0342
< 0.001
0.0011
0.0011
0.0034

24(S)-hydroxycholesterol

−1.85

< 0.001
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Purine metabolism,
(hypo)xanthine/inosine containing

Purine metabolism, adenine containing
Nucleotide
Purine metabolism, guanine containing
Purine metabolism, urate metabolism
Pyrimidine metabolism, cytidine
containing

Dipeptide derivative

Peptide
gamma-glutamyl

Benzoate metabolism
Chemical
Xenobiotics

Food component/Plant
Sugar, sugar substitute, starch

xanthosine
inosine
adenosine
adenosine 2'-monophosphate (2'AMP)
adenosine 3'-monophosphate (3'AMP)
adenosine 5'-monophosphate
(AMP)
guanosine
urate
cytidine
2'-deoxycytidine
uracil
5,6-dihydrouracil
homocarnosine
anserine
gamma-glutamylglycine
gamma-glutamylmethionine
gamma-glutamylglutamate
gamma-glutamylglutamine
gamma-glutamylphenylalanine
gamma-glutamylalanine
hippurate
glycolate (hydroxyacetate)
stachydrine
homostachydrine
erythritol

1.25
−1.06
−1.96

0.0451
0.0368
0.0033

1.74

< 0.001

1.62

0.0035

−1.23

0.0198

−1.89
1.64
1.27
2.49
1.54
−1.20
−1.37
1.83
−1.33
1.33
−1.43
1.28
−1.16
1.42
1.32
1.35
1.51
1.64
−1.30

< 0.001
< 0.001
< 0.001
< 0.001
0.0017
0.0852
< 0.001
0.0369
0.0197
0.0481
< 0.001
0.0275
0.0969
0.0012
0.0514
0.0708
0.0109
0.0052
0.0434
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TABLE 4.1. Spinal cord metabolites with altered concentrations in chronic spinal cordinjured rats versus uninjured, age-matched controls. Abbreviations: 13-HODE + 9-HODE,
13- and 9-hydroxyoctadecadienoic acid; 15-HETE, 15-hydroxyeicosatetraenoic acid; GPE,
glycerophosphoethanolamine; GPC, glycerophosphocholine; SCI + VEH, chronically-injured,
vehicle-treated8. p values are versus uninjured, age-matched controls. Bolded p values < 0.05
(104 metabolites); non-bolded p values < 0.10 (22 metabolites).

8

Chronic SCI animals were treated either with licofelone or vehicle; there were no untreated animals in
this chronic study.
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Figure 4.7. Metabolites increased in the chronically-injured spinal cord. Heat map
illustrates the change in levels of 64 metabolites with increased expression in chronic SCI
animals versus uninjured, age-matched controls. Increases (yellow) and decreases (blue) in
concentration, relative to the median metabolite level, are represented by various shades of
intensity (see color scale). Metabolites are arranged by hierarchical clustering, with
representative cluster highlighted (a). Scale bar (upper left) indicates Pearson correlation
coefficient (r). Colored bars indicate super class of each metabolite (amino acids,
carbohydrates, cofactors and vitamins, energy metabolites, lipids, nucleotides, peptides, and
xenobiotics). The names of representative pro-inflammatory and pro-oxidative metabolites are
shown in pink lettering.
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Figure 4.8. Metabolites decreased in the chronically-injured spinal cord. Heat map
illustrates the change in levels of 62 metabolites with decreased expression in chronic SCI
animals versus uninjured, age-matched controls. Increases (yellow) and decreases (blue) in
concentration, relative to the median metabolite level, are represented by various shades of
intensity (see color scale). Metabolites are arranged by hierarchical clustering, with
representative clusters highlighted (b-c). Scale bar (upper left) indicates Pearson correlation
coefficient (r). Colored bars indicate super class of each metabolite (amino acids,
carbohydrates, cofactors and vitamins, energy metabolites, lipids, nucleotides, peptides, and
xenobiotics). The names of representative anti-inflammatory metabolites are shown in green
lettering.
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example, one cluster of glycolytic intermediates were similarly increased in SCI samples (Fig.
4.7a, r = 0.88, p < 0.05), and two large clusters of lipid metabolites were similarly decreased in
SCI samples (Fig. 4.8b, r = 0.72, p < 0.05; Fig. 4.8c, r = 0.53, p < 0.05). These analyses reveal
alterations in multiple metabolic pathways within the chronically-injured spinal cord.
Evaluation of metabolites increased in chronic SCI revealed that several were strong
indicators of oxidative stress conditions (pink lettering, Fig. 4.7). These included oxidized
glutathione (+3.19 fold), cysteine-glutathione disulfide (+3.19 fold), dehydroascorbate (+1.86
fold), and 13- and 9-hydroxyoctadecadienoic acid (+1.93 fold) (p < 0.05, Fig. 4.9a).
Additionally, chronic SCI tissue contained significantly depleted levels of anti-oxidant and
anti-inflammatory metabolites (green lettering, Fig. 4.8), such as alpha-tocopherol (-1.43 fold)
and 24(S)-hydroxycholesterol (24-OH-Chol) (-1.85 fold) (p < 0.05, Fig. 4.9b).

Effect of Licofelone on Inflammation and Oxidative Stress Following Spinal Cord Injury
In conjunction with our metabolomic characterization of chronically-injured spinal cords,
we also examined the effects of 28-day licofelone treatment on the spinal cord metabolic
profile of animals with chronic (8 months) SCI. We detected changes in 26 named metabolites
in spinal cord tissue of chronic SCI animals treated with licofelone (n = 9), compared to
vehicle-treated SCI animals (TABLE 4.2). Hierarchical clustering revealed clusters, primarily
composed of lipids and carbohydrates, that increased with licofelone treatment (Fig. 4.10).
Among these were anti-inflammatory and anti-oxidative compounds, including 15hydroxyeicosatetraenoic acid (15-HETE) (+1.42 fold), 24-OH-Chol (+1.25 fold), chiro-inositol
(+1.51 fold), inositol 1-phosphate (+1.22 fold), and homocarnosine (+1.14 fold) (p < 0.05, Fig.
4.10b). Interestingly, the only metabolite that decreased with licofelone treatment (−2.44 fold)
was the bile acid taurocholate (TABLE 4.2 & Fig. 4.10a), a pro-inflammatory bile acid that
enhances NF-kB activation (316).
In order to evaluate the ability of licofelone to inhibit production of PGE2 within the
injured spinal cord, we used ELISA to quantify PGE2 levels in injured rats treated with either
vehicle or licofelone (Fig. 4.11). At 24 hours after injury, PGE2 levels within the lesion site
were significantly higher than levels in the thoracic spinal cord of uninjured animals (p <
0.001). Furthermore, this spike in PGE2 was completely abolished in rats that were treated with
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Figure 4.9. Metabolomic analysis reveals oxidative stress and inflammation in the
chronically-injured spinal cord. Box plots illustrate changes in abundance of select
metabolites within spinal cord tissue of uninjured controls (white) and rats 9 mo post-SCI
(gray). For each metabolite, all concentration values have been re-scaled to have a median
value equal to 1 for all groups. Box legend: + inside box represents mean value, bar inside box
represents median value, upper and lower box boundaries represent 75th percentile and 25th
percentile, respectively, upper and lower whiskers represent maximum and minimum of
distribution, circles represents extreme data points. (a) Several metabolites significantly
increased in chronic SCI spinal cords are associated with oxidative stress. (b) Levels of antiinflammatory and anti-oxidative metabolites are decreased in chronic SCI cords.
Abbreviations: 24-OH-Chol, 24(S)-hydroxycholesterol; α-Toco, alpha-tocopherol, GSSG,
oxidized glutathione; Cys-S-SG, cysteine-glutathione disulfide; DHA, dehydroascorbate; 13- +
9-HODE, 13-hydroxyoctadecadienoic acid and 9-hydroxyoctadecadienoic acid. *, p < 0.05
versus uninjured controls.
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Class
Amino acid

Sub-class
Alanine and aspartate metabolism
Aminosugars metabolism

Carbohydrate

Fructose, mannose, galactose, starch,
and sucrose metabolism
Glycolysis, gluconeogenesis, pyruvate
metabolism
Nucleotide sugars, pentose metabolism

Energy

Krebs cycle
Long chain fatty acid
Eicosanoid
Bile acid metabolism
Glycerolipid metabolism

Lipid
Inositol metabolism

Sterol/Steroid

Nucleotide
Peptide
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Xenobiotics

Purine metabolism, urate metabolism
Dipeptide
Dipeptide derivative
Sugar, sugar substitute, starch

Biochemical Name
aspartate
erythronate
N-acetylneuraminate

Fold Change
(SCI + LIC /
SCI + VEH)
1.10
1.18
1.22

p Value
0.0471
0.0287
0.0421

maltose

1.28

0.0417

glucose
lactate
arabitol
ribose
citrate
margarate (17:0)
cis-vaccenate (18:1n7)
behenate (22:0)
15-HETE
taurocholate
glycerol
myo-inositol
chiro-inositol
inositol 1-phosphate (I1P)
cholesterol
7-alpha-hydroxycholesterol
7-beta-hydroxycholesterol
24(S)-hydroxycholesterol
allantoin
glycylglycine
homocarnosine
erythritol

1.27
1.11
1.59
1.47
1.16
1.22
1.26
1.20
1.42
−2.44
1.13
1.20
1.51
1.22
1.06
1.26
1.19
1.25
1.20
1.24
1.14
1.30

0.0633
0.0223
0.0030
0.0836
0.0877
0.0077
0.0183
0.0615
0.0328
0.0625
0.0090
0.0704
0.0224
0.0163
0.0081
0.0209
0.0930
0.0013
0.0709
0.0625
0.0071
0.0755
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TABLE 4.2. Changes in levels of spinal cord metabolites of chronically-injured rats
treated with licofelone. Abbreviations: 15-HETE, 15-hydroxyeicosatetraenoic acid; SCI +
LIC, injured, licofelone-treated; SCI + VEH, injured, vehicle-treated. p values are versus
chronic SCI, vehicle-treated group. Bolded p values < 0.05 (16 metabolites); non-bolded p
values < 0.10 (22 metabolites).
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Figure 4.10. Changes in the spinal cord metabolic profile of chronically-injured rats
following 28-day licofelone treatment. (a) Heat map showing 26 metabolites that exhibit
changes in chronic SCI, licofelone-treated animals (SCI + L), compared to chronic SCI,
vehicle-treated animals (SCI + V). Metabolites are arranged by hierarchical clustering. Scale
bar (upper left) indicates Pearson correlation coefficient (r). Colored bars indicate super class
of each metabolite (e.g., amino acids, carbohydrates). Increases (yellow) and decreases (blue)
in concentration, relative to the median metabolite level, are represented by various shades of
intensity (see color scale). (b) Box plots illustrating changes in levels of select compounds
within the chronic SCI, vehicle-treated (white) or licofelone-treated (gray) groups. For box plot
legend, see Figure 4.9. Abbreviations: 15-HETE, 15-hydroxyeicosatetraenoic acid; 24-OHChol, 24(S)-hydroxycholesterol; 7-β-OH-Chol, 7-beta-hydroxycholesterol; I1P, inositol 1phosphate. *, p < 0.05 versus chronic SCI, vehicle-treated group.
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Figure 4.11. Elevated prostaglandin E2 production within the acutely-injured spinal cord
is eliminated by licofelone treatment. ELISA quantification of prostaglandin E2 levels within
the spinal cord lesion site of animals treated with either vehicle or licofelone at 3 hours after
injury, then again at 18 hours after injury. Uninjured (43.2 ± 4.67 pg/ml; n = 6); SCI + vehicle
(405 ± 47.4 pg/ml; n = 6); SCI + licofelone (16.9 ± 6.87 pg/ml; n = 6). All data are mean ±
s.e.m. *, p < 0.05.
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licofelone starting at 3 hours post-injury (p < 0.001). This data illustrates the efficacy of
licofelone to prevent injury-induced production of prostaglandin E2, which has previously been
shown to drive brain Pgp overexpression in rodent seizure models (235). Because licofelone
inhibits both COX and 5-LOX, we also used ELISA to quantify leukotriene B4 levels in rat
spinal cord tissue using the same treatment paradigm. However, the calculated LTB4 levels in
spinal cord tissue for all three groups fell below the sensitivity limit of the assay [Uninjured
(6.93 ± 1.13 pg/ml; n = 6); SCI + vehicle (7.90 ± 2.56 pg/ml; n = 6); SCI + licofelone (5.02 ±
1.66 pg/ml; n = 6)]. Thus, we cannot draw any conclusions about the effects of licofelone
treatment on LTB4 levels following SCI from this data.

Effect of Licofelone on P-glycoprotein Expression and Spinal Cord Riluzole Bioavailability
Following Spinal Cord Injury
Pekcec et al. showed that brain Pgp overexpression following seizure is mediated by PGE2,
and that antagonizing the EP1 receptor was sufficient to increase therapeutic efficacy of the
anti-convulsant drug phenobarbital in rodents following seizure (235). Because we have shown
that licofelone is effective at decreasing PGE2 levels in the acutely-injured spinal cord (Fig.
4.11), we next wanted to evaluate whether treatment with licofelone could abrogate the effects
of SCI on spinal cord Pgp expression and thereby increase riluzole bioavailability. In order to
increase the clinical relevance of our experimental paradigm, we chose to focus our subsequent
studies on the effects of licofelone treatment during the acute phase of SCI. 72 hours post-SCI
was selected as an optimal time point for evaluating these outcome measures because of two
main contributing factors. First, our overall goal is to enhance the spinal cord bioavailability
and therapeutic efficacy of riluzole, a neuroprotective compound that likely exerts the greatest
therapeutic benefit early after SCI. Therefore, we reasoned that positive results with licofelone
treatment would hold more clinical relevance if observed as early as possible after injury.
Secondly, previous studies in our laboratory have demonstrated that peak BSCB permeability
to the protein albumin occurs between 48 and 72 hours post-SCI (Fig. 4.12). Accordingly, we
hypothesized that 72 hours post-SCI would be a more ideal time point for the assessment of
Pgp expression and function, as it is past the peak of BSCB leakiness and might eschew some
of the complications arising from increased passive diffusivity at the BSCB during earlier time
points.
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Figure 4.12. Time course of blood-spinal cord barrier permeability to albumin during
acute spinal cord injury. Albumin (~68 kDa) is a large blood-borne molecule that is normally
restricted from passing through the BSCB into the spinal cord tissue. The albumin-binding dye
Evans Blue (EB) is therefore a useful tool for the assessment of BSCB permeability to large
molecules following injury to the spinal cord. (a) EB was delivered i.v. to rats at various time
points following spinal contusion injury. 30 minutes later, rats were transcardially perfused
with saline, and spinal cords were harvested. Extravasation of EB from T10 spinal cord tissue
was quantified by fluorometric measurement at 620 nm. Compared to uninjured controls (100 ±
2.38%), EB extravasation was significantly higher in rats 1-3 days following SCI (24 h postSCI = 264 ± 59.5%; 48 h post-SCI = 348 ± 14.3%; 72 h post-SCI = 290 ± 105%). Furthermore,
EB extravasation remained increased for up to one week after injury, though not statistically
significant (5 d post-SCI = 195 ± 21.4%; 7 d post-SCI = 160 ± 26.1%). Based on this data, the
peak BSCB permeability to albumin following traumatic SCI appears to occur at about 48
hours post-injury. All data are mean ± s.e.m. and presented as percentage of uninjured controls.
*, p < 0.05 versus uninjured controls. (b) Photo illustrating gross anatomy of spinal cord tissue
of uninjured rat (top) and rat 48 hours post-SCI (bottom), following systemic delivery of EB
dye, and subsequent transcardial perfusion. Spinal cords of uninjured rats appear white because
intact BSCB function prevents the entry of the albumin-EB complex into the spinal cord
parenchyma. In contrast, vascular leakage of albumin-EB at 48 hours post-SCI is apparent in
the spinal cord parenchyma, both within the epicenter of injury (arrowhead), as well as several
millimeters rostral and caudal to the lesion site. Data provided courtesy of Dr. Raymond Grill.
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Animals were treated with either licofelone (100 mg/kg) or vehicle via the clinicallyrelevant oral route beginning at 3 hours post-SCI, then once daily for 3 days. At 72 hours,
immunoblotting revealed that T10 Pgp expression was significantly increased in the injured,
vehicle-treated group compared to uninjured controls (Fig. 4.13). This increase is reflective of
that observed previously (Fig. 3.8). Importantly, we observed that T10 Pgp expression was
significantly lower in the injured, licofelone-treated group versus that of the injured, vehicletreated group. This finding demonstrates that pathological Pgp overexpression within the
injured spinal cord can indeed be attenuated by oral treatment with licofelone. Our results also
corroborate those of previous studies, which have demonstrated that antagonism of the
COX/PGE2 signaling axis is effective in reducing Pgp overexpression in other neurological
disease models.
We next examined whether licofelone treatment exhibited an effect on spinal cord riluzole
bioavailability at this same time point. Animals were treated with licofelone or vehicle
beginning at 3 hours after injury, then once daily for 3 days. All three groups (both SCI groups
as well as uninjured controls) also received riluzole (i.p.) during the same dosing schedule. At
72 hours post-injury, spinal cord/plasma ratios of riluzole were assessed (Fig. 4.14). We found
that normalized spinal cord riluzole levels were slightly decreased in SCI compared to
uninjured controls, though this difference is not statistically significant (p = 0.201). We have
previously demonstrated that normalized spinal cord riluzole levels are significantly decreased
in T10 spinal tissue at 10 days post-SCI (Fig. 3.12), as well as in whole spinal cords at 21 days
post-SCI (Fig. 3.11). In light of these observations, the lack of a statistically significant
decrease in normalized riluzole levels at 72 hours after SCI might be attributed to increased
BSCB permeability observed at 3-7 days post-SCI, an observation supported both in our
laboratory (Fig. 4.12) and by other groups (189). Notably, we observed that normalized spinal
cord riluzole levels of licofelone-treated animals at 72 hours post-SCI were significantly higher
versus vehicle-treated animals (Fig. 4.14). Together with the observation that licofelone
treatment attenuates Pgp overexpression at 72 hours post-SCI (Fig. 4.13), the finding that
licofelone can also enhance the spinal cord uptake of riluzole supports our hypothesis that proinflammatory signaling drives Pgp-mediated spinal cord drug resistance following SCI. These
results suggest a new therapeutic avenue for enhancing the therapeutic efficacy of riluzole, a
drug that is currently being evaluated in an ongoing clinical trial as a neuroprotective
intervention for acute SCI.
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Figure 4.13. Licofelone treatment attenuates P-glycoprotein overexpression 72 hours
following spinal cord injury. Immunoblots of T10 spinal cord samples from rats 72 hours
post-SCI. Pgp expression levels are normalized to β-actin and expressed as a percentage of
uninjured controls (100 ± 9.01%, n = 8). Pgp levels in the lesion site of injured, vehicle-treated
rats are significantly higher than uninjured controls (SCI + vehicle = 306 ± 34.4%, n = 10, p <
0.001). Pgp levels of injured, licofelone-treated rats are significantly reduced versus injured,
vehicle-treated rats (SCI + licofelone = 198 ± 26.4%, n = 15, p = 0.008), but are still
significantly higher than uninjured levels (p = 0.022). Representative immunoblots are pictured
below graph. All data are mean ± s.e.m. *, p < 0.05.
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Figure 4.14. Licofelone treatment enhances spinal cord riluzole bioavailability 72 hours
after spinal cord injury. Animals were treated with riluzole alone, or riluzole and licofelone,
beginning 3 hours after SCI and again once daily for three days. Normalized spinal cord
riluzole levels were reduced (although not significantly so) in the riluzole-treated group 72
hours after injury (81.1 ± 4.53%, n = 6) versus uninjured controls (100 ± 4.24%, n = 7, p =
0.201). Normalized spinal cord riluzole levels were significantly enhanced in injured animals
treated with riluzole + licofelone (124 ± 13.8%, n = 8) versus the injured, riluzole-treated group
(p = 0.017). Additionally, the increase in spinal cord/plasma riluzole ratio in animals treated
with riluzole + licofelone approached statistical significance compared to uninjured controls (p
= 0.092). All data are mean ± s.e.m., expressed as percentage of uninjured controls. *, p < 0.05.
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We also evaluated whether there was differential plasma riluzole bioavailability in these
groups (Fig. 4.15). Interestingly, we observed that although the raw spinal cord riluzole
concentrations in both SCI groups were almost identically lower than uninjured controls (Fig.
4.15a), the plasma bioavailability of riluzole in the licofelone-treated group was substantially
lower than both uninjured controls and injured, riluzole-treated animals (Fig. 4.15b). From this
data, we have drawn two conclusions: 1) Because there is no injury-associated effect on plasma
riluzole bioavailability at 72 hours (See pink bar in Fig. 4.15b), the observed decrease in
plasma riluzole bioavailability in the licofelone-treated group must be attributed to licofelone
treatment; 2) Though there is no difference in raw spinal cord riluzole concentrations between
SCI groups (Fig. 4.15a), the reduction in plasma levels in the licofelone-treated group indicates
that licofelone enhances plasma-to-spinal cord delivery of riluzole, and suggests that a higher
systemic dose of riluzole may increase spinal cord drug delivery further. Because of these
observations, we speculate that at this acute time point following SCI, licofelone acts to
enhance clearance of riluzole from the plasma and to promote increased delivery of riluzole
from the plasma to the spinal cord tissue.
Up-regulation of Abcb1 transcription at the blood-brain barrier can also occur as a result of
drug treatment via activation of the pregnane X receptor, a ligand-activated nuclear receptor
(317). Therefore, it is possible that, independent from the effects of SCI-associated
inflammation on Pgp expression, treatment with riluzole during the acute phase of injury might
also alter spinal cord Pgp expression levels, and consequently the spinal cord uptake of riluzole.
We therefore performed a subsequent experiment to rule out this possibility. Beginning 3 hours
after injury, rats were treated with vehicle alone, riluzole alone, or riluzole and licofelone, once
daily for three days. Immunoblot analysis of Pgp expression revealed no significant effect of
riluzole treatment on Pgp expression within the lesion site at 72 hours post-SCI (Fig. 4.16). In
contrast, spinal cord Pgp expression in rats treated with both riluzole and licofelone was
significantly lower than those of vehicle-treated and riluzole-treated groups. Because repeated
treatment with riluzole does not significantly affect Pgp expression levels during this acute
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Figure 4.15. Effects of injury and licofelone treatment on raw spinal cord and plasma
riluzole concentrations. Abbreviations: RLZ, riluzole; RLZ + LIC, riluzole + licofelone. (a)
Compared to raw spinal cord riluzole concentrations of uninjured control rats (100 ± 4.25%),
both SCI groups displayed statistically significant decreases (SCI + RLZ = 74.4 ± 8.70%, p =
0.022; SCI + RLZ + LIC = 74.5 ± 7.86%, p = 0.016) that were almost identical (p = 0.988). (b)
In contrast, there was no significant reduction in plasma riluzole concentrations in the injured,
riluzole-treated group (93 ± 13.2%) compared to uninjured controls (100 ± 3.39%, p = 0.640).
However, injured rats treated with riluzole and licofelone displayed significantly reduced
plasma riluzole levels (64.9 ± 9.81%) compared to uninjured controls (p = 0.036) as well as
injured, riluzole-treated animals (p = 0.049). All data are mean ± s.e.m., expressed as
percentage of uninjured controls. *, p < 0.05.
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Figure 4.16. Repeated riluzole treatment does not affect spinal cord P-glycoprotein
expression. Immunoblots of T10 spinal cord samples from rats 72 hours following SCI. Protein
expression levels are normalized to β-actin and expressed as percentage of injured, vehicletreated (VEH) levels (100 ± 15.4%, n = 8). Pgp levels in the lesion site of riluzole (RLZ)treated rats are not significantly different than vehicle-treated (RLZ = 91.8 ± 8.83%, n = 9, p =
0.598). Injured rats treated with both RLZ and licofelone (LIC) have significantly reduced Pgp
expression (RLZ + LIC = 59.5 ± 7.19%, n = 9) compared to the vehicle-treated group (p =
0.036) and also compared to the riluzole-treated group (p = 0.039). Representative
immunoblots are pictured below graph. All data are mean ± s.e.m. *, p < 0.05 versus SCI +
VEH.
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period of SCI, we conclude that the reduced riluzole bioavailability observed in injured,
riluzole-treated rats (Fig. 4.14) is not attributed to the effects of riluzole treatment itself, but
rather can only be due to pathological mechanisms induced by injury.
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CHAPTER 5
Effect of Licofelone Treatment on Functional Recovery
Following Spinal Cord Injury in the Rat
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Background
At present, there are no proven effective therapeutic interventions that can significantly
improve functional recovery in SCI patients. To date, a large number of preclinical studies have
identified neuroprotective compounds that, if administered to experimental animals in the
minutes to hours following injury, can improve functional recovery. Several of these promising
neuroprotective compounds have been translated to clinical trials over the last few decades;
unfortunately, all have failed to show a robust, statistically significant improvement in
functional outcome of human patients. Therefore, a major goal of current SCI research is to
identify robust interventions that retain this neurological efficacy when translated to the clinic.
The central principle underlying therapeutic neuroprotection for acute SCI is the desire to
attenuate the destructive biochemical cascades that are set into motion immediately upon injury
to the spinal cord. Thus, an ideal neuroprotective intervention must be delivered as soon as
possible after SCI, in order to quickly attenuate the toxic biochemical processes of secondary
injury, minimize the expansion of cell death and tissue degeneration, and therefore maximize
preservation of neurological function (318). To minimize delay of treatment, the drug should be
administered systemically (intravenously or orally), rather than via invasive and time-intensive
surgical delivery (77). An ideal therapy should also exhibit high “translational potential”,
meaning that it should fall under one of the following categories: 1) an already FDA-approved
drug, or 2) a drug that has either undergone extensive evaluation for safety and efficacy in
human clinical use or 3) exhibits high potential to be translated to human trials, based on
preclinical studies (77). In this way, the time to translation “from bench to bedside” would be
minimal, and years of delay before FDA approval could be avoided.
Riluzole is an anti-glutamatergic compound that is FDA-approved as an oral therapy for
ALS. Currently, riluzole is under evaluation as an acute SCI intervention in a Phase I clinical
trial through the North American Clinical Trials Network (NACTN) (87). The translation of
riluzole to clinical trials was largely a result of preclinical evidence suggesting that it provides
neuroprotection when delivered 15-30 minutes following injury (77, 78, 82), and was greatly
facilitated by its status as an FDA-approved drug. However, subsequent experimental studies in
clinically relevant animal models, in which the initial delivery of the drug was delayed to a
more clinically realistic time point of 2 hours post-injury, reported that riluzole treatment did
not provide any neurological or histological benefits (81). It is reasonable to conclude from
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these findings that riluzole may exert therapeutic efficacy for SCI only if administered during a
crucial window of efficacy very early after injury. Despite the lack of experimental data
supporting any neuroprotective effect of riluzole when delivered at a more clinically relevant
time frame following SCI, the current clinical trial seeks to evaluate the efficacy of riluzole in
human SCI patients, with an initial therapeutic window extending up to 12 hours following
injury (87). It is, then, plausible that this trial may fail to observe any significant neurological
improvement in patients receiving riluzole several hours after SCI.
Based on our evidence that increased Pgp expression and activity during acute SCI results
in reduced spinal cord bioavailability of systemically-delivered riluzole (See Chapters 3 & 4),
we speculate that there is a time-dependent loss of efficacy of treatment due to Pgp upregulation within the injured spinal cord. This injury-induced mechanism could potentially
explain the observation that riluzole’s efficacy diminishes as the therapeutic window is delayed
(81). Moreover, this mechanism might also underlie the failure of neuroprotective drugs
previously seen in SCI clinical trials. If this is the case, then identifying a route to overcoming
Pgp-mediated drug resistance in the acutely-injured spinal cord is a therapeutic goal of high
priority.

Specific Aims
1. Our results thus far have shown that: 1) Spinal cord riluzole bioavailability is decreased
during the acute and sub-acute phases of SCI [See Chapter 3], and 2) Licofelone
treatment enhances riluzole delivery to the injured spinal cord [See Chapter 4]. Because
of the ability of licofelone treatment to enhance spinal cord riluzole delivery, we sought
to examine whether, following SCI in rats, combined treatment of licofelone and
riluzole would result in enhanced neurobehavioral outcome compared to riluzole
treatment alone.
2. Licofelone is a new generation anti-inflammatory drug that inhibits COX-1 and -2 as
well as 5-LOX (159). Previous research studies have indicated that COX and 5-LOX
pro-inflammatory signaling pathways both contribute to the pathophysiology of SCI,
and that pharmacologically inhibiting either of these branches improves functional
recovery in rodent models of SCI (121, 136, 142, 144). For these reasons, the potential
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efficacy of NSAIDs for SCI treatment has been recently discussed (77). We speculated
that licofelone may hold promise as a neuroprotective treatment for acute SCI based on
two reasons. First, there is evidence that dual inhibition of both pathways has a
synergistic anti-inflammatory effect, as COX inhibition can shunt AA to 5-LOX
metabolism, thus increasing inflammation (153, 319). Second, licofelone use is
associated with a lower incidence of GI complications in patients compared to classical
COX inhibitors such as naproxen (320), thus making it a more attractive candidate for
clinical use than classical NSAIDs. We therefore evaluated whether licofelone
treatment following SCI in rats could improve functional recovery.

Results
Basso, Beattie, and Bresnahan Open Field Locomotor Scale
We assessed whether licofelone, alone or in combination with riluzole, could improve
locomotor outcome in rats over a six-week period following SCI. In order to evaluate rodents’
neurological recovery following a clinically-relevant drug dosing schedule, we reproduced the
time course of treatment utilized in the current NACTN riluzole SCI trial (87), in which
riluzole treatment is initiated in patients ≤12 hours post-SCI, then continued for 14 days.
Following SCI, rats were treated with: 1) vehicle (VEH), 2) riluzole (RLZ), 3) licofelone (LIC),
or 4) licofelone and riluzole (LIC + RLZ), beginning at 3 hours following injury, then again
once daily until post-injury day 14 (DPI 14). Beginning on DPI 1, motor recovery was assessed
using the BBB Open Field Locomotor Scale, a sensitive assessments allowing quantification of
multiple aspects of hindlimb motor function in rats (280). BBB scores were assessed on postoperative days 1, 2, 3, 5, 7, 10, 14, 21, 28, 35, and 42. Average BBB scores for all treatment
groups at each time point are displayed in tabular format in TABLE 5.1 and graphically in
Figure 5.1.
Beginning on DPI 14, BBB scores of the SCI + LIC group and the SCI + LIC + RLZ group
were significantly greater than those of the SCI + vehicle group. This effect was observed
consistently at each time point from DPI 14 until the last measured time point, DPI 42. In
contrast, the SCI + RLZ group scores were not significantly greater than the SCI + vehicle
group scores at any point during this study. We also failed to detect any significant difference
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Baseline

Day 1

Day 2

Day 3

Day 5

Day 7

Uninjured

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

VEH

21.0

± 0.0

0.3

± 0.1

1.3

± 0.3

1.9

± 0.3

4.5

± 0.7

5.6

± 0.9

RLZ

21.0

± 0.0

0.6

± 0.1

1.8

± 0.6

1.9

± 0.7

4.6

± 1.1

5.9

± 1.1

LIC

21.0

± 0.0

0.9

± 0.2

2.1

± 0.7

4.8

± 1.0

6.9

± 0.6

7.8

± 0.7

RLZ + LIC

21.0

± 0.0

0.7

± 0.2

2.9

± 0.7

3.6

± 0.7

6.5

± 0.6

7.9

± 0.4

Day 10

Day 14

Day 21

Day 28

Day 35

Day 42

Uninjured

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

21.0

± 0.0

VEH

6.6

± 0.8

7.8

± 0.4

8.5

± 0.3

8.8

± 0.4

9.0

± 0.3

9.1

± 0.5

RLZ

8.2

± 0.7

9.3

± 0.6

10.0

± 0.7

10.2

± 0.6

10.4

± 0.6

10.4

± 0.7

LIC

9.3

± 0.9

9.9

± 0.9

10.7

± 0.6

11.3

± 0.6

11.6

± 0.7

12.1

± 0.7

RLZ + LIC

9.0

± 0.2

9.8

± 0.2

10.2

± 0.2

10.8

± 0.3

11.4

± 0.3

12.1

± 0.4

TABLE 5.1. BBB open field locomotor scores. Average hindlimb BBB scores at time points before (baseline) and after injury. Uninjured, n
= 17; SCI + Vehicle (VEH), n = 9; SCI + Riluzole (RLZ), n = 7; SCI + Licofelone (LIC), n = 9; SCI + Riluzole + Licofelone (RLZ + LIC),
n = 10. All data are mean ± s.e.m.
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Figure 5.1. BBB scores. Average hindlimb BBB scores at time points before (Pre) and after injury. All data are mean ± s.e.m. *, p < 0.05
versus injured, vehicle-treated animals.
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between BBB scores of the licofelone-treated group and the licofelone-and-riluzole-treated
group at any time point during this study.

Photobeam Activity System
The PAS is a sensitive assessment of multiple measures of gross and fine locomotor
activity. During the 20-minute testing period, animals’ movements were recorded by the PAS
computer, and the following parameters were tabulated: distance traveled, speed of movement,
time at rest, fine movement, ambulatory movement, number of rears, and time spent rearing.
Each of these activity parameters reflects different aspects of locomotor function and/or ability.
For example, an increased speed of movement and/or distance traveled by an animal indicates a
heightened overall level of activity; conversely, increased time spent at rest might indicate a
state of increased pain or a relative difficulty moving (321). Rearing, in which an animal stands
up on its hindlimbs, utilizes not only hindlimb muscles but also trunk muscles for maintenance
of posture. It has therefore been suggested that the extent of rearing by animals with SCI is a
useful parameter for studying the effects of treatments on postural maintenance that may be
relevant to human patients (322).
Distance, Speed, and Rest Time: Total distance traveled by all animals over the 20minute testing period is displayed graphically in Figure 5.2.

All SCI groups covered a

significantly lower distance versus uninjured controls (p < 0.05) at all time points following
injury. Similarly, the speed of movement of all SCI groups was significantly reduced versus
uninjured controls at all time points point-injury (Fig. 5.3), but there was no significant
difference in speed between injured groups. Lastly, we examined the time spent resting during
the 20-minute testing period (Fig. 5.4). We detected statistically significant increases in resting
time compared to uninjured controls for the following comparisons: SCI + VEH at DPI 14, -35,
and -42; SCI + RLZ + LIC at DPI 14; and RLZ at DPI 21. At DPI 42, time spent at rest by the
SCI + LIC group was significantly lower than that of the SCI + VEH group.
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Figure 5.2. Total distance of movement. Total distance (cm) traveled by rats during the 20minute testing period. All data are mean ± s.e.m.
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Figure 5.3. Average speed of movement. Average speed (cm/s) of rats’ movement during the
20-minute testing period. All data are mean ± s.e.m.
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Figure 5.4. Total time spent at rest. Average resting time (s) by rats during the 20-minute
testing period. All data are mean ± s.e.m. *, p < 0.05 versus SCI + VEH.
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Fine and Ambulatory Movement: Animals’ total fine movement over the 20-minute
testing period is displayed in Figure 5.5a. The amount of fine movement observed in SCI
groups was higher than that of uninjured controls at every assessed time point after injury,
though statistical significance was only achieved for the following comparisons: SCI + VEH at
DPI 21, -28, -35, and -42; SCI + RLZ at DPI 14 and -35; SCI + LIC at DPI 7, -21, -35, and -42;
SCI + RLZ + LIC at DPI 7, -21, -35, and -42. There were no significant differences between
injured groups at any time point. For ambulatory movement (Fig. 5.5b), all SCI groups
exhibited significantly reductions versus uninjured controls at all time points post-injury.
There were no treatment-dependent effects on ambulatory movement between SCI groups.
Rearing: The total number of rearing events exhibited by each group is displayed in
Figure 5.6a. At each time point from DPI 7 through DPI 35, total rearing events exhibited by
each injured group are significantly lower than that of uninjured controls; however, at DPI 42
only the SCI + VEH group is significantly lower than controls. At DPI 42, number of rearing
events of the SCI + LIC + RLZ group was significantly higher than in the SCI + VEH group.
Total time spent rearing is displayed in Figure 5.6b. Total rearing time is significantly reduced
at DPI 7, -14, -21, and -28 for all SCI groups versus uninjured controls. At DPI 35, only SCI +
RLZ + LIC exhibited significantly reduced rearing time versus controls, and there were no
significant differences detected between groups at DPI 42.
Despite the wealth of activity data assessed here, we conclude that the only robust and
significant result of this study was the improvement in BBB scores exhibited by both
licofelone-treated groups from DPI 14 to -42. Though there were two significant effects of
licofelone treatment on activity parameters at DPI 42 (Figs. 5.4 & 5.6a), it is doubtful that these
slight improvements are functionally meaningful. In contrast, the more than three-point
improvement in BBB scores that we have observed in licofelone-treated rats has a large degree
of functional significance (See Chapter 6).
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Figure 5.5. Total fine and ambulatory movement. Total fine movement (a) and ambulatory
movement (b) during the 20-minute testing period. All data are mean ± s.e.m.
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Figure 5.6. Total rearing events and time spent rearing. Total number of rearing events (a)
and total time (s) spent in the rearing posture (b) during the 20-minute testing period. All data
are mean ± s.e.m. *, p < 0.05 versus SCI + VEH.
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CHAPTER 6
Conclusions, Translational Significance, and Future Directions
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Potential Roles for Other ABC Transporters in the Injured Spinal Cord
In the current study, we have shown that P-glycoprotein is only one among several ABC
transporters that undergo differential expression following SCI. Our microarray results (TABLE
3.1) indicate that several genes belonging to the ABC transporter family are also significantly
increased or decreased within the spinal cord lesion site at 7 days after injury. Aside from
abcb1, among the genes that we have found to be up-regulated by injury were abcb4 (+6.07fold, p < 0.001), abcb7 (+2.06-fold, p = 0.006), abcc3 (+2.14-fold, p < 0.001), and abcg1
(+3.36-fold, p < 0.001). Of these, abcc3, the gene encoding Multidrug resistance-associated
protein 3 (Mrp3), is the only member which has been described in the literature as exhibiting
drug transport activity; thus, it is not implausible that increased expression of Mrp3 may also
contribute to spinal cord drug resistance following traumatic SCI.
ABC transporter genes that were down-regulated following injury included abca5 (-2.59fold, p = 0.002), abcb6 (-1.71-fold, p < 0.001), abcb9 (-3.91-fold, p < 0.001), abcc2 (-13.92fold, p < 0.001), abcc6 (-3.44-fold, p = 0.008), abcc8 (-3.00-fold, p < 0.001), abcd2 (-5.54-fold,
p < 0.001), abcd3 (-1.55-fold, p < 0.001), and abcg2 (-1.62-fold, p = 0.010). Of these, abcc2
(mrp2) is of particular interest in terms of drug transport. The Mrp2 gene product is
functionally similar to Pgp; it is expressed on the luminal membrane of brain capillary
endothelial cells, where it transports a wide variety of compounds, including drugs susceptible
to multidrug resistance as well as endogenous organic anions (9). Pgp and Mrp2 have some
overlapping activity; for example, up-regulated Pgp functions in a compensatory role for antiepileptic drug transport in rats deficient in Mrp2 (323). To date, there have been no reports
describing an affinity of Mrp2 for riluzole, so whether reduced activity of this transporter may
influence riluzole disposition, e.g., in the current study, remains to be determined.
In contrast, the gene product of abcg2, Breast cancer resistance protein (Bcrp), was
recently shown by Milane et al. to transport riluzole at the blood-brain barrier in mice (324).
Though much less is known about the regulation of Bcrp expression compared to that of Pgp,
this group also demonstrated that repeated riluzole treatment led to increased Bcrp efflux
activity and decreased brain riluzole levels in mdr1a-/- mice (324), implying that Bcrp can be
up-regulated at the blood-brain barrier by drug treatment. Here, we have shown that repeated
riluzole treatment does not alter Pgp expression in the injured spinal cord, but we did not assess
Bcrp levels. Therefore, we cannot rule out the possibility that enhanced Bcrp expression in the
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spinal cord lesion site, following repeated riluzole treatment, may contribute to reduction of
spinal cord riluzole levels. Interestingly, Milane and colleagues did not observe any differences
in Bcrp expression or function in mice expressing the mutant human G86R SOD1 isoform
(224), despite their observations of increased Pgp expression and activity in this model. This
disparity suggests that the pathological mechanisms driving Pgp overexpression in neurological
disease do not necessarily also regulate Bcrp expression in the same way. We have observed a
1.62-fold decrease in abcg2 expression one week following injury within the spinal cord lesion
site, compared to a 10-fold increase in abcb1 expression. Based on this data, it is obvious that
the pathological processes within the injured spinal cord do not modulate expression of these
two transporters in equal ways. It has recently been shown that Bcrp and Pgp act in concert to
diminish drug delivery in brain cancer (325); thus, it is not inconceivable that a similar
mechanism might be observed in SCI. Whether Bcrp and other drug transporters negatively
influence spinal cord drug delivery following SCI remains an important question for future
study. Active drug transport at the blood-brain/-spinal cord barriers is not entirely understood,
as it is an extraordinarily complex system comprised of multiple, tightly regulated family
members that often exhibit functional redundancy (182). Thus, the pathological consequences
of SCI may very well include altered expression and activity of multiple drug transporters, with
potential to alter the CNS disposition of a multitude of bioactive drugs. Future studies are
needed to examine the roles of other drug transporter proteins in the injured spinal cord and the
extent to which they might also contribute to multidrug resistance.
Given the broad functional diversity of the ABC transporter family members, it is
conceivable that some of these proteins, which carry out biological functions other than drug
transport, may function in roles that otherwise influence SCI pathology. The most dramatically
up-regulated of the ABC transporter genes that we observed at 7 days post-SCI (apart from
abcb1) was abcb4, which encodes Mdr2, a phosphatidylcholine transporter that plays a crucial
role in the liver, transporting hepatic phospholipids into the bile. It is known that Mdr2 is
expressed in the brain at low levels, but its function in the CNS is unknown (326).
Additionally, abcg1, encoding the White1 transporter, is important for cholesterol homeostasis,
suggesting possible implications for the regulation of myelination following SCI. The abcd2
gene, which encodes the adrenoleukodystrophy-related protein (Aldrp), is expressed in
peroxisomal membranes. Aldrp plays a vital function in the transport of very long-chain fatty
acids (VLCFA) during normal fatty acid oxidation (326). In the metabolic disease
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adrenoleukodystrophy (ALD), dysfunction of abcd1 and abcd2 results in accumulation of
VLCFA, causing lipotoxicity-induced, demyelinating inflammation of the brain (299).
Interestingly, it has recently been shown that this lipotoxic effect of VLCFA accumulation is
mediated through 5-LOX activity and enhanced production of the pro-inflammatory CysLTs
and LTB4 (327). Perhaps the substantial down-regulation of abcd2 observed here at 7 days
post-SCI may impart a similar VLCFA-mediated lipotoxic effect via increased production of
leukotrienes. These are only speculations, and there is a limit to the information that can be
gleaned from a study of differential gene expression within such a complex pathophysiological
system. Regardless, our array data may provide important clues into the multifaceted
pathological response of ABC transporter family members to SCI, and serve as a useful starting
point toward the design of further investigations of the potentially injurious (or
neuroprotective) influences of these proteins within the injured spinal cord.

P-glycoprotein Expression Patterns in the Injured Spinal Cord
We have shown that Pgp immunoreactivity in the uninjured spinal cord is restricted to
blood capillary endothelial cells (Figs. 3.2, 3.3). This finding is consistent with the vast
majority of previously published accounts (203). Only one group has repeatedly reported Pgp
expression on the cell membranes of astrocyte end-foot processes (301-304). However, whether
Pgp has a functional role in astrocytes or other cells in the brain parenchyma, under normal or
disease conditions, is not known. We have not extensively examined cellular distribution of
Pgp immunoreactivity following SCI in this study, but we did observe that Pgp expression
remained localized to spinal cord vasculature at one week post-SCI (Fig. 3.4). Thus, it is
reasonable to assume that our immunoblot quantification of Pgp levels is an accurate
representation of Pgp expression in capillary EC membranes at the BSCB.
Here, we have reported increased Pgp expression within the spinal lesion site from as early
as 72 hours post-injury, up to 10 months after injury (Fig. 3.8). Due to the practical limitations
of these experimental studies, we have only assessed protein expression levels at four acute and
chronic time points: 72 hours, 7 days, 4 months, and 10 months post-SCI. We have not
examined earlier time points, so it is possible that Pgp up-regulation may occur even earlier
than 72 hours within the injured spinal cord. Similarly, we have not examined Pgp expression
at time points between one week and four months. During this substantial time window, the
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BSCB is generally thought to regain most of its functional integrity; however, some reports
have demonstrated prolonged BSCB permeability for months following injury (177, 189). In
the context of the sparse and incomplete information that has been gained about BSCB function
during the sub-acute and chronic phases of SCI, it will be interesting to see whether future
investigations reveal a relationship between the temporal dynamics of BSCB leakiness and the
expression patterns of selective transport systems such as Pgp. Characterizing the relationship
between “passive” barrier dysfunction (e.g., loss of tight junctional integrity) and differential
regulation of “active” barrier function (i.e., Pgp up-regulation) will increase our understanding
of how changes in BSCB properties contribute to outcome following traumatic injury to the
spinal cord. Certainly, further studies are warranted in order to gain a more complete
understanding of the temporal regulation of expression of Pgp (and possibly other drug
transporters) within the spinal cord lesion site.
Similarly, another question of high interest is whether the delayed increases in cervical and
lumbar Pgp expression that we report here (Figs. 3.9, 3.10) mirror a progressive spatial spread
of passive BSCB deficits. Previous studies in our laboratory have identified increased BSCB
permeability to large molecules such as albumin and IgG that is detectable 1 cm rostral to the
lesion site 1 month after contusion injury at T10, as far rostral as the brainstem by 8 months
post-SCI, and as far caudal as the lumbar cord by 9 months post-SCI (unpublished data;
experiments performed by Dr. Raymond Grill). Our laboratory has also shown that this
progressive barrier dysfunction correlates with reduced vascular expression of the adherens
junction protein, vascular endothelial (VE)-cadherin (unpublished data). Together, these
observations provide compelling evidence for a temporal and spatial spread of passive BSCB
dysfunction. In this study, we have detected increased Pgp expression in cervical (C6-C7)
spinal cord tissue as early as one week after injury; this alteration appears to be sustained for as
long as 10 months (Fig. 3.9). We have also made similar observations in lumbar spinal cord
tissue at 4 and 10 months post-SCI (Fig. 3.10). We have not evaluated Pgp expression in other
areas of the spinal cord or brainstem in this project, but we plan to investigate this possibility in
future studies. If SCI is followed by a progressive spread of increased vascular Pgp expression,
similar to the spread in passive BSCB dysfunction that we have previously observed, there may
be important implications for drug delivery in the chronic phase of SCI. Further study is also
needed to investigate whether the active and passive components of BSCB pathology are
distinct, or whether they might be driven by common molecular mechanisms. If the latter is
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true, simultaneously targeting both of these aspects of BSCB dysfunction by antagonizing a
common signaling network may be a desirable therapeutic goal.

Functional Significance of P-glycoprotein Up-regulation
P-glycoprotein is an incredibly promiscuous drug transporter with an affinity not only for
endogenous substrates, but also for xenobiotic compounds. How—and why—Pgp has evolved
to recognize such a large variety of substrates is an intriguing philosophical question. Some
insight might be gained by examining the biochemical basis for the transporter’s ability to
recognize such a large variety of structurally disparate compounds. Aller and colleagues (199)
recently elucidated the crystal structure of Pgp in the presence and absence of bound substrate.
They found that the transporter possesses a large substrate binding domain, which contains
multiple hydrophobic, aromatic, and polar residues (Fig. 6.1). Unique subsets of these residues’
side chains make contact with different drug compounds within the binding pocket, thereby
forming the basis for the protein’s substrate poly-specificity (199).
Most Pgp substrates are small and hydrophobic, and consequently exhibit an increased
tendency to partition into the cell membrane (328). It is therefore easy to appreciate the
evolutionary advantage gained by stationing such a highly promiscuous and efficient efflux
system at a biological barrier that is susceptible to transcellular diffusion of potentially toxic
molecules. These properties endow Pgp with an unparalleled ability to protect the various
sensitive tissues at which it is expressed (e.g., the CNS (329), the testes (204), and even the
developing fetus (205)) from exposure to harmful compounds in the blood. ABC transporters
are ancient, and these proteins are expressed in organisms as distant from humans as bacteria.
Each member of this very diverse family has some type of specialized active transport activity,
but only the MDR (ABCB), MRP (ABCC), and BCRP (ABCG) family members confer
multidrug resistance in humans. One perplexing philosophical question, therefore, is why Pgp
evolved the ability to recognize such a large variety of synthetic drugs that do not occur in
nature. It is difficult to speculate as to why Pgp evolved substrate poly-specificity before the
advent of modern medicine. It is likely that Pgp originated from related ABC transporters that
functioned in the transport of endogenous substrates (a function that Pgp also retains), and that
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Figure 6.1. Drug-binding residues of P-glycoprotein. QZ59-RRR and QZ59-SSS are two
stereoisomers of cyclic hexapeptide inhibitors. (A) Crystal structures of drug-bound Pgp
substrate binding pockets. Binding of each of these drugs, as well as the Pgp substrate drug
verapamil, within the Pgp substrate binding domain involve associations with unique subsets of
amino acid side chains (B) within the binding pocket. Figure from: Structure of PGlycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Stephen G. Aller,
Jodie Yu, Andrew Ward, Yue Weng, Srinivas Chittaboina, Rupeng Zhuo, Patina M. Harrell,
Yenphuong T. Trinh, Qinghai Zhang, Ina L. Urbatsch, and Geoffrey Chang. Science 27 March
2009: 323 (5922), 1718-1722. Reprinted with permission (199).
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at some point during evolutionary history, Pgp gained an increased substrate promiscuity that
conferred the organism(s) expressing it with a biological advantage. This advantage lies in its
ability to “adapt” its binding site to accommodate a diverse variety of substrates, thus providing
barrier defense against new and previously unencountered substances. In this way, Pgp activity
is analogous to that of the cytochrome P450 (CYP) class of enzymes, which perform oxidative
breakdown of substances in a diverse range of organisms from bacteria to humans. There is an
incredible range of CYP family members and isoforms, and like Pgp, they act on diverse
substrates including a large number of synthetic xenobiotics. It is easy to understand the
evolutionary advantage of enzymes with such labile binding sites in the context of
detoxification of exogenous, potentially harmful substances.
It is these same qualities of Pgp, however, that often prevent therapeutic levels of bloodborne drugs from reaching the CNS, unless such high doses are used that peripheral side effects
may be experienced (182). Similarly, the up-regulation of Pgp expression following repeated
drug treatment is probably a protective response that evolved in order to more efficiently
protect the organism against a repetitive barrage of toxic insults. Others have shown that upregulation of Pgp can be driven by inflammation and oxidative stress—molecular processes
that are principally associated with disease and injury. Pgp up-regulation might therefore serve
as an endogenous protective response. In neurological disease and trauma, it is plausible that
blood-brain/-spinal cord barrier up-regulation of Pgp could be spurred in part by passive
deficits in blood-CNS barrier integrity. The resulting increase in extravasation of circulating
substances through the barrier would lead to accumulation of toxic blood-borne compounds and
endogenous metabolites; thus, an increase in efflux transport activity at the blood-CNS
interface would function to protect the CNS tissue by contributing to clearance of toxic
metabolites.

Dual Modulation of the Blood-Spinal Cord Barrier by Anti-Inflammatory Therapy
It seems logical to assume that increased paracellular flow of substances from the
circulating blood into the CNS would effectively increase delivery of systemic drugs to the
CNS. Paradoxically, however, increased passive permeability of the blood-CNS barriers may
not necessarily assure drug permeability, and in some cases may actually reduce brain drug
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concentrations. Marchi and colleagues showed that osmotic blood-brain barrier disruption
caused increased serum protein extravasation and reduced levels of free phenytoin (an antiepileptic drug) in the brain (330), an effect likely attributed to increased drug-protein binding.
A similar effect may occur in SCI, where vasogenic edema resulting from BSCB opening may
increase sequestration of drug molecules by extravasated albumin in the injured spinal cord
tissue. If this is the case, it is possible that passive BSCB dysfunction, in addition to alterations
in active transport, also contribute to reduced efficacy of systemically-delivered therapeutic
drugs.
It is interesting to consider the possible contributions of inflammation to both passive and
active aspects of BSCB function following traumatic injury to the spinal cord. Extensive work
by Potschka and colleagues has implicated the COX-2/PGE2/EP1 signaling axis as key in
driving Pgp overexpression at the blood-brain barrier following seizure activity (235, 236,
244). In light of our observations that licofelone is effective in attenuating BSCB Pgp levels
during acute SCI (Fig. 4.13), it is highly likely that similar regulatory mechanisms of Pgp
expression are at work in both pathologies. This is not altogether surprising, as it is well known
that neuroinflammation drives multiple pathophysiological mechanisms that contribute to the
progression of CNS disease. It is well established that inflammation modulates opening of the
blood-brain barrier (331); likewise, following SCI and peripheral nerve injury, inflammatory
mediators promote BSCB permeability (72, 178, 332, 333). Thus, treatment with antiinflammatory drugs such as licofelone may serve a double purpose in improving BSCB
function after SCI, by both preventing inflammation-driven up-regulation of drug efflux
transport via Pgp, and attenuating inflammatory-mediated opening of the BSCB. Previous work
by other groups has demonstrated that treatment with the COX inhibitors ibuprofen and
indomethacin reduces edema and BSCB permeability following SCI (124, 127). Though we
have not yet addressed whether licofelone treatment can also improve aspects of passive BSCB
function, we intend to evaluate this possibility in future studies in our laboratory.
Previous reports have shown that the COX and 5-LOX signaling pathways are critical
factors shaping the pathological molecular processes and influencing functional outcome
during acute SCI (121, 142, 144, 246). It is these observations that have fueled our laboratory’s
interest in simultaneous COX/5-LOX inhibition as a means not only to target Pgp upregulation, but also to combat other aspects of SCI pathophysiology and potentially improve
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functional outcome. We have shown that licofelone completely abolishes the sharp increase in
PGE2 production observed 24 hours after injury (Fig. 4.11). However, our failure to detect
quantifiable levels of LTB4 is a caveat that undermines the argument for a therapeutic role for
5-LOX inhibition in these studies. One possible explanation is that LTB4 production may only
occur very early after injury, and fall to baseline (uninjured) levels by 24 hours after SCI. This
possibility is supported by the work of Moreland and colleagues (141), in which peak LTB4
production was observed within the first 4 hours post-SCI in rabbits and returned to control
levels by 24 hours. An alternative approach would be to evaluate the effects of licofelone on
CysLT production, given that we have previously observed a marked elevation in CysLT levels
24 hours post-SCI (Fig. 4.1).
We have shown that acute licofelone treatment is efficacious in partially abrogating the upregulation of Pgp by SCI (Fig. 4.13), providing strong support for the inflammatory modulation
of Pgp expression within the injured spinal cord. Potschka’s group have revealed COXmediated PGE2 signaling to be a major factor promoting Pgp expression in the epileptic brain
(187), and more recently other groups have reported similar findings in cancer cells (238, 241,
309). We have hypothesized the likelihood of a comparable regulatory mechanism in SCI,
given the common pathological cascades (e.g., inflammation, oxidative stress, excitotoxicity)
that are exhibited in these diseases. In the absence of a systematic study comparing Pgp levels
following COX inhibition versus combined COX/5-LOX inhibition in spinal cord-injured rats,
it is difficult to speculate whether licofelone treatment would be more efficacious than a COX
inhibitor such as ibuprofen. It is also known that oxidative stress drives Pgp up-regulation in
brain capillary ECs (334). We have shown that expression of all three enzymes—COX-1,
COX-2, and 5-LOX—is increased 72 hours after injury (Fig. 4.2), so it is feasible that
licofelone’s effect on Pgp expression at this time point is partially due to blocking the oxidative
stress produced by COX- and 5-LOX- metabolism of AA. Certainly, more mechanistic studies
are needed to investigate this possibility.

Novel Evidence of Inflammation and Oxidative Stress in Chronic Spinal Cord Injury
Inflammation plays a major role in shaping the pathophysiology of acute SCI. During the
hours-to-days following the initial impact to the spinal cord, the inflammatory response
contributes to disruption of vascular integrity (72), formation of the glial scar (100),
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cytotoxicity (98), and sensitization of neural pathways (30). In contrast, relatively few studies
have undertaken the task of characterizing the molecular milieu of the spinal cord beyond one
to two months post-injury. Recently, studies have reported the presence of infiltrating
peripheral immune cells and activated microglia within the spinal cord up to 1 year post-SCI
(69, 70). These findings raise the possibility that neuroinflammation might not simply be a
transient phenomenon, but may rather continue into the chronic phase of injury, fueling
ongoing pathological processes that plague SCI patients with long-standing injuries, such as
neuropathic pain.
In the current study, we have provided novel evidence of both pro-inflammatory AA
metabolism and oxidative stress within the chronically-injured spinal cord. The presence of
LTB4 and PGE2 in the spinal cord lesion site 9 months after injury (Fig. 4.6) is compelling
evidence that the inflammatory response is not simply a phenomenon confined to the earlier,
acute phase of injury. Rather, our results have demonstrated that pro-inflammatory signaling
through COX and 5-LOX pathways is also present in the chronically-injured spinal cord.
Furthermore, using a high-throughput metabolomic screen (Figs. 4.7-4.9 & TABLE 4.1), we
have shown that the chronically-injured spinal cord contains elevated levels of oxidative stress
markers and a depletion of endogenous anti-oxidative and anti-inflammatory compounds. This
included elevated levels of the major indicators of cellular ROS damage, oxidized glutathione
(335), cysteine-glutathione disulfide (336), and dehydroascorbate (337). Chronic SCI tissue
also possessed increased levels of 13-HODE and 9-HODE, markers of oxidative stress and
lipid peroxidation (338). Additionally, chronically-injured spinal cords contained decreased
levels of the antioxidant alpha-tocopherol, which plays an especially important role in
protecting the highly sensitive CNS from pathological lipid peroxidation (339). These are
significant findings, due to the existing deficiency in knowledge of the molecular environment
within the chronically-injured spinal cord. Our observations of neuroinflammation and
oxidative stress in the far chronic period will contribute to understanding of the pathological
mechanisms that shape the myriad adverse conditions, including neuropathic pain, that are the
hallmark of the chronic phase of SCI.
Ours is the first study featuring a metabolomic profile of chronically-injured spinal cord
tissue. In this report, we have placed an emphasis on the metabolic alterations indicative of
oxidative stress and inflammation in the cord, because of their previously identified role in
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promoting up-regulation of P-glycoprotein (214). However, our metabolomic screen has
illuminated a large number of additional metabolic alterations in various other biochemical
pathways (Figs. 4.7, 4.8 & TABLE 4.1). Our metabolomic results reveal chronic alterations in
nucleotide metabolism, reductions in levels of several metabolites associated with
neurotransmission, decreased phospholipid levels, and alterations in cholesterol metabolism,
among many other changes. We have also detected increases in glycolytic intermediates in the
chronically injured spinal cord, such as glucose (+2.73 fold), glucose-6-phosphate (+2.53 fold),
and fructose-6-phosphate (+2.29 fold). In view of our results of chronically increased Pgp
expression, we anticipate that enhanced glycolysis in the chronically injured spinal cord may
reflect an increased need for energy to fuel active transport systems, as has been previously
described in multidrug-resistant tumors (340). Lending support to this idea, a recent metabolic
profiling study has shown increased glycolysis and phospholipid turnover in drug resistant
tumor cells (341). As a side note, the possible relationship between increased glycolytic flux
and heightened active transporter activity may also be worth considering in another form of
neurotrauma, traumatic brain injury (TBI), which is often accompanied by brain
hyperglycolysis (342). Though Pgp-mediated drug resistance has not yet been characterized in
TBI, injury-associated resistance to pharmacotherapy has previously been observed (343).
Our observations of chronic inflammation in the injured spinal cord also led us to
investigate the effects of dual COX/5-LOX inhibition in the chronic phase of SCI. We observed
that months-delayed licofelone treatment resulted in statistically significant increases in a
number of compounds that exhibit anti-inflammatory and anti-oxidative properties (Fig. 4.10 &
TABLE 4.2). However, the precise mechanism by which licofelone mediates this effect is
unclear, as AA metabolism is a complex cascade with a plethora of molecular targets. Based on
the wide range of metabolic pathways enhanced by licofelone, it is possible that licofelone may
activate a “master regulator” of the antioxidant response such as nuclear factor erythroid-2related factor-2 (Nrf2), which induces transcription of multiple protective anti-oxidant genes
(344). Due to experimental constraints, we did not evaluate the effect of licofelone treatment on
prostaglandin and leukotriene production in the chronically-injured spinal cord. However, we
intend to investigate this in future studies, as the eicosanoids have been shown to play a
significant role in the development and maintenance of neuropathic pain (345, 346), a condition
that afflicts a substantial percentage of individuals with chronic SCI (276).
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Implications of P-glycoprotein-Mediated Drug Resistance in Spinal Cord Injury
One might anticipate that a lack of Pgp efflux activity at the BSCB would result in
enhanced spinal cord drug delivery under normal (non-disease state) conditions. An interesting
finding of this study is that uninjured mdr1a-/- rats did not exhibit greater spinal cord riluzole
penetration compared to uninjured wild-type rats (Fig. 3.12). This is in contrast to Milane’s
observation that mdr1a-/- mice showed 1.4-fold higher brain uptake of riluzole than mdr1a+/+
mice (225). The most logical explanation for this discrepancy is that the rat may possess some
degree of compensatory riluzole efflux due to activity of other drug transporters, such as Bcrp.
Further analysis will be needed to substantiate this possibility. Regardless, our observation that
loss of Pgp is sufficient to abolish an injury-induced decrease in spinal cord riluzole uptake, is a
very strong piece of evidence showing that Pgp is responsible for the reduction in blood-tospinal cord riluzole delivery that we have observed following SCI.
Also interesting is our finding that mdr1a-/- rats with SCI have significantly lower plasma
levels of riluzole than their injured, wild-type counterparts (Fig. 3.13). Following i.p. drug
delivery, clearance of drug from the plasma is regulated to a large extent by active transportmediated excretion of drug by the liver and kidneys into the bile and urine, respectively.
Importantly, Pgp activity is involved in both of these aspects of drug clearance (347, 348). In
the liver, Pgp transports drugs from the hepatocytes into the bile, and in renal epithelial cells
the transporter acts in a similar role of drug transport to the urine. One might therefore expect
healthy mdr1a-/- rats to exhibit reduced drug clearance from the plasma due to loss of hepatic
and renal Pgp function. Our results show that this is not the case, and suggest that
compensatory drug transport activity might also serve to explain the lack of significant
difference in plasma drug levels between uninjured wild-type and knockout rats. However, the
sizeable SCI-induced reduction in riluzole plasma levels of mdr1a-/- rats, but not wild-type rats,
is somewhat puzzling. In their characterization of the mdr1a-/- rat, Chu et al. showed that these
animals retain strong expression of what is presumably the Mdr1b gene product in the liver, but
only faint expression in the kidney (Fig. 3.14) (307). Perhaps, then, this closely related isoform
becomes up-regulated following SCI in the absence of Mdr1a function. Though the current
study has not addressed Mdr1a/1b expression in the liver, kidneys, or intestines, Chu et al. also
reported a five-fold increase in mdr1b expression in the liver, and a two-fold decrease of mdr1b
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expression in the kidney of male mdr1a knockout rats, compared to wild-type animals9. Taken
together with experimental evidence that Mdr1b efflux activity can increase in response to
inflammation (245), it seems quite plausible that increased liver Mdr1b function may explain
the augmented drug plasma clearance in mdr1a-/- rats with systemic inflammation resulting
from SCI (31).
We chose riluzole for these studies because of the obvious clinical relevance of examining
post-SCI drug resistance using a drug that is currently in clinical trials. However, studies in the
mdr1a-/- rat are very likely complicated by our use of riluzole to measure Pgp activity, since
this drug is also a substrate for the Bcrp efflux transporter. Hence, it is possible that
compensatory Bcrp activity at the BSCB, intestines, liver, and kidneys of the mdr1a-/- rat may
obfuscate the interpretation of these results to some degree. Chu et al. did not detect any change
in abcg2 expression in the liver, kidneys, intestine, or brain of the male mdr1a-/- rat, though the
reported expression patterns are those of healthy, uninjured rats (307). Areas of ongoing
investigation in our laboratory will include the characterization of Mdr1b and Bcrp expression
in the liver, kidney, intestine, and spinal cord of wild-type and mdr1a-/- rats in response to SCI.
However, to determine the exact contribution of Pgp-mediated transport to the development of
spinal cord drug resistance after SCI, future studies would necessitate the use of drugs that are
“pure” Pgp substrates, such as the opioid-receptor antagonist loperamide.
Curiously, we have also observed a significant reduction in plasma riluzole levels 72 hours
post-SCI in (wild-type) rats treated with licofelone in combination with riluzole, but not in rats
treated with riluzole alone (Fig. 4.15). Despite this considerable drop in plasma drug levels,
raw spinal cord concentrations of riluzole are not decreased. The net effect of these factors is a
significantly higher normalized spinal cord riluzole bioavailability compared to riluzole-treated
injured rats as well as uninjured controls (Fig. 4.14). This implies two actions of licofelone.
First, licofelone enhances the plasma-to-spinal cord penetration of riluzole, presumably by
partial attenuation of Pgp up-regulation (Fig. 4.13). Second, licofelone also enhances the
plasma clearance of riluzole. How the latter might occur is a subject of speculation that might
be better addressed by assessing expression patterns of efflux transporters (Pgp, Bcrp) in the
9

The mdr1a knockout rats characterized by Chu et al. were Wistar Hannover rats and the mdr1a
knockout rats utilized in the present study were Sprague Dawley. Thus, differences in genetic
background could conceivably contribute to different pharmacokinetics between the strains used in our
study and those used previously.
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liver and kidneys of rats following SCI, with and without licofelone treatment. However, as
there is no difference from control drug plasma levels in the injured, riluzole-alone group, it
seems unlikely that the effect observed in the licofelone group would be due to licofelone’s
modulatory effect on transporter-mediated excretion of riluzole. Perhaps instead, licofelone
enhances drug metabolism in the liver, possibly through a CYP-mediated mechanism.
Alternatively, it is possible that the high dose of licofelone (100 mg/kg) used in this study
induces an up-regulation in liver enzymes underlying this observation. Whatever the
mechanism, a reduction in plasma drug levels is an unexpected result of licofelone therapy that
is counterproductive to the goal of this study—to enhance therapeutic delivery of drugs such as
riluzole while achieving efficacy with lower doses. Hence, this is a very important question that
will be addressed in future investigations in our laboratory.

Licofelone as a Neuroprotective Agent
We have shown that treatment with licofelone, beginning at 3 hours post-injury and
continued for two weeks, is sufficient to improve functional outcome following SCI. This
conclusion is based on the improvement in BBB scores that we observed in rats treated with
either licofelone alone, or both licofelone and riluzole, versus rats treated with vehicle alone
(Fig. 5.1 & TABLE 5.1). We are confident that the improvement in BBB scores we have
observed with licofelone treatment (3.0-point improvement in both licofelone-treated groups
versus vehicle-treated group) is robust and meaningful, because of the conservative statistical
analytic methods used to interpret the effects of treatment, as well as the functional significance
corresponding to the observed behavioral improvements.
Dr. Stephen W. Scheff, a researcher at the University of Kentucky, has presented an
argument for the use of appropriate statistics in analysis of BBB data, suggesting that
parametric statistical analysis may often be appropriate (349). However, rather than promoting
one specific analytical method over another, Scheff emphasizes that a cautious interpretation of
BBB data, using a statistical comparison best suited to the distribution of data, as well as
judicious choice of post hoc analysis, is crucial. After all, most studies utilizing an outcome of
BBB locomotor scores are chiefly interested in assessing the efficacy of potential SCI
treatments, and because of the researcher’s vested interest in identifying effective therapies, it
is best to take a more cautious approach to data analysis. Scheff concludes his argument by
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emphasizing that “investigators [should] choose to be more conservative in their choice of post
hoc statistics in order that only those difference that are strongly revealed can be identified as
appropriate avenues for further investigation in SCI experiments.”
We have therefore taken a conservative approach to statistical analysis of BBB data in this
study and utilized the Kruskal-Wallis test for single time point comparisons of nonparametric
data, followed by a Dunn’s post test to determine significant effects of treatment at each
individual time point. We feel that a nonparametric analysis is generally more appropriate for
cautious interpretation of BBB data. This is chiefly because the BBB locomotor rating scale is
comprised of ordered (ranked) data, with no numerical values between individual scores, and
with the improvement between points on the scale not being numerically equal (e.g., the
functional difference between a 0 and a 2 is unequal to the functional difference between a 17
and a 19). Importantly, our BBB data was not normally distributed in this study, making the
choice of a nonparametric statistical test appropriate in this case.
It is important to remark on the significance of the extent of hindlimb functional
improvement we have observed in licofelone-treated animals. At the end of this study, vehicletreated SCI rats exhibited an average BBB score of 9.1 ± 0.5 (mean ± s.e.m.). The distribution
of individual animals’ scores on DPI 42 is displayed in Figure 6.2. Vehicle-treated rats were
scored between 7 (n = 2) and 11 (n = 1), with the most frequent score being 10 (n = 3) on DPI
42. A BBB score of 10 is characterized by occasional (≤50% of the time) weight supported
plantar stepping, with no forelimb (FL)-hindlimb (HL) coordination (See APPENDIX B). These
scores are consistent with those of previous studies. Other groups have reported similar time
courses of locomotor recovery in vehicle-treated rats following the same moderate spinal
contusion injury paradigm (parameters = 150 kdynes, 1 s dwell) (See Fig. 5.1) (350, 351). Of
the vehicle-treated group, 4 of 8 exhibited any plantar stepping, and only one exhibited frequent
(50-94% of the time) stepping10. Additionally, only one rat from this group showed any FL-HL
coordination.

10

There were originally nine rats in the SCI + vehicle group, but one of the rats died between DPI 35
and -42, thus only eight animals were assessed on DPI 42. Similarly, one of the riluzole-treated rats died
between DPI 35 and -42, thus DPI 42 scores reflect six animals in the riluzole group.
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Figure 6.2. Distribution of individual BBB scores on post-injury day 42. Data is presented
as the number of animals in each treatment group receiving each score on day 42 post-injury.
BBB scores represent an average rating for both hindlimbs of one subject. BBB scores
associated with plantar stepping are contained within the gray shaded area; gradient shading
indicates stepping frequency, with consistent plantar stepping beginning at 14. Blue shaded
area illustrates the range of BBB scores associated with forelimb-hindlimb coordination;
gradient shading indicates frequency of coordination, with consistent coordination beginning at
14.
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Average BBB scores of riluzole-treated animals were slightly higher, and ranged between
8 (n = 1) and 13 (n = 1). The most frequently observed DPI 42 score for this group was 11 (n =
2), which corresponds to frequent (50-94%) to consistent (95-100% of the time) weight
supported plantar stepping without coordination. Only one out of seven riluzole-treated rats
achieved frequent coordination. The time course of locomotor recovery observed in our riluzole
group is remarkably similar to that reported by Mu et al. (81), who treated with riluzole at 2
and 4 hours after injury, then once daily for one week; at 42 DPI, the authors reported an
average BBB score of about 12 for their riluzole-treated animals.
In contrast, rats treated with both licofelone and riluzole had noticeably higher DPI 42
BBB scores, ranging from 10 (n = 1) to 14 (n = 2); rats treated with licofelone alone exhibited a
greater range of locomotor function, ranging from 9.5 (n = 1) to 16 (n = 1). Importantly, 89% (8
of 9) of the licofelone group, and 100% (10 of 10) of the licofelone + riluzole group exhibited
plantar stepping. This is a clear functional advantage compared to 50% of the vehicle group,
and 67% of the riluzole group, that displayed plantar stepping. Also notable is the proportion of
animals per group that exhibited coordination (12.5% of vehicle, 50% of riluzole, 67% of
licofelone, 80% of licofelone + riluzole). The only animals to exhibit both consistent stepping
and consistent coordination in this study were animals that received licofelone. Furthermore,
both licofelone-treated groups exhibited significantly improved BBB scores beginning at DPI
14 (Fig. 5.1 & TABLE 5.1), and sustained throughout the end of the study. Because of these
observations, we assert that licofelone treatment, both alone and in conjunction with riluzole,
confers significant neuroprotection that is sustained well after discontinuation of treatment.
The vast majority of the animals at the end of this study fell within one of two categories:
1) the period which Basso et al. termed the “intermediate recovery phase” (BBB score between
8 and 12), defined as the period of functional recovery following SCI in which rats have
established plantar placement of the hindpaws and display various levels of coordinated FL-HL
movement; or 2) the “late recovery phase” (BBB score between 13 and 21), in which finer
aspects of locomotor function, such as toe clearance, limited paw rotation during swing, and
improved balance, are regained (280) (TABLE 6.1). Only two rats, both of which were in the
vehicle-treated group, remained in the “early recovery phase”, scoring below 8 on DPI 42.
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Treatment Group

Early Recovery
Phase (n)

Intermediate
Recovery Phase (n)

Late Recovery
Phase (n)

Vehicle

25% (2)

75% (6)

-

Riluzole

-

83% (5)

17% (1)

Licofelone

-

56% (5)

44% (4)

Licofelone + Riluzole

-

60% (6)

40% (4)

TABLE 6.1. Percentage of animals in each phase of recovery on DPI 42, by treatment
group. Phases of recovery following SCI are defined in: A Sensitive and Reliable Locomotor
Rating Scale for Open Field Testing in Rats, D. Michele Basso, Michael S. Beattie, Jacqueline
C. Bresnahan, Journal of Neurotrauma. February 1995: 1-21. (280)

Stepping and coordination are very important aspects of locomotor functional recovery in
rat models of SCI. The region of the BBB scale pertaining to differences in stepping and
coordination frequency is associated with functionally important milestones in the overall
recovery of locomotor ability. For example, the three-point separation between a BBB score of
9 (plantar placement with weight support in stance only or dorsal stepping, with no plantar
stepping) and 12 (frequent to consistent plantar stepping and occasional FL-HL coordination)
corresponds to a much more functionally significant improvement than, say, the difference
between a score of 1 (slight movement of one or two joints) and 4 (slight movement of all three
joints) (APPENDIX B). An animal with a BBB score of 9 can support its body weight, and, at
best, may exhibit bouts of disjointed, uncoordinated dorsal stepping. In contrast, an animal with
a BBB score of 12 possesses a higher degree of motor control, and shows substantially
improved regulation of muscles and joints involved in the normal biomechanics of coordinated
stepping. Thus, the improvements in BBB scores conferred by licofelone treatment at the end
of this study are not only statistically significant, but moreover, are associated with
physiologically important functional gains that dramatically enhance overall locomotor ability.
Moreover, though we have limited our assessment to a 6-week period following injury,
recovery of function in licofelone-treated animals did not appear to plateau by 6 weeks post-
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SCI. Thus, it is possible that the improvement in locomotor recovery conferred by licofelone
treatment could continue beyond this time point, leading to an even better functional outcome.
In the current study, we have also utilized the photobeam activity system to evaluate
additional measures of locomotor function and overall activity at multiple time points after
injury. Among the parameters assessed by the PAS were distance and speed of locomotion,
time spent resting, fine and ambulatory movement, and rearing. Rearing is thought to be a
particularly useful indicator of clinically relevant physiological functions, like postural control,
that are important for upright walking in human patients (322). Other readouts of the PAS (e.g.,
extent of ambulatory movement, total distance, speed, and rest time) reflect the ease with which
an animal can freely move about. For example, increased distance and speed of movement
during the testing period might be observed in an animal with better control of stepping and
coordination compared to an animal with a lower level of locomotor control; the latter animal
might expend more energy dragging its hindlimbs or compensating for uncoordinated,
inefficient stepping, and spend more time resting to recover. However, factors such as
increased time spent resting without any movement may also be attributed to various factors
such as pain state (321), so activity data must be interpreted judiciously.
Though we analyzed multiple different aspects of overall activity in this study, we only
detected two statistically significant effects of treatment on activity parameters. First, we
observed that the licofelone-treated group spent significantly less time at rest than the vehicletreated group on DPI 42 (SCI + vehicle = 154 ± 22.6 s; SCI + licofelone = 51 ± 11.9 s, p <
0.05) during the 20-minute testing period (Fig. 5.4). Though this effect was only significant on
DPI 42, the total resting time of the licofelone group was consistently lowest and closest to that
of uninjured controls compared to all other treatment groups from DPI 14 to -42. This
observation may indicate that licofelone treatment enhances the ability to locomote, or the ease
of locomotion, in rats recovering from SCI. Secondly, we observed that rats treated with both
licofelone and riluzole exhibited significantly more rearing during the testing period than did
injured, vehicle-treated rats (SCI + vehicle = 2.6 ± 1.5; SCI + licofelone = 6.4 ± 1.5, p < 0.05)
(Fig. 5.6a). This may be indicative of improved muscle control in the trunk in rats treated with
licofelone and riluzole, contributing to an enhanced ability to rear up on hindlimbs, a functional
measure that may correlate to postural control in human SCI patients. Other than these two
results, our PAS data did not reveal any statistically significant effects of treatment.
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Notably, we have failed to detect any significant improvements in locomotor function in
riluzole-treated animals during this study. These results are consistent with previous findings,
which did not detect any improvement in behavior in animals treated with riluzole beginning at
2 hours post-SCI and continued for one week (81). In fact, the only studies reporting positive
effects of riluzole treatment on functional outcome have utilized a treatment window of 15-30
minutes post-SCI (77, 78, 82). Taken together, these results suggest that riluzole may exert
therapeutic efficacy for SCI only if administered very early after injury. If this is the case, the
lack of therapeutic efficacy at later treatment windows may be due to enhanced efflux transport,
as we have reported in this study (See Chapters 3 & 4). However, it is also plausible that the
dose of riluzole used in this study is simply inefficient to confer enough neuroprotection to
translate into significant functional improvement. Despite the ability of licofelone to enhance
blood-to-spinal cord delivery of riluzole (Fig. 4.14), we have detected no significant difference
between locomotor scores of licofelone-treated and licofelone-and-riluzole-treated groups in
this study. Thus, more systematic studies are needed to optimize factors such as dose and
treatment schedule, in order to more thoroughly assess the therapeutic potential of combined
treatment with licofelone and riluzole for acute SCI.
Several studies have reported neuroprotective efficacy of NSAIDs, when administered
prior to experimental SCI (119, 123-128), at the time of injury (129-132, 135), or after a short
delay period (e.g., 15 min post-SCI) (121). Unfortunately, there are very few published reports
of improved behavioral outcome following a clinically relevant treatment window with COX
inhibitors. Two recent studies have reported beneficial effects of delayed, sustained ibuprofen
treatment for improving functional recovery in rats after SCI. Fu et al. (136) reported a ~2.0point increase in BBB scores, along with improved performance in other locomotor
assessments, in rats treated with 60 mg/kg/d ibuprofen (osmotic pump) beginning at 7 days
after spinal contusion injury and continuing for one month (SCI + vehicle ≈ 13.5, SCI +
ibuprofen ≈ 15.5). Similarly, Wang and colleagues (352) reported increased BBB scores (SCI +
vehicle ≈ 7.7, SCI + ibuprofen ≈ 9.4) in rats treated with 70 mg/kg/d ibuprofen (osmotic pump)
beginning at 3 days post-SCI and continuing for one month. That both of these studies have
reported statistically significant gains in locomotor function following a days-long delay in
treatment with ibuprofen, is exciting. These findings suggest that a delayed window of efficacy
may exist when targeting the pro-inflammatory COX arm of the secondary injury cascade
following SCI. However, neither of these studies evaluated gastric mucosal erosion following
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the extended course of ibuprofen treatment, despite the known deleterious GI side effects of
long-term NSAID use. Because of the improved GI tolerance of licofelone (320), as well as the
evidence showing that antagonism of 5-LOX signaling supports functional improvement in
preclinical SCI studies (142, 144, 145), it would therefore be interesting to evaluate whether
simultaneous COX/5-LOX inhibition would exhibit neuroprotective efficacy following delayed
treatment similar to that used in the aforementioned ibuprofen studies.
Ultimately, it is difficult to compare our results to these two reports, as there are
considerable differences in experimental design, type and severity of injury, and time course of
treatment. However, the three-point improvement in BBB scores that we have observed with
licofelone is a robust and significant finding that has never before been shown in experimental
studies of anti-inflammatory therapies. We have used a clinically relevant SCI model, a spinal
contusion/compression injury that approximates the type of human SCI most often observed in
the clinic (4). Furthermore, we have demonstrated significant and sustained functional recovery
following a clinically relevant delay in treatment (3 hours post-SCI) via the clinically relevant
oral route with licofelone, a drug that has successfully passed Phase III clinical trials and is safe
in humans. For these reasons, we conclude that licofelone exhibits high translational potential
as a treatment to improve functional recovery following SCI.
The central question of how licofelone works within the spinal cord to supply this
neuroprotective efficacy will be among the most important future areas of investigation. We
have not yet examined histological outcome measures—such as lesion size, neuronal and glial
cell counts, white matter tract sparing, extent of myelination, or BSCB structural alterations—
in the rats utilized for the current study. All of these parameters are important contributors to
neurological outcome following SCI, and assessing them will be critical for developing a
mechanistic model of how licofelone might confer enhanced functional outcome. Though
licofelone has not been studied in published reports of neurological trauma, some insight as to
the molecular basis for its neuroprotective properties might be gained from studies of rodent
models of Huntington’s disease (162, 163). In these preclinical studies, licofelone treatment
enhanced oxidative defenses and reduced levels of anti-inflammatory compounds in the brain, a
finding similar to what we have observed in chronic SCI (Fig. 4.10 & TABLE 4.2). The authors
also observed reduction in the size of chemically-induced striatal lesions with licofelone
treatment, which corresponded to enhanced functional outcome. It is possible that the anti160

inflammatory and anti-oxidative properties of this drug may exhibit a similar effect on the
spinal cord lesion site in our model. Further studies are needed to evaluate this possibility and
better characterize the biochemical and cellular changes within the injured spinal cord that
result from licofelone treatment.

§

Overall Translational Significance of this Study

I. P-glycoprotein overexpression causes spinal cord drug resistance following SCI
There is currently no proven effective treatment for SCI, so the vast majority of SCI
patients face a lifetime of paralysis, intractable pain, and other complications (263). We have
identified an important pathophysiological mechanism arising early after SCI that imparts the
spinal cord with resistance to a wide variety of drugs, thus establishing a major, previously
unknown barrier to effective therapeutic intervention for SCI. This finding holds important
implications not only for the acute delivery of neuroprotective drugs immediately after SCI, but
also for the long-term clinical management of pain and muscle spasticity in chronic SCI
patients. We propose that overcoming Pgp-mediated drug resistance, thereby enhancing spinal
cord bioavailability of systemically-administered neuroprotective drugs after SCI, will provide
a significant therapeutic advantage to patients who otherwise have very little hope for
functional recovery.
The neuroprotective drug riluzole is currently being evaluated in a Phase I clinical trial as
an intervention for SCI, with daily delivery for 14 days subsequent to injury (87). Our
observations of increased Pgp expression and diminished spinal cord riluzole bioavailability
during the acute phase of SCI strongly support the existence of Pgp-mediated drug resistance in
the injured spinal cord. Importantly, we have shown that licofelone treatment can enhance
blood-to-spinal cord delivery of riluzole during acute SCI. We anticipate that this finding has
potential to develop into a new combinatorial treatment strategy to attenuate the expression of
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post-SCI drug resistance and improve therapeutic efficacy for riluzole, as well as a variety of
other neuroprotective drugs.
Based on the data obtained in this study, we propose a working model (Fig. 6.3) in which
Pgp expression at the BSCB is up-regulated following traumatic SCI, resulting in a reduction in
spinal cord bioavailability of systemically-delivered drugs that are Pgp substrates. Because of
previously established mechanisms of Pgp up-regulation in other neurological disease models,
we hypothesize that this process is driven by pro-inflammatory COX signaling. We have shown
that acute treatment with the dual COX/5-LOX inhibitor licofelone is sufficient to both
attenuate Pgp overexpression and enhance blood-to-spinal cord delivery of riluzole during the
acute phase of SCI.
Importantly, this work has defined a new combinatorial mechanism with applications to
human disease beyond SCI research. Pgp overexpression is a recognized obstacle to effective
treatment of neurological diseases such as ALS (224) and epilepsy (222), as well as multiple
types of cancer (353). The ability to target the molecular signaling pathways driving Pgp upregulation with licofelone is therefore a highly useful strategy with potential to impact any
pathological condition in which Pgp activity reduces efficacy of drug treatment.
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Figure 6.3. Working model of P-glycoprotein-mediated drug resistance in the injured
spinal cord. (a) Under normal conditions, Pgp is expressed on the luminal surface of
endothelial cells lining blood vessels at the BSCB. Blood-borne drug molecules must diffuse
through the endothelial cell in order to enter spinal cord tissue. However, the drug efflux
transport activity of Pgp pumps drugs back into the bloodstream at a discrete rate, thus limiting
spinal cord drug concentrations. (b) Following SCI, pro-inflammatory COX signaling within
the damaged spinal cord tissue drives Pgp overexpression at the BSCB. This increased Pgp
expression and drug transport activity results in diminished drug delivery to the spinal cord.
Treating rats with the dual COX/5-LOX inhibitor licofelone after SCI attenuates spinal cord
Pgp overexpression, thus enhancing spinal cord drug delivery and efficacy of treatment.
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II. Licofelone treatment promotes significant neurological recovery following SCI
Inflammation is a major factor involved in shaping outcome during the early, acute phase
of traumatic SCI, and there is much evidence that pro-inflammatory COX and 5-LOX activity
are key among the adverse pathological processes negatively affecting functional outcome
following SCI. Antagonizing the COX-2 (119) or 5-LOX (142, 144) pathways independently
has led to modest reductions in the pathological and behavioral deficits following SCI.
However, the therapeutic potential of combined COX and 5-LOX inhibition to improve
functional outcome following SCI has not previously been assessed.
We have shown that, in a clinically relevant model of spinal contusion/compression injury,
oral licofelone treatment significantly and robustly improves hindlimb locomotor function in
rats, starting from two weeks after injury. Furthermore, we have demonstrated that this
functional improvement is sustained following cessation of treatment, for up to four weeks. We
have utilized a clinically relevant delayed treatment window (beginning at 3 hours after injury),
thus our findings display high translational potential for movement to clinical trials.
Furthermore, our findings indicate that licofelone is more effective as a neuroprotective
intervention for acute SCI than riluzole, a drug which is currently undergoing clinical trials as a
promising SCI intervention. Thus, licofelone holds great promise as a stand-alone therapeutic
intervention to improve functional recovery following SCI.
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APPENDIX A
ASIA Impairment Scale
&
Autonomic Assessment Form

165

166

167

168

APPENDIX B
Basso, Beattie, and Bresnahan Open Field Locomotor Scale
&
Definition of Terms Used in the BBB Scale
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THE 21-POINT BASSO, BEATTIE, BRESNAHAN LOCOMOTOR RATING SCALE
AND OPERATIONAL DEFINITIONS OF CATEGORIES AND ATTRIBUTES

0 No observable hind limb (HL) movement
1 Slight movement of one or two joints, usually the hip and/or knee
2 Extensive movement of one joint or extensive movement of one joint and slight movement
of one other joint
3 Extensive movement of two joints
4 Slight movement of all three joints of the HL
5 Slight movement of two joints and extensive movement of the third
6 Extensive movement of two joints and slight movement of the third
7 Extensive movement of all three joints of the HL
8 Sweeping with no weight support or plantar placement of the paw with no weight support
9 Plantar placement of the paw with weight support in stance only (i.e., when stationary) or
occasional, frequent, or consistent weight supported dorsal stepping and no plantar
stepping
10 Occasional weight supported plantar steps, no forelimb (FL)-HL coordination
11 Frequent to consistent weight supported plantar steps and no FL-HL coordination
12 Frequent to consistent weight supported plantar steps and occasional FL-HL coordination
13 Frequent to consistent weight supported plantar steps and frequent FL-HL coordination
14 Consistent weight supported plantar steps, consistent FL-HL coordination; and
predominant paw position during locomotion is rotated (internally or externally) when it
makes initial contact with the surface as well as just before it is lifted off at the end of
stance or frequent plantar stepping, consistent FL-HL coordination, and occasional dorsal
stepping
15 Consistent plantar stepping and consistent FL-HL coordination; and no toe clearance or
occasional toe clearance during forward limb advancement; predominant paw position is
parallel to the body at initial contact
16 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe
clearance occurs frequently during forward limb advancement; predominant paw position
is parallel at initial contact and rotated at lift off
17 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe
clearance occurs frequently during forward limb advancement; predominant paw position
is parallel at initial contact and lift off
18 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe
clearance occurs consistently during forward limb advancement; predominant paw position
is parallel at initial contact and rotated at lift off
19 Consistent plantar stepping and consistent FL-HL coordination during gait; and toe
clearance occurs consistently during forward limb advancement; predominant paw position
is parallel at initial contact and lift off; and tail is down part or all of the time
20 Consistent plantar stepping and consistent coordinated gait; consistent toe clearance;
predominant paw position is parallel at initial contact and lift off; tail consistently up; and
trunk instability
21 Consistent plantar stepping and coordinated gait, consistent toe clearance, predominant
paw position is parallel throughout stance, consistent trunk stability, tail consistently up
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DEFINITIONS OF TERMS USED IN THE BBB LOCOMOTOR RATING SCALE
Slight: Partial joint movement through less than half the range of joint motion
Extensive: Movement through more than half of the range of motion
Sweeping: Rhythmic movement of HL in which all three joints are extended, then fully flex
and extend again; animal is usually sidelying, the plantar surface of paw may or may not
contact the ground; no weight support across the HL is evident
No Weight Support: No contraction of the extensor muscles of the HL during plantar
placement of the paw; or no elevation of the hindquarter
Weight Support: Contraction of the extensor muscles of the HL during plantar placement of
the paw, or elevation of the hindquarter
Plantar Stepping: The paw is in plantar contact with weight support then the HL is advanced
forward and plantar contact with weight support is reestablished
Dorsal Stepping: Weight is supported through the dorsal surface of the paw at some point in
the step cycle
FL-HL Coordination: For every FL step an HL step is taken and the HLs alternate
Occasional: Less than or equal to half; ≤50%
Frequent: More than half but not always; 51-94%
Consistent: Nearly always or always; 95-100%
Trunk Instability: Lateral weight shifts that cause waddling from side to side or a partial
collapse of the trunk
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